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Angiogenesis is a fundamental process entailing the generation of nascent vasculature from pre-
existing blood vessels. Driven by endothelial cells (ECs) in response to pro-angiogenic factors, the 
angiogenic cascade results in the upregulation of multiple essential proteins in these cells; including 
integrin-β3, integrin-α5 and neuropilin-1. All three molecules are attractive anti-angiogenic targets. 
Despite an array of studies supporting their druggability, attempts at targeting them in patients 
have failed. With breast cancer (BC) being the second most common cancer globally, gaining an 
understanding of how angiogenesis affects the development of the mammary gland throughout its 
lifecycle will provide insight into why current anti-angiogenics are ineffective. I hypothesized that 
the ablation of these three molecules to impede angiogenesis during different stages of the 
mammary life cycle would offer the opportunity to ascertain how angiogenesis influences 
mammary epithelial morphogenesis. I developed model systems in which I can deplete the EC 
expression of integrin-β3, integrin-α5 and neuropilin-1, simultaneously, and then study the effects 
of this depletion on the mammary gland in vivo, or on mammary ECs in vitro. My findings show that 
impairing the angiogenesis that is mediated by these three proteins during pubertal development 
of the gland has minor effects on mammary ductal branching morphogenesis. Similarly, there is 
little to no effect on mammary alveolar development during gestation and early lactation. However, 
I uncovered changes in placental development that may help to explain these findings. In contrast 
to what happens during the physiological life cycle of the mammary gland, I observed a significant 
reduction in BC growth when all three targets were depleted, suggesting pathological development 
of the breast is dependent on angiogenesis driven by integrin-β3, integrin-α5 and neuropilin-1. 
Lastly, the in vitro study of mammary ECs provide insight into potential alternative signalling 











Access Condition and Agreement 
 
Each deposit in UEA Digital Repository is protected by copyright and other intellectual property rights, 
and duplication or sale of all or part of any of the Data Collections is not permitted, except that material 
may be duplicated by you for your research use or for educational purposes in electronic or print form. 
You must obtain permission from the copyright holder, usually the author, for any other use. Exceptions 
only apply where a deposit may be explicitly provided under a stated licence, such as a Creative 
Commons licence or Open Government licence. 
 
Electronic or print copies may not be offered, whether for sale or otherwise to anyone, unless explicitly 
stated under a Creative Commons or Open Government license. Unauthorised reproduction, editing or 
reformatting for resale purposes is explicitly prohibited (except where approved by the copyright holder 
themselves) and UEA reserves the right to take immediate ‘take down’ action on behalf of the copyright 
and/or rights holder if this Access condition of the UEA Digital Repository is breached. Any material in 
this database has been supplied on the understanding that it is copyright material and that no quotation 
from the material may be published without proper acknowledgement. 
 





ABSTRACT ................................................................................................................................................... 2 
CONTENTS ................................................................................................................................................... 3 
LIST OF FIGURES .......................................................................................................................................... 7 
LIST OF TABLES .......................................................................................................................................... 10 
ACKNOWLEDGMENTS ............................................................................................................................... 11 
1 INTRODUCTION ................................................................................................................................ 12 
1.1 PREFACE ............................................................................................................................................ 12 
1.2 THE VASCULAR SYSTEM ......................................................................................................................... 13 
1.2.1 Vasculogenesis – The primordial vascular network .................................................................... 13 
1.2.2 Angiogenesis............................................................................................................................... 16 
 Angiogenic Factors and Regulators ................................................................................................... 16 
 Remodelling the ECM in Prelude to Endothelial Expansion .............................................................. 19 
 Sprouting Angiogenesis .................................................................................................................... 21 
 Intussusceptive Angiogenesis ........................................................................................................... 26 
 Pathological Angiogenesis ................................................................................................................ 28 
1.2.3 Integrins ...................................................................................................................................... 32 
1.2.4 Neuropilin-1 ................................................................................................................................ 35 
1.3 THE MURINE MAMMARY GLAND ............................................................................................................. 37 
1.3.1 Embryonic development ............................................................................................................. 37 
1.3.2 Pubertal development ................................................................................................................ 41 
1.3.3 Pregnancy and Lactation ............................................................................................................ 42 
1.3.4 Involution .................................................................................................................................... 43 
1.3.5 Mammary gland vasculature ..................................................................................................... 46 
1.3.6 Breast Cancer ............................................................................................................................. 46 
 Diagnosis ........................................................................................................................................... 47 
 Subtypes ........................................................................................................................................... 49 
 Treatment ......................................................................................................................................... 49 
1.4 THE PLACENTA .................................................................................................................................... 52 
1.4.1 Placental development ............................................................................................................... 52 
1.5 RESEARCH AIMS AND HYPOTHESES .......................................................................................................... 54 
2 MATERIALS AND METHODS .............................................................................................................. 55 
2.1 REAGENTS AND HOUSEKEEPING .............................................................................................................. 55 
2.1.1 Table(s) of Primary Antibodies ................................................................................................... 56 
2.1.2 Table(s) of Secondary Antibodies ............................................................................................... 58 




2.2 ANIMALS ............................................................................................................................................ 59 
2.2.1 Breeding ..................................................................................................................................... 59 
2.2.2 Timed mating ............................................................................................................................. 59 
2.2.3 Genotyping ................................................................................................................................. 59 
 DNA Preparation ............................................................................................................................... 60 
 PCR Reactions ................................................................................................................................... 60 
2.3 TAMOXIFEN PREPARATION .................................................................................................................... 62 
2.4 ORTHOTOPIC MAMMARY GLAND TUMOUR ASSAYS ................................................................................... 62 
2.4.1 Immunofluorescent Staining and Analysis – Tumours ................................................................ 62 
2.5 ENDOTHELIAL CELL CULTURE AND ISOLATION ............................................................................................ 63 
2.5.1 Triple-floxed Mammary Endothelial Cell Isolation ..................................................................... 63 
2.5.2 Mammary Endothelial Cell Immortalisation .............................................................................. 64 
2.5.3 TAT.Cre-recombinase Nucleofection .......................................................................................... 65 
2.6 WESTERN BLOTTING ............................................................................................................................ 65 
2.6.1 Western Blot Sample Preparation .............................................................................................. 65 
2.6.2 8% Polyacrylamide gel (SDS-PAGE) and Gradient gel (5 – 12%) Electrophoresis ....................... 65 
2.6.3 Protein Transfer and Immunoblot .............................................................................................. 66 
2.7 WHOLE MAMMARY GLAND EXTRACTION ................................................................................................. 66 
2.7.1 Haematoxylin Staining ............................................................................................................... 67 
 Haematoxylin Analysis ...................................................................................................................... 67 
2.7.2 Immunofluorescent Staining and Analysis – Mammary Glands ................................................. 67 
2.7.3 H&E Staining ............................................................................................................................... 68 
2.8 PLACENTAL EXTRACTION AND PROCESSING ............................................................................................... 68 
2.8.1 Placental Immunohistochemistry and Stereology ...................................................................... 69 
2.9 FLOW CYTOMETRY ............................................................................................................................... 69 
2.9.1 Cell Isolation ............................................................................................................................... 69 
 Tumour Lysate .................................................................................................................................. 69 
 Immortalised Endothelial Cells ......................................................................................................... 69 
2.9.2 Staining Protocol ........................................................................................................................ 70 
2.9.3 Data Collection and Analysis ...................................................................................................... 70 
2.10 IMMUNOCYTOCHEMISTRY...................................................................................................................... 70 
2.11 IN VITRO ASSAYS ................................................................................................................................. 71 
2.11.1 VEGF Stimulation and Signalling Assay .................................................................................. 71 
2.11.2 Non-Pregnant Serum and Pregnant Serum Stimulation and Signalling Assays ..................... 71 
2.11.3 Microarray Sample Preparation ............................................................................................. 71 
2.12 STATISTICAL ANALYSIS .......................................................................................................................... 72 
2.12.1 Power Calculations ................................................................................................................. 73 




3 GENERATING THE IN VIVO AND IN VITRO TOOLS AND MODELS REQUIRED TO STUDY THE ROLE OF 
ANGIOGENESIS IN THE FUNCTIONAL LIFECYCLE OF THE MURINE MAMMARY GLAND ............................... 74 
3.1 THE CRE/LOXP SYSTEM – BREEDING AND GENERATING GENETICALLY ENGINEERED MOUSE MODELS AS AN IN VIVO 
TOOL 74 
3.2 DEDUCTION OF AN EFFECTIVE TAMOXIFEN REGIMEN TO INDUCE TARGET DEPLETION WITHOUT IMPEDING EPITHELIAL 
GROWTH 77 
3.3 ISOLATION, TRANSFECTION, AND IMMORTALISATION OF MAMMARY DERIVED ENDOTHELIAL CELLS PROVIDES A TOOL TO 
STUDY MAMMARY ENDOTHELIAL CELL BEHAVIOUR IN VITRO ....................................................................................... 82 
3.4 CONFIRMATION OF MAMMARY ENDOTHELIAL CELL IDENTITY PRIOR TO IN VITRO STUDIES .................................... 84 
3.5 DISCUSSION ........................................................................................................................................ 86 
4 ANGIOGENIC SIGNALLING MEDIATED THROUGH INTEGRIN-Β3, INTEGRIN-Α5 AND NEUROPILIN-1 IS 
NOT REQUIRED FOR SUCCESSFUL EPITHELIAL MORPHOGENESIS IN THE MURINE MAMMARY GLAND 
DURING PUBERTAL DEVELOPMENT........................................................................................................... 88 
4.1 EPITHELIAL OUTGROWTH OF THE MURINE MAMMARY GLAND DURING PUBERTAL DEVELOPMENT IS NOT AFFECTED BY 
ANGIOGENIC IMPEDIMENT .................................................................................................................................. 88 
4.2 TERMINAL END BUD TRIFURCATION EVENTS ARE SIGNIFICANTLY INCREASED IN THE ABSENCE OF PRO-ANGIOGENIC 
TARGETS 95 
4.3 DISCUSSION ...................................................................................................................................... 101 
5 MATURATION AND ALVEOLOGENESIS OF THE MAMMARY EPITHELIUM DURING PREGNANCY IS 
MODERATELY REDUCED WHEN ANGIOGENESIS IS IMPAIRED, BUT LACTATION AND INVOLUTION APPEAR 
UNAFFECTED ........................................................................................................................................... 104 
5.1 EPITHELIAL MATURATION DURING MID-GESTATION (E10.5) IS UNAFFECTED BY ANGIOGENIC IMPAIRMENT HOWEVER 
EMBRYO WEIGHT IS SIGNIFICANTLY REDUCED ........................................................................................................ 105 
5.2 EPITHELIAL MATURATION DURING LATE GESTATION (E15.5) IS UNAFFECTED BY ANGIOGENIC IMPEDIMENT THROUGH 
THE CO-DEPLETION OF ENDOTHELIAL INTEGRIN-Β3, INTEGRIN-Α5, AND NEUROPILIN-1 .................................................. 107 
5.3 THE JUNCTIONAL ZONE OF THE PLACENTA IS LARGER WHEN ENDOTHELIAL INTEGRIN-Β3, INTEGRIN-Α5, AND 
NEUROPILIN-1 ARE CO-DEPLETED ....................................................................................................................... 111 
5.4 LACTATION (P2) AND INVOLUTION (P12) WERE NOT AFFECTED BY THE DEPLETION OF INTEGRIN-Β3, INTEGRIN-Α5, 
AND NEUROPILIN-1 ......................................................................................................................................... 114 
5.4.1 The epithelium of the mammary gland during lactation (P2) and involution (P12) by the 
depletion of integrin-β3, integrin-α5, and neuropilin-1 resembles that of the Cre-negative ................ 114 
5.5 DISCUSSION ...................................................................................................................................... 118 
6 EXPLORING THE EFFECTS OF COMBINATORIAL DEPLETION OF ENDOTHELIAL INTEGRIN-Β3, 
INTEGRIN-Α5 AND NEUROPILIN-1 IN THE DEVELOPMENT OF BREAST CANCER ....................................... 121 
6.1 TRIAD DEPLETION OF ENDOTHELIAL INTEGRIN-Β3, INTEGRIN-Α5 AND NEUROPILIN-1 SIGNIFICANTLY IMPAIRS TUMOUR 
GROWTH AND VASCULARISATION ....................................................................................................................... 122 




6.2 DISCUSSION ...................................................................................................................................... 125 
7 MAMMARY GLAND DERIVED ENDOTHELIAL CELL ISOLATION, CHARACTERISATION AND 
COMPARISON TO LUNG DERIVED ENDOTHELIAL CELLS ........................................................................... 127 
7.1 TARGET DEPLETED MAMMARY DERIVED ENDOTHELIAL CELLS SHOW ONLY MODEST CHANGES IN VEGF SIGNALLING 128 
7.2 PROGESTERONE RECEPTOR IS PROFOUNDLY DECREASED IN TARGET DELETED LUNG ENDOTHELIAL CELLS COMPARED TO 
MAMMARY ENDOTHELIAL CELLS ......................................................................................................................... 130 
7.3 TREATMENT OF MAMMARY DERIVED ENDOTHELIAL CELLS WITH PREGNANT SERUM RESULTS IN ALTERED SIGNALLING 
RESPONSES WHEN EC TARGETS ARE DEPLETED ...................................................................................................... 132 
7.4 MICROARRAY, AND SUBSEQUENT STRING ANALYSIS, REVEALS SIGNALLING DIFFERENCES BETWEEN MAMMARY AND 
LUNG DERIVED ENDOTHELIAL CELLS IN RESPONSE TO VEGF, SERUM AND PREGNANT SERUM .......................................... 136 
7.5 SUBSEQUENT WESTERN BLOT ANALYSIS FOR SIGNALLING PROTEINS IDENTIFIED BY STRING ANALYSIS REVEALS 
DIFFERENTIAL SIGNALLING RESPONSES TO HORMONAL INPUT ................................................................................... 140 
7.6 DISCUSSION ...................................................................................................................................... 143 
8 FINAL DISCUSSION AND FUTURE WORK ......................................................................................... 145 
9 APPENDIX – SUPPLEMENTARY FIGURES .......................................................................................... 151 
10 ABBREVIATIONS ............................................................................................................................. 165 
11 REFERENCES .................................................................................................................................... 169 
 
  




List of Figures 
Figure 1.1 Formation of the primitive streak and emergence of mesoderm cells (top). Schematic of 
mesodermal blood island fate (bottom). .......................................................................................... 15 
Figure 1.2 The VEGFR and VEGF family members, their predominant tissue expressions sites and 
the biological activity they contribute towards. ............................................................................... 18 
Figure 1.3 Schematic of sprouting angiogenesis............................................................................... 20 
Figure 1.4 The VEGFR signalling pathway. ........................................................................................ 24 
Figure 1.5 Notch-1/Dll4 Mediated tip cell selection. ........................................................................ 25 
Figure 1.6 Schematic illustrating the four consecutive steps involved in intussusceptive pillar 
formation. ......................................................................................................................................... 27 
Figure 1.7 Phases of Intussusceptive Angiogenesis. ......................................................................... 27 
Figure 1.8 Basic schematic of angiogenesis resulting in either normal or abnormal (tumour) 
vasculature. ....................................................................................................................................... 31 
Figure 1.9 An illustration of the known pairing patterns of α and β subunits, and the potential 
integrin heterodimers that can form. ............................................................................................... 34 
Figure 1.10 A schematic diagram of the structure and function of an integrin heterodimer. ......... 34 
Figure 1.11 Structural diagram of neuropilin-1. ............................................................................... 36 
Figure 1.12 Embryonic milestones in the development of the mouse mammary gland. ................ 40 
Figure 1.13 Diagram illustrating the post-embryonic development of the murine mammary gland.
 .......................................................................................................................................................... 45 
Figure 1.14 Schematic of murine placental development. ............................................................... 53 
Figure 3.1 Illustration of the Cre/LoxP system. ................................................................................. 76 
Figure 3.2 Immunofluorescent staining shows co-expression of TdTomato and endomucin in the 
pubertal gland. .................................................................................................................................. 80 
Figure 3.3 Experimental Tamoxifen regimens used for studying mammary morphogenesis at various 
stages. ............................................................................................................................................... 81 
Figure 3.4 Immunofluorescent whole gland staining shows co-expression of TdTomato and 
endomucin in the mature virgin gland, 8 weeks post Tamoxifen administration. ........................... 81 
Figure 3.5 Representative Western blot showing in vitro depletion of floxed target genes in MECs 
through tat-Cre-recombinase transfection. ...................................................................................... 83 
Figure 3.6 Western blot confirmation of endothelial cell status. ..................................................... 85 
Figure 4.1 Ventral diagrams of the mouse depicting the position and location of all five pairs of 
mammary glands............................................................................................................................... 90 




Figure 4.2 Quantification of epithelial outgrowth of the number three gland proved difficult due to 
imaging limitations. ........................................................................................................................... 90 
Figure 4.3 Epithelial outgrowth of the mammary gland during pubertal development is not impeded 
by co-depletion of endothelial integrin-β3, integrin-α5 and neuropilin-1. ...................................... 92 
Figure 4.4 Epithelial density and the number of branch points are unaffected when endothelial 
integrin-α5, integrin-β3 and neuropilin-1 are depleted. .................................................................. 94 
Figure 4.5 Depletion of endothelial integrin-α5, integrin-β3 and neuropilin-1 does not affect 
terminal end bud (TEB) number. ...................................................................................................... 96 
Figure 4.6 Trifurcation events take place more frequently in the mammary gland when when 
endothelial integrin-α5, integrin-β3 and neuropilin-1 are depleted. ............................................... 98 
Figure 4.7 H&E staining shows terminal end bud (TEB) structure is unaffected when endothelial 
integrin-α5, integrin-β3 and neuropilin-1 are depleted. ................................................................ 100 
Figure 5.1 E10.5 embryonic weight is significantly reduced, and embryonic number and epithelial 
maturation are (statistically) unaffected when endothelial integrin-α5, integrin-β3 and neuropilin-
1 are depleted. ................................................................................................................................ 106 
Figure 5.2 Number of embryos, embryonic weight, placental weight, uterine line position, number 
of reabsorption events and location of reabsorption events at E15.5 are when endothelial integrin-
α5, integrin-β3 and neuropilin-1 are depleted. .............................................................................. 108 
Figure 5.3 Epithelial development at E15.5 is unaffected when endothelial integrin-α5, integrin-β3 
and neuropilin-1 are depleted. ....................................................................................................... 110 
Figure 5.4 The volume of the junctional zone (JZ) is significantly increased, at E15.5, when 
endothelial integrin-α5, integrin-β3 and neuropilin-1 are depleted. ............................................. 113 
Figure 5.5 Epithelial density is unaffected during lactation (P2) when endothelial integrin-α5, 
integrin-β3 and neuropilin-1 are depleted. .................................................................................... 116 
Figure 5.6 Epithelial density is unaffected during involution (P12) when endothelial integrin-α5, 
integrin-β3 and neuropilin-1 are depleted. .................................................................................... 117 
Figure 6.1 Triad-depletion of integrin-β3, integrin-α5 and neuropilin-1 impairs tumour growth. 124 
Figure 7.1 VEGF stimulation of triple MECs shows a dampened response to VEGF as determined 
through pERK expression. ............................................................................................................... 129 
Figure 7.2 Target deletion in lung derived endothelial cells significantly reduces progesterone 
receptor (PgR) expression. .............................................................................................................. 131 
Figure 7.3 Western blot analysis of MECs treated with serum and pregnant serum. .................... 134 
Figure 7.4 Densitometric analysis of western blotting performed on MECs treated with serum and 
pregnant serum............................................................................................................................... 135 




Figure 7.5 Hierarchical protein cluster analysis, performed on Qlucore™, from the three MEC-WT 
and MEC-KO samples. ..................................................................................................................... 138 
Figure 7.6 STRING analysis generated from hierarchical protein clustering. ................................. 139 
Figure 7.7 Western blot analysis of mammary and lung derived endothelial cells treated with VEGF, 
and MECs treated with serum (S) or pregnant serum (PS). ............................................................ 142 
Figure 8.1 Schematic summary of the findings from the work presented in this thesis. ............... 150 
Figure 9.1 Tamoxifen delivery through Elvax-40P® yielded systemic administration of Tamoxifen, 
not local to the implanted mammary gland. .................................................................................. 151 
Figure 9.2 Tamoxifen administration doses as recommended by Jax Lab. .................................... 152 
Figure 9.3 Quantification of mammary gland epithelial outgrowth in a pubertal gland after whole 
gland staining (WGS). ...................................................................................................................... 153 
Figure 9.4 Quantification of mammary gland epithelial outgrowth in a E10.5 pregnant mammary 
gland after whole gland staining (WGS). ........................................................................................ 154 
Figure 9.5 All E10.5 whole gland stain images. Cre-negative and Cre-positive animals underwent the 
pregnancy Tamoxifen regimen described in chapter 3.2, underwent WGS and subsequently 
epithelial outgrowth was quantified............................................................................................... 155 
Figure 9.6 All lactating (P2) whole gland stain images. Cre-negative and Cre-positive animals 
underwent the pregnancy Tamoxifen regimen described in section 3.2. ...................................... 156 
Figure 9.7 All involuting (P12) whole gland stain images. Cre-negative and Cre-positive animals 
underwent the pregnancy Tamoxifen regimen described in section 3.2. ...................................... 157 
Figure 9.8 Flow cytometric analysis on Nrp1fl/fl.Pdgfb.iCreERT2(pos/neg) tumours proves ineffective at 
identifying ECs, preventing confirmation of target deletion. ......................................................... 158 
Figure 9.9 Using confirmed MEC-WT and MEC-KO cells to optimise tumour EC flow cytometry did 
not provide a straightforward answer. ........................................................................................... 159 
Figure 9.10 Further tumour EC flow optimisation using confirmed MEC-WT and MEC-KO cells, using 
a simplified antibody panel, yielded no improvement in optimisation. ......................................... 160 
Figure 9.11 Immunofluorescent staining of tumours derived from triple floxed GEMMs for our 
targets confirms target deletion. .................................................................................................... 161 
Figure 9.12 Co-depletion of endothelial fibronectin receptors impairs tumour angiogenesis. ..... 162 
Figure 9.13 VEGF stimulation of triple-depleted lung ECs (LECs) shows a dampened response to 
VEGF as determined through phosphorylated ERK (pERK) expression. ......................................... 163 
Figure 9.14 Microarray plate layout and sample comparisons made. ........................................... 164 
  




List of Tables 
Table 1.1 Summary of the TNM staging system, extrapolated from the American Joint Committee 
on Cancer (AJCC) 8th Edition [172]. .................................................................................................. 48 
Table 1.2 Summary of Breast Cancer Subtypes: IHC Status, Effective Treatments and Prognosis. . 51 
Table 2.1 List of primary antibodies used for western blotting. ....................................................... 56 
Table 2.2 List of primary antibodies used for flow cytometry. ......................................................... 57 
Table 2.3 List of primary antibodies used for immunocytochemistry, immunofluorescence and 
endothelial cell sorting...................................................................................................................... 57 
Table 2.4 List of secondary antibodies used for western blotting. ................................................... 58 
Table 2.5 List of primary antibodies used for immunocytochemistry, immunofluorescence and 
endothelial cell sorting...................................................................................................................... 58 
Table 2.6 Primers and reaction conditions used for the PCR of all GEMMs. .................................... 61 
Table 2.7 Power calculation for B6BO1 tumour experiments. ......................................................... 73 
Table 3.1 Simple breeding schematic for the phases of breeding to achieve the triple floxed GEMM 
(FL3). ................................................................................................................................................. 76 
  





To personally thank everyone who has helped me in some way, shape or form along this journey 
would be impossible. Having said that, I must namely thank several people who have greatly 
contributed to helping me achieve this feat and shaped me into the man I am today. 
The first and sincerest thanks goes to Dr. Stephen Robinson. Mentor, gym buddy, boss man and 
friend, this man granted me the opportunity to undertake a PhD from which I walk away with fond 
memories and a friendship that will last my lifetime. People radiate towards Stephen for one, 
predominant, reason. Worn on his sleeve more often than not, his heart; this man wields the most 
incredible heart. Stephen is eternally seeking what is best for others, extracting their true potential, 
doing his damnedest to make sure they succeed, all whilst exuberating nothing but care and trust 
along the way. If not the PhD, the greatest thing to have come from this journey is the opportunity 
to have worked by your side. 
Second to Stephen, I owe thanks to Sarah. My rock. From the beginning of my undergraduate full 
circle to the end of my PhD, this woman is one in a million, and without her love and support I most 
definitely would not be where or who I am today. Through my worries, my grumps and my outright 
despair, she profusely offered me reassurance and encouragement – I cannot express how grateful 
I am to have you in my life. 
Third I thank Dr. Robert Johnson, my scientific partner in crime. This mans unbridled passion for 
science saw me as a useful asset early on, for which I am grateful (as was he I am sure). Perpetually 
ensuring my enthusiasm was sated, I owe thanks to Rob for nurturing my scientific learning and 
ensuring I was ready for the science that lay ahead of me. Next, I cannot spend more word count 
thanking you all personally, however I shall name everyone who has contributed in some manner 
to my time in the Robinson lab. Thanks to Aleks, Ben, Kate, Jordi, Sam, Abdu, Tim, Stuart, Sally, 
Alastair, James, Chris B and Chris P – you have all made this time in my life memorable in more ways 
than one.  
Last, and by no means least, I humbly thank my parents Vanessa and Timothy. Without you both, I 
would not be where, or who, I am today – thank you.   
 
 






The mammary gland is an incredible organ. It develops both pre- and post-embryonically, exhibits 
transient remodelling throughout female adulthood, and can undergo huge waves of proliferation 
and regression during pregnancy to synthesise milk for the nourishment of offspring. Coinciding 
with such feats, remodelling of the vasculature through angiogenesis is presumed given the 
mitogenic demand ensuing epithelial expansion and remodelling. Despite this, sparse research 
exists exploring the role of angiogenesis throughout the dynamic behaviour of the mammary gland, 
warranting exploration into whether angiogenesis is a permitting factor in its functionality. Aside 
from this, given changes in vasculature have been observed through the life cycle of the mammary 
gland, evidence of the mechanisms by which these changes occur are incomplete. Acknowledged, 
the plasticity exhibited by the mammary gland although impressive, burdens the mammary gland 
with many opportunities in which cancer can arise. A plethora of cell lineages to be maintained by 
mammary stem cells, highly metabolic phases during pregnancy and lactation, signalling cues to 
instigate involution (controlled cellular regression via apoptosis), all attribute points at which 
tumorigenesis can occur. This thesis aims to address the fundamentals regarding the role, if any, 
angiogenesis plays in the life cycle of the mammary gland, how angiogenesis is achieved (in terms 
of signalling pathway(s)) and the anti-tumorigenic effect of impeding angiogenesis in breast cancer 
(BC).  The introduction proceeding shall aim to describe the canonical processes involved in 
formation, maturation and remodelling of the vascular system, the roles and targetability of 













1.2 The vascular system 
The vascular system is a vital component of many multicellular organisms. Conceptualised during 
embryogenesis, the rudimentary, and continuing, function of the vascular system is to provide a 
steady supply of nutrients, oxygen, and removal of metabolic waste, throughout a lifetime. 
Composed of arteries, arterioles, capillaries, venules and veins, this vessel hierarchy established 
early in life undergoes allometric growth, maturation, and remodelling, to summate these feats. 
However, this is not a flawless process. As with most fundamental systems, their continual use, 
proliferative capacity, or exposure to carcinogens deems them susceptible to disease – the vascular 
system is no exception. Although beyond the scope of this thesis, it is worth mentioning that the 
vascular system possesses its own innate potential to give rise to disease, alongside being a  
perpetrator in perpetuating tumorigenesis. 
1.2.1 Vasculogenesis – The primordial vascular network 
In prelude to exploring what angiogenesis is and the mechanisms involved, it is important to 
understand the process which allows angiogenesis to proceed, that is, vasculogenesis. Early on in 
gestation, embryonic development occurs in an avascular environment where organ and tissue 
growth is achieved by simple diffusion of oxygen and nutrients [1]. During embryonic growth, 
however, there reaches a point of critical mass whereby an embryo must regimentally undergo 
rapid de novo vascularisation in order to maintain adequate access to oxygen and nutrients – 
vasculogenesis. For the human embryo, the point in which simple diffusion becomes insufficient in 
supplying adequate nutrients and oxygen to perpetuate growth is approximately embryonic day 21 
(E21) and the mouse is E7 [2–4]. Broadly speaking, vasculogenesis is the process by which the 
primordial vasculature is formed, conceptualising gaseous exchange and removal of metabolic 
waste in embryos too large to exercise these feats via simple diffusion alone [5]. During 
vasculogenesis, a primitive vascular system is formed through the aggregation of Endothelial Cell 
(EC) precursors, giving rise ultimately to a vascular plexus. This vascular plexus then undergoes vast 
maturation through functional and morphological remodelling to enable it to function as a 
rudimentary vasculature system, permitting exchange of gases and nutrients and paving the way 









The first sighting of vasculogenesis dates back to the mid 1800’s when His Wilhelm documented 
the in situ formation of blood vessels whilst microscopically investigating early chick embryos, with 
the process being later characterised and coined by Risau et al. in 1988 [6,7]. The process of 
vasculogenesis has been largely discerned, including the cellular mechanisms involved. The cascade 
of events leading to vasculogenesis begins during gastrulation with the invagination of the 
ectoderm resulting in the formation of the primitive streak. Pluripotent stem cells then pass 
through the posterior of the primitive streak, giving rise to the intraembryonic mesoderm (Figure 
1.1) [8]. A subset of mesodermal cells within these two regions are destined as precursor cells that 
sequentially migrate, associate, and differentiate into clusters called blood islands (Figure 1.1). 
Within these blood islands, physical location of the mesodermal cells defines their fate. Peripherally 
located progenitor cells differentiate into angioblasts and later into ECs, defining the blood vessel 
structure, composition and permeability, whilst those that are centrally situated differentiate first 
into hematopoietic stem cells (HSCs) and further into both ECs and primitive erythrocytes, hence 
perfusing the vessel lumen (Figure 1.1b) [9–11]. Angioblasts are recognised as EC progenitors as 
they possess an incomplete set of characteristic markers for ECs, along with haemangioblasts 
sharing some of these markers and being spatially associated [12–14]. Post formation, blood islands 
coalesce to form the primary vascular plexus, the subsequent growth and remodelling of which 
constitutes vasculature maturation through angiogenesis (Figure 1.1b) [15,16]. A key driver and 
regulator of embryonic vasculogenesis is the Vascular Endothelial Growth Factor (VEGF) signalling 
pathway, comprised of two major binding receptors for VEGF, namely VEGFR1 (Flt-1) and VEGFR2 
(Flk-1/KDR) [17,18]. Alongside the VEGF signalling pathway, studies have also shown the 















Figure 1.1 Formation of the primitive streak and emergence of mesoderm cells (top). Schematic of 
mesodermal blood island fate (bottom). a) Gastrulation, formation of the three germ layers, highlighting the 
formation of the primitive streak and differentiation of ectoderm into mesoderm. Mesodermal cells migrate 
into the sub-germinal space, a portion of which are fated to become blood island derivatives. b) Blood island 
fated mesodermal cells aggregate (1) and differentiate into blood islands pre-cursors (peripheral cells into 
angioblasts and centrally located into hematopoietic stem cells) (2), before fusing and forming the primary 
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Angiogenesis broadly describes the process by which new blood vessels are formed from the 
remodelling and expansion of pre-existing vasculature. The formation of these new blood vessels 
can occur via two main mechanisms, Sprouting Angiogenesis (SA) or Intussusceptive Angiogenesis 
(IA); the latter being a much rarer form, however both forms will be covered in section 1.2.2.3. As 
alluded to, angiogenesis differs from vasculogenesis in that angiogenesis builds upon, and matures, 
the primordial vascular network generated during early embryogenesis (section 1.2.1). In terms of 
being a biological process for allometric tissue growth, angiogenesis is crucial in that it enables 
successful wound healing, execution of the menstrual cycle, morphogenesis to take place in the 
mammary gland and vascularisation of the placenta and uterus during pregnancy [23–25]. 
However, as well as being a fundamental part of embryonic and postnatal development, 
angiogenesis also harbours the ability to promote several ischaemic and inflammatory diseases, 
including cancer development and its ability to metastasise [26]. 
 Angiogenic Factors and Regulators 
Angiogenesis is initiated in response to pro-angiogenic stimuli, often factors secreted by nearby 
tissue entering a hypoxic state. Although a broad range of growth factors and cytokines can initiate 
angiogenesis, i.e. Fibroblast Growth Factor (FGF), Tumour Necrosis Factor-Alpha (TNF-α), 
Transforming Growth Factor-Beta (TGF-β) and Angiopoietins (ANG) – a non-exhaustive list, the 
most renowned factor is VEGF [27]. VEGF is a family of homodimeric glycoproteins which 
collectively play fundamental roles across vasculogenesis, lymphangiogenesis and angiogenesis – 
lymphangiogenesis defined as the formation of lymphatic vessels from the pre-existing lymphatic 
system [28]. Identified members of the VEGF family include: VEGF-A, VEGF-B, VEGF-C, VEGF-D, 
Placental Growth Factor (PLGF) plus a viral homolog to VEGF, derived from Orf Virus NZ-7, denoted 
as VEGF-E (Figure 1.2) [29,30]. VEGF-A (also known as Vascular Permeability Factor – VPF) is 
documented as the most important member for angiogenesis. Previous studies investigating VEGF 
and its family identified VEGF-A as lacking exons 6 and 7, although no differences were observed 
between the VEGF members with regards to their activity, VEGF-A interestingly is unable to bind 
heparin [31]. VEGF-A interacts with and binds to both VEGFR1 (Flt-1) and VEGFR2 (Flk-1/KDR), the 
latter with an affinity approximately 10-fold less [30]. To discuss with evidence, a multitude of 
studies have demonstrated the importance of VEGF-A in angiogenesis. Disruption of the VEGF-A 
gene, resulting in either VEGF-A+/- or VEGF-A-/- mutant mice, results in embryonic death. VEGF-A+/- 
animals showed poorly developed and segmented branchial arches in the cranium, an 
underdeveloped forebrain, mispositioned and un-segmented forelimb buds with the 
compartments of the heart and its vessels lagging in development [32]. Furthermore, VEGF-A-/- 




embryos showed the most severe developmental defects, including complete lack of aortic 
development, widespread necrosis and delayed endothelial development [33]. 
As aforementioned, the receptors through which VEGF signals are members of the VEGFR family. 
VEGFR1 and VEGFR2 both bind VEGF-A, are highly expressed on vascular endothelium and have 
been shown as vital propagators of angiogenesis [34]. VEGFR1 and -2 are both transmembrane 
spanning glycoproteins comprised of an extracellular domain containing 7 immunoglobulin-like 
domains, a single transmembrane domain and an intracellular domain containing a consensus 
tyrosine kinase sequence, interrupted by a kinase-insert domain (Figure 1.2) [35,36]. However, 
when it comes to angiogenesis both receptors seem to play rather different yet fundamental roles.  
VEGFR1 has been seen to have an essential yet controversial function. Early developmental studies 
on VEGFR1-/- mice demonstrated its absence to be embryonic lethal, with ECs developing but lacking 
organisation combined with excessive angioblast proliferation; interestingly this lethality showed 
the function of VEGFR1 to be a negative regulator of angiogenesis, controlling angioblast 
proliferation [37]. Further confirmation comes from Kendall and Thomas who identified a vascular 
EC derived cDNA sequence encoding a truncated, secreted and soluble form of VEGFR1 [38]. This 
version of VEGFR1 had a high affinity for VEGF and hence negatively regulated VEGF induced 
mitogenic activity. Furthermore, a study utilising partial gene targeting interrupted the exon 
encoding the tyrosine kinase domain of VEGFR1, proving non-lethal and non-detrimental to 
vascular development, plus supporting the notion that VEGFR1 is primarily a “decoy” receptor for 
VEGF to mitigate its activity [39].  
VEGFR2, on the other hand, performs a pro-angiogenic function when in contact with VEGF. The 
vitality of this receptor during both developmental angiogenesis and haematopoiesis is evident 
from its embryonic lethality in VEGFR2 null mice; embryonic death 8.5 – 9.5 consequence of lacking 
blood island formation and blood vessel organisation [40]. This isoform gains its function via ligand 
induced homodimerization resulting in autophosphorylation, which in turn induces survival, 
proliferation, mitogenesis and permeability signals. These signals are transduced through a number 
of intracellular signalling pathways including: MAPK/ERK, PI3K, IP3/DAG and PLC-γ [41]. Specifically, 
activation of the mitogenic and proliferative pathways are what enable endothelial cells (ECs) to 
proliferate and migrate, thus forming new blood vessels. Consequence these pro-angiogenic 









Figure 1.2 The VEGFR and VEGF family members, their predominant tissue expressions sites and the 
biological activity they contribute towards. VEGF-A binds preferentially to VEGFR2 which is expressed near 



























































 Remodelling the ECM in Prelude to Endothelial Expansion 
Prior to the mass mitogenic onslaught that ensues pro-angiogenic stimulation, the ECM that 
summates the basement membrane of the activating vessel, and path toward the secreted pro-
angiogenic stimuli, must be remodelled to enable EC migration. Stimulation of endothelium with 
pro-angiogenic stimuli results, sequentially, in the detachment of supporting pericytes, loosening 
of EC junctions and increased EC permeability. In turn, this enables the extravasation of plasma 
proteins, i.e. fibrinogen and fibronectin, and proteases, specifically matrix metalloproteinases 
(MMPs) and A disintegrin and metalloproteinases (ADAMs), to remodel the ECM (Figure 1.3c) [42]. 
The combinatorial work of proteases and plasma proteins concludes in an angiogenic-competent 
matrix, permitting EC migration. Concomitant with this interplay, proteases release a slurry of 
cytokines and pro-angiogenic factors, previously sequestered in the ECM, exacerbating the 
mitogenic activity of the ECs and aiding in directional EC motility (Figure 1.3d) [43,44]. Key receptors 













Figure 1.3 Schematic of sprouting angiogenesis. Pro-angiogenic stimuli (pink spheres) induce a cascade of 
events instigating vascular expansion. Initial stimulation leads to the detachment of pericytes (grey). b) Tight 
junctions between endothelial cells loosen and the supporting basement membrane slackens. c) 
Subsequently, endothelium permeability is increased, resulting in the extravasation of proteases (turquoise) 
and plasma proteins (purple). d) Proteases degrade and remodel the ECM to enable endothelial cell 
proliferation and migration, whilst simultaneously release sequestered cytokines and pro-angiogenic factors 






















 Sprouting Angiogenesis 
The physical process of angiogenesis can occur via two mechanisms, SA and IA [45]. IA entails the 
division of a single blood vessel into two vessels, however is a rare and infrequently observed 
process, especially in comparison to SA [46]. During SA cells initially receive an aforementioned 
stimulus, such as hypoxia or inflammation, which triggers the synthesis of pro-angiogenic factors, 
such as VEGF; aside from VEGF stimulation, ECs possess other oxygen sensing molecules such as 
oxygen-sensitive NADPH oxidases, endothelial nitric oxide synthase (eNOS) and heme-oxygenases 
and hypoxia-inducible factor 1 (HIF-1α)  [47–49]. Hypoxia induced angiogenesis is primarily driven 
by HIF-1α. Under normoxic conditions, HIF-1α becomes hydroxylated and subsequently poly-
ubiquitinated by an enzyme family known as Prolyl Hydroxylases (PHDs). This leads to the 
recognition of the ubiquitinated HIF-1α by VHL E3 ubiquitin ligase complex, resulting in its 
degradation by proteasome 26S. However, in low oxygen conditions HIF-1α is unable to undergo 
hydroxylation by PHD and translocates to the nucleus where it forms a complex with HIF-1β [50,51]. 
This HIF-1αβ complex serves as a transcription factor for several pro-angiogenic factors, one of 
which is VEGF [52].  Following this, these pro-angiogenic factors are secreted into the extracellular 
environment in a bid to trigger angiogenesis. The secreted factors bind to their respective receptors 
on the surface of ECs; in the case of VEGF these receptors are VEGFR1 and VEGFR2 [34]. As 
previously mentioned, the binding of VEGF to its receptors VEGFR1/2 induces, sequentially, 
receptor dimerization, autophosphorylation and intracellular signalling via the MAPK/ERK signalling 
pathway, among others. The consequential MAPK/ERK signalling results in the upregulation of 
genes responsible for cell proliferation and migration, such as MMPs, and survival (Figure 1.4) 
[53,54].  In order to drive the expansion of a new blood vessel, a tip cell is selected through delta-
like ligand 4 (DLL4)/Notch-mediated lateral inhibition. Exposure of ECs to VEGF induces the 
expression of DLL4 on their surface. Binding of DLL4 to notch on neighbouring ECs triggers the notch 
signalling cascade. Sequentially, ligand engagement induces proteolytic cleavage of Notch 
intracellular domain (NICD) from the Notch extracellular domain (NECD), primarily by ADAM-17 
(TACE) and ultimately by γ-secretase [55]. Cleaved NCID is then able to translocate to the nucleus 
where it recognises and binds Recombination Signal Binding Protein for Immunoglobulin Kappa J 
Region (RBPJ) followed by recruitment of  transcriptional coactivator mastermind-like (MAML) [56]. 
This transcriptional complex (NCID-RBPJ-MAML) upregulates genes from the Hairy enhancer of split 
(HES) and Hes-related with YRPW motif families (HEY1), down regulating the expression of VEGFR-
2 as well as dampening pathways for migration and proliferation, rendering the fate of these ECs 
as stalk cells (Figure 1.5) [57–59]. In response to VEGF, tip cells guide the direction of the sprouting 
vessel, whilst stalk cells proliferate in response, physically elongating the sprouting vessel [60]. 




Genes coding for integrins are one of many to be upregulated via the MAPK/ERK signalling pathway 
in response to VEGFR1/2 activation. These cell surface proteins aid in migration through the 
formation of focal adhesions with the ECM, and intracellular signalling via Focal Adhesion Kinase 
(FAK) [61–63]. To emphasise, the angiogenic process is rigorous, each step being an essential pre-
requisite for the next in order for angiogenesis to occur successfully [64]. Given this, integrins 
provide a key role in facilitating the migration of ECs, and hence offer an exploitable potential in 
which to prevent angiogenesis and investigate the subsequent effects. Integrins are discussed detail 
in section 1.2.3. 
The ultimate stage in SA is the fusion and integration of the nascent vascular sprouts into the 
existing vascular system, achieved through a process called anastomosis [65]. Proximity of tip-cells 
leads to an accumulation of macrophages which orchestrate the interaction, and fusion, of two 
nascent vessels [66]. Consolidation of the newly integrated vessels is established through the 
formation of tight junctions comprised of VE-cadherin, resulting in vessel perfusion. Consequence 
perfusion, VEGF expression is reduced in response to the influx of oxygen and nutrients, shifting 
the phenotypic state of the vessel to quiescence and instigating maturation [67]. PDGFB and TGF-β 
are secreted by ECs triggering the recruitment and differentiation of mural cells to pericytes, 
enabling physical stabilisation of the newly fused vessel, and the synthesis of collagen (types IV, XV 
and XVIII) for basement formation [68]. Concomitantly, vessel permeability is reduced through the 
expression of Ang-1, enhancing pericyte-EC interaction and tightening EC-EC junctions, whilst 
protease activity is inhibited through expression of tissue inhibitors of MMPs (TIMPs) [69–71].  
To ensure anastomosis is successful and a functioning vascular system is formed, one final factor 
must be considered – vessel identification. Specifically, new vessels need to be identified as either 
artery or vein to permit directional perfusion concomitant with the current vascular system. The 
system involved in enabling such a feat is the Ephrin/Eph system, namely the receptors Ephrin-B2 
and EphB4 [72]. Several studies have highlighted the importance of these two molecules in 
successful angiogenesis, demonstrating perturbation of either to result in highly disorganised 
vasculature, no boundaries between arteries and veins, and consequently embryonic lethality by 
E11 [73–75]. One factor which contributes towards arterio-venous identity via Ephrin-B2 and EphB4 
are haemodynamic forces. Haemodynamic forces (arterial/venous blood flow) results in the 
expression of Ephrin-B2 in arterial ECs and EphB4 in venous ECs [76]. Aside these forces, the Notch 
signalling pathway has also been implicated in defining arterio-venous boundaries. Mutation in the 
gene encoding for Dll4 ligand proved embryonic lethal whilst resulting in vascular defects. 
Furthermore, mutations in a primary transcription factor for Notch signalling demonstrated arterio-
venous malformation and embryonic lethality [77]. These findings all suggest that the absence of 




either Ephrin-B2 and/or EphB4, be it directly or indirectly, manifests in arterio-venous malformation 















Figure 1.4 The VEGFR signalling pathway. Upon binding VEGF, VEGFR2 undergoes receptor dimerization and 
autophosphorylation. This subsequently leads to the upregulation of genes in multiple cellular pathway. 
Specifically, integrin upregulation via ERK and p38 for cell migration and proliferation and cell survivability 













Figure 1.5 Notch-1/Dll4 Mediated tip cell selection. ECs exposed to VEGF express DLL4. DLL4 recognises and 
binds to notch on neighbouring ECs, triggering notch signalling. Activation of the notch signalling cascade 
inhibits the expression of VEGFR2, through the release of the Notch Intracellular Signalling Domain (NICD). 
NCID is then able to translocate to the nucleus where it forms a transcriptional complex (NCID-RBPJ-MAML). 
This complex upregulates HES/HEY1 genes which consequently downregulate VEGFR-2 expression, 
preventing the binding and signal transduction of VEGF (fating these cells as stalk cells), whilst also dampening 
































 Intussusceptive Angiogenesis 
IA is a much rarer form of angiogenesis but occurs where dynamic remodelling of vasculature is 
required, such as the primitive vascular plexus or the mammary gland during late pregnancy [79]. 
IA is described as the process by which pre-existing vessels undergo internal division to increase the 
number of vessels within in given space; an increase in vascular density [80]. This type of blood 
vessel formation was first recorded in the 1980’s by Caduff et al. who detected with scanning 
electron microscopy multiple tiny holes within vascular corrosion casts of rat pulmonary vessels 
[81]. It was later postulated, and confirmed, that these tiny holes were in fact the remnants of tissue 
posts, intra-luminal pillars which connected opposing sides of the vascular lumen which had been 
digested away during the vascular corrosion castings [82]. The process of IA has now been much 
further defined. The formation of the tissue posts, the fundamental aspect to the whole process, 
takes place via a regimented four step process: Phase I – Two opposing sides of a vessels lumen 
invaginate and make contact, Phase II – Inter-endothelial cell junctions are reorganised and 
perforation of the bilayer occurs, Phase III – An interstitial pillar core is formed and invaded by 
pericytes and myofibroblasts which then laydown collagen fibrils, Phase IV – The pillar increases in 
girth (Figure 1.6) [46].  
The described process of pillar formation is a regimented process much like the steps involved in 
SA. However, the coordination, placement and sequential fusing of these pillars can result in varying 
morphological and functional outcomes. The process of IA can achieve two phenotypically distinct 
form of vessel expansion, namely, Intussusceptive Microvascular Growth (IMG) and Intussusceptive 
Arborisation (IAR) – IAR is followed by Intussusceptive Branching Remodelling (IBR) as a means of 
refinement (Figure 1.7) [83]. IAR is responsible for remodelling vasculature into the classical 
vascular tree pattern. This is achieved by several vertical pillars forming and then fusing in a linear 
fashion, creating new vessels, followed by horizontal pillar formation and fusion to segregate the 
new vessels from the capillary plexus (Figure 1.7a-c) [84]. On from IAR, IBR entails the refinement 
of vessels, adjusting for the hemodynamic requisites that exists throughout the vascular system. 
IBR is achieved by means of augmenting vessel geometry and, in some cases, vascular pruning to 
optimize perfusion and establish vessel hierarchy. This is accomplished through a series of 
transluminal pillars at points of branching (bifurcation points), culminating in vessel elongation or 
enlargement (Figure 1.7d-f) [85]. Lastly, IMG employs a sheer amplification in vessel density and is 
concomitant with capillary growth. Pillars arise sporadically throughout vascular the vascular plexus 
increasing its complexity, and thus surface area, permitting exchange of oxygen, carbon dioxide, 
nutrients and removal of metabolic waste (Figure 1.7a and g-i) [86].  





Figure 1.6 Schematic illustrating the four consecutive steps involved in intussusceptive pillar formation.(a-
b) Opposing sides of the vascular lumen invaginate and encroach towards each other. (c) Contact is 
established, and perforation of the bilayer is preceded by inter-endothelial junctions having been 
reorganised. (d) The transluminal pillar is fully formed, pericytes and myofibroblasts are recruited to 
complete the structure by secreting collagen fibrils to amplify pillar girth (adapted from Djonov et al., 2003 
[46]). 
 
Figure 1.7 Phases of Intussusceptive Angiogenesis. The Primitive Capillary Plexus is a rudimentary 
vasculature through which vascular remodelling occurs. This simple tissue undergoes preliminary expansion 
via the insertion of pillars (black arrows) followed by either IMG or IAR; the latter proceeded by IBR (adapted 
from Makanya et al., 2009 [79]) 
 




 Pathological Angiogenesis 
As is common with many biological processes, it is no surprise that angiogenesis can be associated 
with the stigma of disease. Albeit a fundamental process, there exists a harmonic interplay between 
pro- and anti-angiogenic signals within the body. Given this, it is easy to imagine that disruption of 
this balance could result in the development and progression of disease – a tip in these balances 
being referred to as the angiogenic switch, on being pro-angiogenic and off being anti-angiogenic. 
Malfunction in the way of angiogenesis has been deemed the cause, or contributor, of a wide range 
of diseases. In the instance of an insufficient angiogenic response, diseases and ailments such as 
ischaemic heart disease, stroke, pre-eclampsia and delayed wound healing can occur [87–89]. 
Conversely, other diseases including cancer, psoriasis, retinopathies and diabetic nephropathy all 
derive from an excessive state of angiogenesis [90–93]. As the realms of disease besides cancer are 
beyond relevance for this thesis, this section shall focus on tumour growth and progression, and 
the role angiogenesis plays.  
Tumorigenesis stems from the uncontrolled growth and proliferation of a cell, driven largely by 
mutation, and subsequent augmentation, of proto-oncogenes to oncogenes. Although essential in 
the human body for normal development, the proteins encoded for by proto-oncogenes, entailing 
processes such as cell proliferation, differentiation and apoptosis, highlights their potential 
volatility in terms of cancer formation and progression. However, in order to grow and metastasise 
around the body tumours require an adequate blood supply, which they obtain through hijacking 
angiogenesis. Fortunately, the human body favours an anti-angiogenic state, boding against tumour 
progression, and in most cases upregulates the expression of anti-angiogenic molecules to negate 
pro-angiogenic molecules being released by a tumour. Given this favoured state most tumours are 
gated to a size of 1mm or less in diameter, however, this innate mechanism is not fool-proof [94]. 
Upon achieving this dimension these avascular neoplasms undergo an angiogenic “switch” enabling 
them to recruit a blood supply to continue growth as well as opening the potential of metastatic 
spread; this switch is recognised as a hallmark of cancer [95]. It stems from this fundamentality that 
tumour angiogenesis is a highly relevant therapeutic target and hence a multitude of researchers 









In 1945, studies by Algire et al. alluded to the capacity of tumours to elicit the growth of new blood 
vessels to sustain and propagate tumour growth, overcoming the body’s favoured anti-angiogenic 
state [96]. It was these early studies which set into motion the endeavour to target angiogenesis as 
a form of anti-tumorigenic therapy, justly pursued by Folkman et al. in 1971 [97]. Over the following 
years, a magnitude of work from this group yielded numerous purified and characterised pro- and 
anti-angiogenic factors, flooding the field with an array of targets, the modulation of which might 
serve as a means of anti-tumorigenic therapy [98]. As a consequence of these identified factors, 
and with prior research having demonstrated its fundamental role in angiogenesis, VEGF and its 
signalling pathway were swiftly set upon. In 2004 the first anti-angiogenic therapy was FDA 
approved, bevacizumab (commercial name Avastin); a monoclonal antibody against VEGF [99]. 
Initially used to treat colorectal cancer, administration of this antibody in combination with 
chemotherapy was shown to significantly improve patient survival [100]. Since the deployment of 
bevacizumab, many other anti-angiogenic drugs have been engineered including a range of 
Tyrosine Kinase Inhibitors (TKIs)  and other monoclonal antibodies against a range of pro-angiogenic 
pathways, concomitant with the investigative utilisation of endogenous anti-angiogenics [101–
103].  
There exists a broad range of trials and tribulations in the field of anti-angiogenic drugs, with 
disappointing results ranging from failure at the start of clinical trials to cancer developing 
resistance to commissioned drugs [104–106]. Arguments are had that pre-clinical data affords some 
of these failures due to, in part, the tumours used during these studies being grown subcutaneously, 
as opposed to orthotopically, taking away physiological relevance [26]. Furthermore, some studies 
have added to this disarray in drug efficacy by administering inappropriate drug doses; those that 
are not safely achievable in humans as opposed to animal models [107]. A prime example of a drug 
boasting huge potential preclinically, bolstered by efficacy issues discussed, was sunitinib. Sunitinib 
is a TKI designed to target and inhibit primarily VEGF receptors, as well as Platelet-Derived Growth 
Factor Receptors (PDGFRs) and Fibroblast Growth Factor Receptors (FGFRs) [108]. Work by Abrams 
et al. produced compelling evidence for sunitinib as an effective clinical treatment for BC [109]. As 
a consequence of the promising pre-clinical data, four randomised phase III clinical trials took place. 
However, all four trials failed with all showing no benefit in progression free survival or overall 
survival [110]. Despite shortfalls, many FDA approved antiangiogenics are currently in use. These 
drugs range from antibody against VEGF (i.e. Ranibizumab), antibodies against VEGFR-2 (i.e. 
Ramucirumab), TKIs targeting downstream VEGF signalling (i.e. Sorafenib – multi-kinase targets, 
also inhibits downstream signalling from PDGFR and Raf [111]), soluble decoy receptors (i.e. 
Aflibercept), and antibodies against other growth factors known to stimulate angiogenesis (i.e. 




Cetuximab against EGFR) with antibodies against FGF2 showing promise with no clinical trials to 
date – reviewed in [112,113]. 
Given the points discussed throughout this section, our lab harnesses the Cre/LoxP system 
(discussed in section 3) to study the anti-tumorigenic effects of deleting key players in the 
angiogenic cascade as a means of targeted therapy, specifically endothelial integrin-α5, integrin-β 
and neuropilin-1 [114]. Moreover, when utilising this system, we employ the use of a mouse breast 
carcinoma model derived from mouse mammary tumour virus-polyoma middle tumour-antigen 
(MMTV-PyMT) mice, acknowledging the use of the appropriate model with the appropriate disease; 
referencing the lack in physiological relevance some studies practiced. 
A closing point to briefly touch upon is the inherent “oddity” of tumour vasculature. Hitherto I have 
discussed tumour angiogenesis as if it embodies that of normal angiogenesis; a sequential series of 
regimented, un-expendable, steps. This is not generally the case. Vascularisation of a tumour is 
achieved through the overexpression of pro-angiogenic factors in an uncontrolled manner, 
independent of the sequential cascade required to form functional, stable, vessels [115]. 
Consequently, vasculature within a tumour resembles a chaotic labyrinth of immature vessels, 
comprised of varying diameter and shape, which exhibit no vessel hierarchy (Figure 1.8) [116,117]. 
These facts in turn relate to functionality; vessels are hyperpermeable and falter in their ability to 
perform exchange of nutrients and metabolic waste, a knock-on effect being the delivery of anti-
tumorigenic drugs [118,119]. As such, research groups are now commencing in studies that seek to 
”normalise” the tumour vasculature in a bid to enhance the delivery and retention of anti-



























Figure 1.8 Basic schematic of angiogenesis resulting in either normal or abnormal (tumour) vasculature. 
Angiogenesis can follow two suits, normal or tumour. Normal angiogenesis generates functional, stable 
vessels which exhibit vessel hierarchy. Tumour angiogenesis is chaotic lacking all the former traits of normal 





























Integrins play a key, non-exclusive, role in the modulation of angiogenesis in the body, through the 
interaction of ECs with their surroundings. These cell surface molecules are transmembrane, 
heterodimeric, glycoproteins comprised of non-covalently bonded α and β subunits [121]. To date, 
it is known 24 unique integrins exist comprised of 18 α and 8 β subunits [122]. The 
heterodimerisation of these subunits can be diverse, such that one α subunit can bind several 
different β subunits and vice versa (Figure 1.9) [123]. The functionality of these glycoproteins exists 
through their ability to bind ligands, either those on the surface of other cells or directly to proteins 
found within the ECM, such as fibronectin, collagen and laminin (Figure 1.10) [28]. The ligands to 
which specific integrins bind is an area governed by affinities. Hence, although integrins have 
predominant ligands to which they bind, they also possess low affinities for a wide range of other 
ligands ; hitherto perpetuating the ongoing debate as to whether integrins can “compensate” each 
other’s function due to this overlap in viable ligands [124,125]. 
Integrins modulate cellular homeostasis through their ability to utilise bidirectional signalling; 
namely “outside-in” and “inside-out” signalling. Outside-in signalling is instigated when an integrin 
encounters, and binds, its extracellular ligand (Figure 1.10). Binding of an integrin to its ligand 
triggers homotypic clustering, forming organised aggregations of ligand bound integrins termed 
focal adhesion complexes [126]. These complexes in turn initiate a cascade of protein 
phosphorylation events resulting in the polymerisation of new actin filaments, anchoring the cell 
through the actin cytoskeleton, via the ligand bound integrin, to the ECM thus enabling cell 
adhesion and migration (Figure 1.9) [127]. Outside-in signalling assumes the integrin heterodimer 
is in a high affinity state, enabling sufficient binding to its ligand; the extracellular domain is in a 
straight, high-affinity, conformation as opposed to a bent, low-affinity, conformation (Figure 1.10) 
[128,129]. Inside-out signalling takes place from the former, bent, conformation and aims to 
achieve a straight conformation to permit outside-in signalling. Talin, a cytoskeletal linker protein, 
undergoes a conformational change in response to a G-protein coupled receptor (GPCR) signalling 
cascade, independent of integrins, enabling it to bind the β-cytoplasmic tail of an integrin 
heterodimer [130–133]. Binding of talin induces a conformational change in both integrin 
cytoplasmic tails, in turn inducing a conformational change in the extracellular domain to a high-
affinity state, allowing outside-in signalling to ensue [134,135].  
 
 




The heterodimers of interest to discuss are those formed by the integrin subunits α5 and β3. These 
subunits were temporally removed utilising the Cre/LoxP system as a tool throughout this thesis to 
study the effects of impeding angiogenesis on the life cycle of the murine mammary gland. Namely, 
the heterodimers comprised of these subunits are: α5β1, αVβ3 and αIIbβ3 (Figure 1.9), receptors 
for fibronectin, vitronectin and fibrinogen respectively [136–138]. In terms of spatial situation, 
α5β1 and αVβ3 integrins are expressed on ECs, whereas expression of αIIbβ3 integrin is restricted 
to cells of the megakaryocyte lineage, such as platelets, with functional roles in aggregation and 
adhesion [139]. Previous studies have demonstrated that integrins α5 and β3 play roles in 
angiogenesis. As early as 1994, Brooks et al. noted that during developmental angiogenesis in 
chicks, the chorioallantoic membrane had high expression of integrin αVβ3, and that application of 
a monoclonal antibody (mAb) against this integrin prevented angiogenesis; adducing fundamental 
evidence for β3 integrin in angiogenesis [140]. Ablation of αV- or α5-integrin in mice showed no 
lethality nor defects, with knockout mice being both viable and fertile. However, simultaneous 
ablation of both αV and α5 proved to be embryonic lethal, with an extremely low chance of survival 
(<4% survive). The majority of mice missing both subunit died at E14.5 (embryonic day), around the 
time branchial arch artery remodelling takes place [141]. This preliminary evidence demonstrated 
that α5 indeed plays a role in angiogenesis, but also alludes to the complex interplay between 
integrins – Figure 1.9 highlights the broad range of heterodimers associated with αV. Given the 
fundamentality of these integrins in permitting angiogenesis, integrin-α5 and integrin-β3 can be 
seen as attractive anti-angiogenic targets, especially as their heterodimeric pairing is far more 





















Figure 1.9 An illustration of the known pairing patterns of α and β subunits, and the potential integrin 
heterodimers that can form. The rings in red highlight the heterodimers affected by the genetic manipulation 
of either α5 or β3. The purple rings highlight the broad range of heterodimers affected upon manipulation of 





Figure 1.10 A schematic diagram of the structure and function of an integrin heterodimer. Binding of the 
integrin with the ECM results in the interaction of the N-terminal domain with a variety of intracellular 
molecules. Two, structural, cellular processes modulated by cell-ECM interactions, achieved through 
integrins, are the formation of focal adhesions, and intracellular signalling via FAK; signalling via FAK results 
in the expression of genes involved in cell migration. The ECM (yellow) represents a range of potential ligands 
(adapted from Millard et al., 2011 and Kechagia et al., 2019 [143,144]). 
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Initially identified in the developing Xenopus as a semaphorin co-receptor for neuron development 
and guidance in the late 1990s, subsequent studies identified neuropilin-1 to have a high affinity 
for several VEGF isoform, specifically VEGF-A, thus mediating angiogenesis by acting as a co-
receptor for VEGFR-2 [145–147]. Confirmation of neuropilin-1’s involvement in angiogenesis was 
observed in both overexpression and knockout experiments where vascular formation was 
augmented or ablated, respectively, and resulted in major cardiovascular defects in both cases  
[148,149]. Furthermore, it has been documented that neuropilin-1 over-expression correlates with 
tumour angiogenesis and subsequently tumour progression, further demonstrating the role of 
neuropilin-1 in angiogenesis whilst highlighting its potential as therapeutic target [150].  
Neuropilin-1 is transmembrane glycoprotein comprised of a large extracellular N-terminal domain, 
a transmembrane domain and a small cytoplasmic domain (Figure 1.11) [151]. The N-terminal 
domain is comprised of two semaphorin binding CUB (for complement C1r/C1s, Uegf, Bmp1 – a1 
and a2) domains, two VEGF binding domains (FV/VIII – b1 and b2) and a single MAM (meprin, A5 
antigen, receptor tyrosine phosphatase μ – c) domain [152]. The cytoplasmic domain of neuropilin-
1 contains a PDZ-domain binding motif (SEA) which associates with neuropilin-interacting protein-
1 (NIP1), synectin or RGS-GAIP-interacting protein GIPC, important for the internalisation of 
neuropilin-1 [153]. Despite this, mice expressing C-terminally truncated neuropilin-1 are normal 
with no angiogenic defects [154]. In terms of VEGF signalling, neuropilin-1 recognises and binds 
VEGF-A, moves towards VEGFR-2 and forms a complex. The formation of this complex augments 
VEGFR-2 activity and downstream signalling, described in section 1.2.2.3 [155]. 
Of note, a second member of the neuropilin family exists: neuropilin-2. Comprised of a same 
domain composition, two semaphorin binding CUB domains, two VEGF binding FV/VIII domains a 
MAM domain, and TM and a SEA cytoplasmic domain, neuropilin-1 and -2 share an overall amino 
acid homology of 44% [156]. Whilst studies have shown neuropilin-2 to play a pro-angiogenic role, 
knockout studies revealed neuropilin-2 null animals are viable showing only a significant reduction 
in small lymphatic vessels and capillaries during development [157,158] 
 
 






Figure 1.11 Structural diagram of neuropilin-1. Neuropilin-1 contains an extracellular domain comprised of 
two CUB semaphorin binding domains (a1 and a2), two VEGF binding domains (FV/VIII – b1 and b2) and a 
MAM domain, a single transmembrane domain (TM) and a cytoplasmic SEA domain.  Adapted from Pellet-
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1.3 The murine mammary gland 
The mammary gland is a dynamic organ composed of a variety of tissues which collectively serve 
the sole purpose of supplying offspring with milk, a substance providing nutritional and 
immunological benefits [159]. In order to achieve this feat, the mammary gland must undergo 
morphological and physiological changes, driven both hormonally and non-hormonally, continually 
throughout the life of the animal; involving processes such as cellular proliferation, differentiation 
and apoptosis. [160]. This perpetual cycle of the mammary gland therefore requires a fluctuating 
demand on oxygen, nutrients and other biological molecules, all of which are supplied via the 
vasculature. As a consequence, angiogenesis in the mammary gland must mirror this dynamic 
behaviour, increasing and decreasing vascular density as required, and hence plays a vital role in 
permitting the functions of the mammary gland [161].  
1.3.1 Embryonic development 
As previously mentioned, the mammary gland is a complex and dynamic organ which serves a vital 
purpose when raising offspring through the production of milk, providing nutritional and 
immunological benefits. The development of the mammary gland is broken down into three main 
stages: embryonic, pubertal and reproductive. Utilising mice (Mus musculus) as a model organism 
to study these stages of development has enabled researchers to gain great insight into the human 
breast, with regards to both normal and pathological development.  
The murine mammary gland begins development at around E10.5 with the formation of milk lines 
running bilaterally from anterior, forelimb bud, to posterior, hindlimb bud, on the ventral surface 
of the embryo (Figure 1.12a). These milk lines consist of multi-layered ectoderm that by E11.5 have 
resolved into compact spheroids of mammary epithelium referred to as placodes (Figure 1.12b). 
From here, the underlying mammary mesenchyme is what holds the key to further development of 
the mammary epithelium. Key inductive signals, to be discussed in more detail later, released from 
this mesenchyme propagate the differentiation of the mammary epithelium, driving its embryonic 
growth.  
A variety of evidence exists which demonstrates mesenchyme tissue, not only mammary derived, 
can influence, drive and specify mammary epithelium differentiation. Work by Cunha et al (1995) 
provided grounding evidence for the ability of mammary mesenchyme to induce functional 
mammary differentiation in both mammary and non-mammary epithelium [162]. Skin epithelium 
harvested from either the mid-ventral or dorsal of E13 mice or rats was co-cultured with mouse 
mammary mesenchyme via renal capsule grafting. Histological analysis of the tissue revealed that 
hair bearing keratinised skin had formed, combined with underlying ducts reminiscent of that 




ductal epithelium found within the mammary gland. Furthermore, addition of an adult pituitary 
gland to the mice hosting these combination engraftments triggered lactogenesis. In turn, this led 
to the expression of casein, a protein common in milk, detected by immunohistochemistry, as well 
as the detection of markers indicative of mammary epithelium. Interesting observations were also 
made when performing the same experiment in reverse. Mammary epithelium associated with 
salivary mesenchyme, though renal capsule grafting, resulted in the mammary epithelium 
morphologically resembling that of a salivary gland [163]. All in all, besides resounding evidence for 
the role of mesenchyme in defining the differentiation pattern of the epithelium, it also bodes true 
in the opposite direction. The mammary epithelium influences the mammary mesenchyme’s 
differentiation, such that by E14 there becomes two clear distinct mesenchymal tissue types: the 
dense fibroblastic mesenchyme, closely associated with the mammary epithelium, and the fat pad 
mesenchyme [164]. 
To backtrack, the previously alluded inductive signal which enables the resolution of the milk line 
into placodes at E11.5 is of Wingless-related integration (Wnt) origin. To date, it is not known which 
Wnt is responsible for initiating this stage of mammogenesis but studies exist showing 
overexpression of Dickkopf (DKK1), a Wnt inhibitor, blocks entirely the formation of placodes 
signifying Wnt signals are fundamental to this process [165].  
Moreover, from E11.5 to E12.5 the epithelium comprising the placode invaginates to form a 
compact sub-surface bulb (bud) within the underlying dense mesenchyme (Figure 1.12c) – this is 
when the mammary mesenchyme differentiates into the two distinct types mentioned previously 
[166]. In female embryos, the mammary epithelium remains predominantly quiescent until E16.5, 
besides allometric growth, at which point it begins to proliferate down through the mesenchyme 
until it reaches the dense fat pad (Figure 1.12d-e). Upon reaching the fat pad, the epithelium 
undergoes branching ductal morphogenesis in a dichotomous fashion (Figure 1.12f) [167]. 
Concomitant with this, epidermal cells situated above the bud begins to differentiate to form the 
nipple; hair follicles are suppressed, keratinocytes form a nipple sheath and the epidermis thickens 
[168]. Interestingly, the presence of androgens, and the subsequent lack in their receptors on male 
mammary mesenchyme, results in the termination of the mammary primordium in male embryos. 
Contrastingly, in female embryos the presence of androgen receptors on the mammary 
mesenchyme is what induces the differentiation of the tissue in the presence of androgens [169]. 
Signals which drive bud formation between E11.5 – 12.5 remain elusive and to date require further 
study. However, through E12.5 to E15 it has been shown that TOPGAL (TCF Optimal Promoter-beta-
GALactosidase), a Wnt signalling reporter, is expressed along with many other Wnt genes, and that 
blocking Wnt signalling abolishes bud formation [165,170]. Furthermore, absence of Fibroblast 




Growth Factor Receptor 2-IIIb (FGFR-2b) or its ligand, Fibroblast Growth Factor-10 (FGF-10) during 
embryonic development has been shown to prevent placode formation. Likewise, FGFR-1 and -2 
























Figure 1.12 Embryonic milestones in the development of the mouse mammary gland. a) E10.5 – Formation 
of a pair of bilateral milk lines comprised of multi-layered ectoderm positioned on the ventral surface of the 
embryo running anterior to posterior situated from forelimb bud to hindlimb bud respectively. b) E11.5 – 
Milk line is resolved into 5 symmetrically located pairs of ‘placodes’. c) E12.5 – Placodes invaginate into the 
underlying mesenchyme and the mesenchyme undergoes differentiation into fibroblastic mesenchyme and 
fat pad mesenchyme. d) E14.5 – Mammary epithelium undergoes a small amount of proliferation. e) E16.5 – 
Mammary epithelium undergoes rapid proliferation. Cells descend as a stalk down through the fibroblastic 
mesenchyme into the fat pad precursor mesenchyme. f) E18.5 – Epithelial stalk reaches the fat pad and 
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1.3.2 Pubertal development 
Upon birth and up until puberty (4 weeks of age) the mammary gland remains quiescent besides 
allometric growth to maintain its size in proportion to the overall size of the animal. When puberty 
begins rapid and expansive proliferation of the mammary epithelium is required. This huge 
expansion is orchestrated by Terminal End Buds (TEBs), club shaped structures located at the ends 
of growing epithelium (Figure 1.13a and f). Cap cells, situated at the leading edge of TEBs, are highly 
proliferative and drive the elongation and penetration of the ducts into the fat pad. The cap cells 
that trail behind the proliferative leading edge differentiate into myoepithelial cells which go on to 
form the outer layer surrounding the luminal epithelial cells (Figure 1.13h) [173]. To achieve the 
tree like structure often observed within the mammary gland, lateral branching of off the primary 
ducts occurs to fill around 60% of the available fat pad; the 40% of space remaining is for expansion 
triggered under the influence of pregnancy hormones (Figure 1.13c-f) [174]. At 12 weeks of age the 
gland is mature and will exhibit transient changes in morphology during the estrus cycle; these 
changes are not permanent and mirror, on a small scale, what will occur under the influence of 
pregnancy hormones [175].  
Despite transient epithelial changes during estrus, hormones play a vital role in epithelial 
development during puberty. Mice that have undergone ovariectomy or hypophysectomy exhibit 
a lack of TEB formation and consequently a lack of epithelial expansion. However, exogenous 
estrogen has been shown to rescue epithelial retardation in ovariectomised mice, but cannot 
rescue the same phenotype in hypophysectomised mice [176]. Interestingly, addition of Growth 
Hormone (GH) alongside estrogen to rats that have undergone both ovariectomy and 
hypophysectomy was sufficient to rescue this phenotype, demonstrating both are necessary to 
permit pubertal development [177]. Prolactin (Prl) has also been shown to contribute towards 
epithelial development during puberty. Work by Brisken et al revealed that Prl null mice exhibit a 
normal ductal tree by 6 weeks of age however present with a severe level of infertility come 
pregnancy [178]. Interestingly, studies utilising Prl receptor heterozygous mice (Prl-R+/-) mice 
revealed a smaller, less dense, ductal tree with a more severe phenotype observed in Prl receptor 
knockout mice (Prl-R-/-). Transplantation of Prl-/- epithelium into wildtype fat pads rescued this 
phenotype, highlighting the importance of Prl-R in pubertal development, whilst the former study 
demonstrated the lack of Prl to severely impede pregnancy and not puberty [179,180]. Of note, 
mice lacking progesterone receptor, -A or -B (PgR-A and PgR-B), exhibit normal mammary epithelial 
development both embryonically and during puberty however they are unable to undergo side-
branching and lobuloalveolar development during pregnancy (section 1.3.3) [181]. TGF-β is another 
key molecule in the branching of the epithelium during puberty. Absence of TGF-β demonstrated 




excessive epithelial outgrowth whilst overexpression experiments showed the opposite – epithelial 
outgrowth during puberty was severely impeded, however alveologenesis was unaffected [182–
184]. Downstream of estrogen signalling, the EGF pathway plays a pivotal paracrine signalling role. 
Produced by mammary epithelial cells in response to estrogen, Amphiregulin (AREG), a ligand for 
EGFR, mediates local hormone signals to neighbouring epithelial cells and the surrounding stroma 
to drive epithelial growth [185]. AREG knockout mice exhibit impaired ductal outgrowth during 
puberty, phenotypically mirroring that of ER knockout mice – exogenous AREG was shown to rescue 
the ER knockout phenotype, confirming AREG as a downstream mediator [186]. Of note, AREG is 
anchored to the expressing cells membrane post estrogen stimulation. As such, AREG requires 
cleavage by TACE to enable its activity [187]. FGFs -2, -3 and -10 have all been implicated as vital 
for pubertal branching morphogenesis. With only hypothetical evidence, FGF-10 null mice die 
shortly after birth showing severe defects in pulmonary branching morphogenesis, suggesting a 
morphogenic role in mammary branching morphogenesis [188]. Overexpression of FGF-3 revealed 
stunted ductal growth [189]. Lastly, FGFR-2 has been cleverly demonstrated, through use of genetic 
mosaic analysis, as essential for TEB proliferation and invasion; FGFR-2 heterozygous cells 
ultimately outcompeted FGFR-2 null cells throughout pubertal development [190]. 
 
1.3.3 Pregnancy and Lactation  
The next hurdle for the mammary gland arises during pregnancy. On average, the female mouse 
gives birth to five pups, all of which require nourishment through milk. To achieve this feat, the 
adult mammary gland must undergo two tremendous transformations in the ways of maturation 
and alveologenesis [191]. These events are driven hormonally, specifically by progesterone and 
prolactin (PL) [192]. Differing to pubertal development, where estrogen is the predominant driver 
of ductal morphogenesis, during pregnancy the ovarian steroidal hormone progesterone drives 
epithelial morphogenesis by means of side branch development. Early on in pregnancy, a surge of 
progesterone stimulates the epithelial branches generated during puberty to undergo epithelial 
expansion perpendicular to the main branch – side branching. Binding of progesterone to its 
receptor, progesterone receptor (PgR), mobilises non-canonical Wnt signalling, specifically Wnt-4 
paracrine signalling, instructing epithelial cells to proliferate. The absence of either Wnt-4 or PgR 
has been shown to severely impact gland development during pregnancy. Studies in mice lacking 
progesterone receptor (PgR-/-) reveal only a simple epithelial tree forms, with the presence of 
progesterone availing to no ductal expansion, or alveologenesis, in gestation [193]. Furthermore, 
deletion of Wnt-4 has also been shown to have no effect on rudimentary branching morphogenesis 
during puberty, however exhibits the same phenotype as PgR-/- during pregnancy; failure to 




undergo any form or expansion or differentiation [194,195]. Differing to pubertal expansion, these 
shorter side branches finalise their growth by undergoing alveologenesis; the formation of bud-like 
structures referred to as alveoli (lobuloalveolar) which encompass the side-branches. 
Alveologenesis requires a vital, synergistic, crosstalk between progesterone and PL shown to be 
heavily controlled through RANKL signalling [196,197]. Evidence for this crosstalk being paramount 
is seen upon the deletion of the prolactin receptor (PLR), where studies have shown its absence to 
impede progesterone driven epithelial expansion, as well as abolish alveologenesis [179]. Upon 
entering the secretory phase of gestation, alveoli undergo maturation, through differentiation, 
giving rise to secretory cells able to produce milk, and a contractile mesh of surrounding myo-
epithelial cells capable of exerting mechanical force to move the milk from the secretory cells into 




Post-lactation the mammary gland undergoes a process called involution. This process entails the 
remodelling of the ductal tree to that of a pre-pregnancy state; removal of alveolar buds, reduction 
in side-branches and regression of pregnancy derived vasculature. Involution has been shown by a 
multitude of studies, such as forced weaning and teat sealing, to be initiated via weaning; a lack of 
demand on the milk available [199,200]. Interestingly, and in support of the notion that weaning 
plays an anti-involution role, animals overexpressing T-antigen (promoting early apoptosis) exhibit 
early involution, however suckling throughout induction of T-antigen maintains the presence of the 
alveolar buds [201]. Moreover, involution is a two-stage process. The first stage is purely apoptotic, 
is primarily driven by the accumulation of milk in the alveolar buds and is reversible. An 
accumulation in milk results in the secretion of Leukaemia Inhibitory Factor (LIF), Transforming 
Growth Factor Beta3 (TGFβ3) and Death Receptor (DR) ligands within 12 hours of weaning. These 
three factors stimulate apoptosis of the epithelial cells for up to 36 hours after their secretion via 
both the DR pathway and the JAK/STAT pathway – stage one is reversible if suckling resumes 
between 0 – 48 hours post-wean [202,203]. Stage two of involution occurs 72 – 144 hours post-
wean and is not reversible at any point. The predominant difference between both stages, besides 
stage one being reversible, is that no gross change in ductal architecture takes place during stage 
one. During stage two, however, the cells comprising the alveolar buds begin to collapse as their 
supporting basement membrane (BM) and ECM is degraded; phagocytosis removes the dead 
epithelial cells whilst adipocytes colonise the space left behind. The key propagators of this stage 




are MMPs. MMPs become activated during stage one as a knock-on effect from the activation of 
serine proteases, which were activated by the induction of apoptosis, however, the MMPs remain 
inactive due to the expression of their suppressive counter parts TIMPs. It is after this the mammary 
gland has come full cycle and can now undergo the estrus and the pregnancy cycles again (Figure 
1.13g). Although not explicitly discussed, it is noteworthy to mention that MMPs also contribute to 






















Figure 1.13 Diagram illustrating the post-embryonic development of the murine mammary gland. a) At 
birth, the epithelium is unbranched and contains mitotically inactive TEBs. b-c) At 4 weeks old the TEBs drive 
the expansion of the epithelium through the fat pad, accompanied by laterally branching, to fill 60% of the 
fat pad. At 12 weeks old the gland is fully mature and can undergo changes influenced by estrus and 
pregnancy. d) During estrus the epithelium experiences mild morphological changes such as those that occur 
during pregnancy. e) During pregnancy, a surge in hormones such as progesterone and prolactin stimulate 
further branching and alveologenesis. f) The alveolar buds formed during alveologenesis begin to secrete milk 
and swell, increasing the total volume of the mammary gland. g) The mammary gland undergoes involution 
post weaning and reverts to its pre-pregnancy state. h) Schematic of a TEB illustrating the cell types present 















1.3.5 Mammary gland vasculature 
As alluded to, the mammary gland is a dynamic organ undergoing waves of epithelial expansion 
throughout puberty, estrus and pregnancy, the latter followed by involution; the vast undoing of 
gestational expansion. Concomitant with this transient behaviour, angiogenesis ensues to supply 
the expanding, ultimately lactating, epithelium with vital resources. Being that it is rare that organs 
exhibit angiogenesis outside of embryonic development, it is striking to note that during pregnancy 
the mammary gland utilises both forms of angiogenesis, SA and IA, to meet the increased 
requirement for oxygen and nutrients during the prolific expansion of the epithelium and during 
lactation. Vascular corrosion casts of the mouse mammary gland throughout the pregnancy cycle 
were the key to elucidating this dual angiogenic modality. During the first 14 days of gestation casts 
revealed the presence of capillary sprouts, with the final 7 days shifting from SA to IA through the 
emergence of capillary pillars (discussed in section 1.2.2.3.2) and a decline in sprouts [161]. The 
induction and signalling involved in triggering, and propagating, angiogenesis in the mammary 
gland is presumably identical to that previously described. Post-lactation the process of involution 
occurs, as previously described, concomitant with remodelling of the ductal tree. Hand in hand, 
with the regression of the ductal tree follows the revision of the vasculature which enabled the 
expansion of the epithelium initially. The process of how the vasculature undergoes regression is 
sparsely understood with only visual data, corrosion casts, illustrating the stages [25]. Regardless, 
it is apparent from these data that the vasculature responds to the decline in epithelium, and hence 
a decline in demand for oxygen and nutrients, following suit by reverting to its pre-pregnancy state.  
1.3.6 Breast Cancer 
In 2018 the World Health Organisation (WHO) deemed BC to be the second most common cancer 
worldwide (lung being the most), with BC being the most prevalent cancer in the UK (Cancer 
research UK – CRUK) [206,207]. Incidence of female BC in the UK has increased by 23% between 
1993 to 2017, with a forecast increase of 2% between 2014 to 2034. These increases in BC cases 
coincide with the most common risk factor associated with BC, age. Since 2010, the UK population 
has risen from 63.4million to 67.5million in 2019, with a predicted increase to 70.4million by 2030. 
In conjunction, the median age rose from 39.5 to 40.1, with 2030 showing a median age of 42.4 
[208]. Given these figures cumulatively take place over a period of only 20 years, it is more than 
apparent the UK population is not only growing, but ageing. In a non-mutually exclusive manner, 
an increasing prevalence of BC and aging population both infer costs, socially and economically. In 
addition, although age is the most common factor associated with BC development, through means 
discussed below, environmental and genetic factors are also of importance, and in some cases a 
root cause.  




At first glance, ageing would seem to be the pre-dominant factor with regards to BC development 
due to an increased time in which cells could mutate through mitosis, be exposed to mutagenic 
factors or be influenced by other factors (i.e. lifestyle), resulting in BC formation. However, there is 
a substantial increase in BC cases during pre-menopausal years, with incidence rates doubling every 
10 years until menopause, at which point a considerable decline in cases is seen [209]. Given the 
role of menopause, others factors have also been associated with BC development, such as diet, 
smoking, oral contraception, obesity and alcohol, all of which can be heavily associated with 
western culture; the globalisation of BC being accounted for by westernisation [210]. Aside from 
hormonal disarray and external factors, genetic abnormality is also heavily accountable for the 
aetiology of BC. In the UK up to 16% of BC cases are down to hereditary germline mutations in 
either of the Breast Cancer susceptibility genes, BRCA1 and BRCA2 [211]. These two genes are 
expressed in both breast and ovarian tissue and are fundamental in the repair of double stranded 
breaks through homologous recombination [212]. Mutation or absence of either of these two genes 
can result in chromosomal rearrangements through error prone means of DNA repair (i.e. non-
homologous end joining) which, if stable and followed by successful rounds of division, could result 
in autonomous cell division – a hallmark of cancer [213]. Luminal epithelial cells, lining the ducts 
and milk producing lobules, are the predominant culprit for BC development, however, rarely, the 
basal cells from the outer layer of ducts can also be the root cause [214]. 
 Diagnosis 
Recent innovations in the way of BC diagnosis have paved the way for tailoring treatments to BC 
subtypes, improving the effectiveness of treatments and subsequently patient survival. Analysed 
histologically, BC biopsies are divided into one of three grading categories. Grade one describes 
tissue architecture where the vast majority of cells are differentiated showing normal morphology, 
whereas grade three describes highly undifferentiated cells lacking uniformity or structure, 
exhibiting severe nuclear pleomorphism [215]. More recently the hormone receptor status of 
tumours has come to light as an important indicator of effective treatment regimes. Utilising 
Immunohistochemistry (IHC), the expression of hormone receptors (HR), estrogen receptor (ER) 
and progesterone receptor (PgR), can be investigated and exploited therapeutically [216,217].  
In conjunction with BC subtype, it is also vital oncologists deduce the current stage of a patients BC. 
Staging of BC is a summative way to discern the extent to which the cancer has progressed. 
Formally, BC staging is achieved through the Tumour Node Metastasis (TNM) staging system, 
classifying tumours based on these foremost morphological attributes. Summarised in Table 1.1, T 
refers to the presence and size of primary tumour, N to the presence and extent of lymph node 
involvement and M to the degree, if any, of metastasis [218]. 




Table 1.1 Summary of the TNM staging system, extrapolated from the American Joint Committee on Cancer 
(AJCC) 8th Edition [172].  
 
Stage Tumour Size (T) Lymph Node Involvement (N) Metastasis (M) 
0 No evidence of primary tumour 
present 
No evidence of lymph node 
involvement 
No evidence of metastasis 
I ≤ 20 mm Metastases in 1 – 3 axillary lymph 
nodes 
No evidence of metastasis 
II ≤ 50 mm Metastases in 4 – 9 axillary lymph 
nodes 
No evidence of metastasis 
III ≥ 50mm Metastases in ≥ 10 axillary lymph 
nodes 
No evidence of metastasis 
IV Any size in direct contact with chest 
wall and/or skin. 
Any axillary lymph node 
involvement 





















Collectively, these histological techniques have culminated in the molecular classification of BC into 
three main subtypes: Luminal A and B, Basal-like (Triple-negative) and Human Epidermal Growth 
Factor Receptor-2 (HER2) enriched. 
Luminal A is described as ER and/or PgR positive, HER2 negative and Ki67 negative, often grade low 
with a good prognosis. Like Luminal A, Luminal B are also described as ER and/or PgR positive, 
however can also be HER2 positive or negative, and are Ki67 positive. The presence of Ki67 is often 
a distinguishing factor between Luminal A and Luminal B, indicative of proliferative capacity and 
often correlates with poor prognosis; Luminal B often has a poorer prognosis [219]. 
Basal-like show no expression of ER, PgR or HER2 (often described as Triple-negative). Finally HER2-
enriched may show expression of ER or PR, but heavily express HER2 [220,221]. Of note, there is 
also a Normal-like subtype which highly resembles Luminal A, bar some variation in gene 
expression, however yields a poorer prognosis [222,223]. In descending order, Luminal A/B 
accounts for the majority of BC cases (~70%), followed distantly by HER2 positive (~15-20%) and 
Basal-like (~15%) [224].  
 Treatment 
Courtesy of detailed histological analysis, treatment regimens can be designed to best suit a 
patients BC subtype. In most cases, BC treatment begins with surgical removal of the tumour along 
with, if any, axillary lymph nodes to detain the tumours growth and potential to metastasise; stages 
0 and I entail breast conserving surgery whereas stage II and III often involve mastectomy – stage 
IV is often treated palliatively [225]. Alongside surgical resection, chemotherapy and radiotherapy 
are administered, and depending on the patients BC subtype other targeted drugs may also be 
administered; chemotherapy can be both an adjuvant and neo-adjuvant therapy.  
In instances where a patients BC presents as HR positive (ER+ and/or PgR+), endocrine therapy can 
be used to antagonise the appropriate HRs through administration of hormone therapy drugs, such 
as: Tamoxifen, Goserelin, Leuprorelin and Fulvestrant [226]. In a similar vein, use of aromatase 
inhibitors (i.e. Letrozole, Anastrozole, and Exemestane) act to inhibit estrogen produced by adipose 
tissue, as opposed to ovarian estrogen; limiting their use to predominantly post-menopausal 
women [227]. Patients who present with HER2 positive BC can also be given antibody therapy, 
specifically Trastuzumab (Herceptin), a monoclonal antibody against HER2. Likewise, other 
antibody therapies also exist, targeting other growth factor pathways: i.e. antibodies against FGF, 
VEGF and PDGF, the latter two crossing over into the anti-angiogenics, another treatment approach 
[228]. Targeting growth factor pathways is not limited to antibodies, other strategies also exist, for 




example, TKIs, histone deacetylase inhibitors (HDACi) and PI3K inhibitors [229,230]. Other targeted 
therapies not mentioned above include Poly-ADP Ribose Polymerase inhibitors (PARPi) and Cyclin 
Dependent Kinase inhibitors (CDKi), both of which can be used alongside chemotherapy, 
radiotherapy or other targeted therapies. PARPi act by preventing damaged cancer cells from 
repairing, i.e. after chemotherapy, and examples include: Talazoparib, Rucaparib, Veliparib and 
Niraparib [231]. The purpose of CDKi is to prevent the cell cycle, aiming to slow down or prevent 
tumour growth. Over recent years, CDKi against CDK4/6 have been approved for use in HR positive 
























Table 1.2 Summary of Breast Cancer Subtypes: IHC Status, Effective Treatments and Prognosis. 
 
 Subtype 
Luminal (A and B) Basal-like HER2 Positive 
IHC Status ER+ and/or PgR+  
 HER2 (A-, B-/+) 
Ki67 (A-, B+) 
ER- and PgR-  
 HER2- 
 
ER-/+ and/or PgR-/+  
 HER2+ 
 















Prognosis Good Very poor Poor 
 




















1.4 The placenta 
The placenta is a transient organ that arises during pregnancy orchestrating complex interactions 
between mother and embryo, whilst maintaining gestation through hormone production and 
perpetuating embryo growth through delivery of nutrients and gaseous exchange. In addition to 
nutritional input, the placenta also protects the embryo from the maternal immune system [234]. 
Achieving such remarkable feats is attributed to the placenta’s structure, comprised of three 
distinct layers: the maternal decidua, the junctional zone, and the labyrinth (Figure 1.14). It is this 
triad of regions which enable complex interactions to occur between mother and embryo, 
collectively resulting in successful gestation. 
1.4.1 Placental development 
The blastocyst is comprised of two cell layers, the inner cell mass (ICM) and the trophectoderm. At 
E3.5 these two layers become distinguished resulting in the trophectoderm not in contact with the 
ICM to differentiate into trophoblast giant cells (TGCs). At E4.5, TGCs penetrate the uterine 
epithelium and implant into the endometrium, anchoring the placenta to the uterus [235]). Success 
of implantation permits decidualization of the uterine stroma surrounding the TGC contact, thus 
forming the maternal decidua. The decidua constitutes a vital layer within the placenta, mediating 
direct contact and interaction with the mother termed the maternal-fetal interface [236]. Although 
poorly understood, it is widely accepted that the maternal-fetal interface is vital in maintaining 
pregnancy through upholding maternal tolerance through modulation of the maternal immune 
cells at the site of the decidua [237]. Concomitantly, the polar trophectoderm gives rise to the extra-
embryonic ectoderm and the ectoplacental cone [238]. At E7.5, the extra-embryonic ectoderm 
expands to form the chorionic ectoderm (chorion) whilst the allantois begins to form from the 
posterior mesoderm, contacting the chorion at E8.5 resulting in chorioallantoic fusion – this is 
deemed the primitive placenta, choriovitelline placenta [236]. Shortly after chorioallantoic fusion 
the chorion invaginates forming villi, laying foundation for the growth of feto-placental blood 
vessels from the allantois. As the allantois vascularisation proceeds, at E10 the ectoplacental cone 
gives structural support through development of a spongiotrophoblasts layer. Upon invasion of the 
feto-placental blood vessels into the chorion derived villi, the chorionic trophoblast cells 
differentiate into labyrinth cells [236,239,240]. The spongiotrophoblasts layer once supportive goes 
on to mature into the junctional zone, containing glycogen cells and executing endocrine functions 
(Figure 1.14) [241]. The mature placenta (chorioallantoic placenta) is seen at E14.5, exhibiting all 
three layers and perfused with maternal blood sinuses derived from maternal arteries, capable of 
maintaining and perpetuating embryonic growth [242].  












Figure 1.14 Schematic of murine placental development. At E3.5 the inner cell mass (ICM) and 
trophectoderm become distinguished, resulting in the trophectoderm differentiating into 
trophoblast giant cells (TGCs). TGCs penetrate the uterine epithelium, anchoring the placenta to 
the uterus and for the maternal decidua (DB). From E6 to E7.5 the extra-embryonic ectoderm 
expands and matures to form the chorionic ectoderm (chorion), with the formation and maturation 
of the allantois occurring from E7.5 to E8.5, fusing with the chorion – chorioallantoic fusion. Shortly 
after fusion, chorion invagination gives rise to villi, ultimately forming the labyrinth (LZ). E10 the 
ectoplacental cone gives rise to a supportive spongiotrophoblasts layer. Initially aiding in the 
formation of the labyrinth, this layer matures forming the junctional zone (JZ) (adapted from 















1.5 Research aims and hypotheses 
In light of background literature discussed and findings of our lab, it is evident that integrin-β3, 
integrin-α5 and neuropilin-1 have a complex relationship with each other. The interactive balance 
between these molecules summating in successful angiogenesis. Nonetheless, complete deletion 
all of three molecules exhibits a potent anti-angiogenic effect in the systems we have investigated 
to date. This provides a valuable tool for impeding angiogenesis and studying the subsequent 
outcome on developmental systems, such as the murine mammary gland; the generation of this 
model will be discussed in section 3. Utilising this as a tool to study the role of fibronectin binding 
receptors (integrin-α5β1 and -αVβ3), and the VEGF co-receptor neuropilin-1, during the lifecycle of 
the mammary gland (pubertal development, pregnancy, lactation and involution). Furthermore, 
given the metabolically active state of the mammary gland during the majority of its lifecycle, 
including transiently during estrus, alongside literature demonstrating an expansion of vasculature 
during pregnancy, we propose the following hypothesis: 
• The pubertal, gestational and lactational phases of epithelial growth will be impeded 
through a lack of angiogenesis, caused by the absence of key fibronectin binding receptors 
and neuropilin-1. 
 
Additionally, tumour angiogenesis is a hallmark of cancer and as such offers a targetable means to 
try and prevent tumour growth. Having already discussed the premise of this concept in section 
1.2.2.5, I sought to address whether the three molecules of interest could offer a robust approach 
to mitigating tumour growth. As such, I propose the following hypothesis: 
• Tumour growth will be significantly reduced in the absence of all three molecules, with a 
decipherable interaction discernible from the differing combinatorial absence(s) of the 
three molecules in single and double deletion.  
 
The results chapters within this thesis will be presented as follows. Chapter 1 shall divulge the 
process of generating the tools required to undertake the research questions being asked, followed 
by chapter 2 where I shall explore the role of angiogenesis during the pubertal phase of epithelial 
outgrowth. Chapters 3 and 4 shall investigate the role of angiogenesis in the mature mammary 
gland, specifically its effects on epithelium during pregnancy, lactation and involution (chapter 3), 
and breast cancer development (chapter 4). Lastly, in chapter 5, I shall begin to unpick tissue specific 
EC responses to angiogenic stimuli.  




2 Materials and Methods  
2.1 Reagents and Housekeeping 
Unless otherwise noted, reagents used were purchased from Thermo Fisher Scientific 
(Loughborough, UK). This encompasses: Applied Biosystems, Corning, Fisher Scientific, Gibco, 
Invitrogen and Life Technologies. All other reagents were purchased from the following suppliers, 
listed below: 
Abcam (Cambridge, UK) Microzone Life Science (Stourbridge, UK) 
Agilent – Dako (Cheshire, UK) Nutacon B.V. (Leimuiden, Netherlands) 
Amaxa Biosystems (Cologne, Germany) Olympus (Massachusetts, USA) 
Bio-Rad (Hertfordshire, UK) Qiagen (Sussex, UK) 
Brunel Microscopes (Chippenham, UK) Rockland (Pennsylvania, USA) 
CST (London, UK) Santa Cruz (Dallas, Texas, USA) 
eBioscience (Hatfield, UK) Sigma-Aldrich (Poole, UK) 
FlowJo (Oregon, USA) UVP (Cambridge, UK) 
Leica (Milton Keynes, UK) Vector Laboratories (Peterborough, UK) 
Medisave (Dorset, UK) Zeiss (Cambridge, UK) 
Microm (Bicester, UK)  
 
All methods and techniques employed to generate any work enclosed within this thesis are 
described throughout this chapter. Data generated in this thesis utilising methods which precede 
this work are referenced and briefly described. Unless otherwise stated, protocol steps were 
performed at room temperature and pressure (RTP). 
VEGF-A164 was utilised experimentally to induce pro-angiogenic behaviour of lung and mammary 
derived endothelial cells. This growth factor was made in-house following the protocol published 










2.1.1 Table(s) of Primary Antibodies  
 
Table 2.1 List of primary antibodies used for western blotting. 
Target/Anti- Host Reactivity Conjugate Application Source Cat. No. Clone 
ABL1/ABL2 Rabbit Mouse - WB Sigma-
Aldrich 
SAB4300641 871521530 
AKT Rabbit Mouse - WB CST 9272 - 
CD31 Rabbit Mouse - WB CST 77699 - 
claudin-V Rabbit Mouse - WB Abcam Ab131259 GR3261733 
endomucin Rat Mouse - WB Santa Cruz Sc-65495 K1710 
ERG 1/2/3 Rabbit Mouse - WB Abcam Ab92513 GR305449  
FAK Rabbit Mouse - WB CST 3285 - 
GAPDH Mouse Mouse - WB Abcam Ab9484 GR3257457 
HSC-70 Mouse Mouse - WB Santa Cruz Sc-7298 B2117 
integrin-α5 Rabbit Mouse - WB CST 4705 - 
integrin-β3 Rabbit Mouse - WB CST 4702 - 
LYVE-1 Rabbit Mouse - WB Abcam Ab14917 768540 
neuropilin-1 Rabbit Mouse - WB CST 3725 - 
p44-42 MAPK (ERK) Rabbit Mouse - WB CST 9102 - 
pABL1/ABL2 
(Tyr393/429) 
Rabbit Mouse - WB Sigma-
Aldrich 
SAB4300273 - 
P-AKT (Ser473) Rabbit Mouse - WB CST 4060 - 
P-AKT (Thr308) Rabbit Mouse - WB CST 9275 - 
P-FAK (Y397) Rabbit Mouse - WB CST 3283 - 
P-p44-42 MAPK 
(ERK) (T202, Y204) 
Rabbit Mouse - WB CST 9101 - 
PROX-1 Rabbit Mouse - WB Abcam Ab11941 811267 
pVASP (Ser157) Rabbit Mouse - WB CST 3111 - 
P-VEGFR2 
(Tyr1175) 
Rabbit Mouse - WB CST 2478 - 
pVIM (Ser56) Rabbit Mouse - WB CST 3877 - 
VASP Rabbit Mouse - WB CST 3132 - 
VE-cadherin (Cdh5) Rabbit Mouse - WB Abcam Ab205336 GR229866 
VEGFR2 Rabbit Mouse/Human - WB CST 2479 - 
VIM Rabbit Mouse - WB Abcam Ab92547 GR3186827 
WB – Western blot. 
 
 




Table 2.2 List of primary antibodies used for flow cytometry. 
Target/Anti- Host Reactivity Conjugate Application Source Cat. No. Clone 
CD31 Rat Mouse eFlour-450 FC Thermo 
Fisher 
48-0311-80 390 
endomucin Rat Mouse AF-647 FC Santa Cruz Sc-65495 C1219 
Integrin-α5 Hamster Mouse FITC FC eBioscience 11-0493-81 eBioHMa5-1 
Integrin-β3 Hamster Mouse PE FC eBioscience 12-0611-81 2C9.G3 
neuropilin-1 Rat Mouse Biotin FC Biolegend 145213 3E12 
neuropilin-1 Rat Mouse PE/Cy7 FC eBioscience 25-3041-82 3DS304M 
neuropilin-1 Goat Mouse PE FC eBioscience FAB566P ABZF0212121 
neuropilin-1 
(Streptavidin) 
- Rat BV711 FC Biolegend 405241 B271307 
VE-cadherin 
(Cdh5) 
Rat Mouse BV421 FC Biolegend 138013 BV13 




Table 2.3 List of primary antibodies used for immunocytochemistry, immunofluorescence and endothelial 
cell sorting. 
Target/Anti- Host Reactivity Conjugate Application Source Cat. No. Clone 
endomucin Rat Mouse - IF/ECS Santa Cruz Sc-65495 K1710 
ERG Rabbit Mouse - IF Abcam Ab92513 GR3054491 
Integrin-α5 Rabbit Mouse - IF Abcam Ab150361 GR10593376 
Integrin-β3 Rabbit Mouse - IF Abcam Ab75872 -  





Rabbit Mouse/Human - ICC Abcam Ab63605 GR510226 
TdTomato (RFP) Rabbit Mouse - IF Rockland 600-401-
379 
42896 
ICC – Immunocytochemistry, IF – Immunofluorescence, ECS – Endothelial Cell Sort. 




2.1.2 Table(s) of Secondary Antibodies 
 
Table 2.4 List of secondary antibodies used for western blotting. 
Target/Anti- Host Conjugate Application Source Catalogue 
Mouse Goat HRP WB Dako P0447 
Rabbit Goat HRP WB Dako P0448 
HRP – Horseradish peroxidase, WB – Western blot.  
 
 



















Target/Anti- Host Conjugate Application Source Catalogue 
Goat Rabbit Alexa®-488 ICC/IF Thermo Fisher A-21222 
Rabbit Donkey Alexa®-488 IF Thermo Fisher A-21206 
Rat Donkey Alexa®-488 IF Thermo Fisher A-21208 
Donkey Rabbit Alexa®-555 IF Thermo Fisher A-31572 
Rat Donkey Alexa®-594 IF Thermo Fisher A-21209 
Rabbit Donkey Alexa®-647 IF Thermo Fisher A-31573 
Rat Sheep Dynabeads ECS Thermo Fisher 11035 





Animals were bred on a mixed C57BL/6;129Sv background. All animal experiments were performed 
in accordance with UK Home Office regulations and the European Legal Framework for the 
Protection of Animals used for Scientific Purposes (European Directive 86/609/EEC). The study was 
also approved by the Animal Welfare and Ethical Review Board (AWERB) committee at the 
University of East Anglia, School of Biological Sciences. 
2.2.1 Breeding  
In order to study the effects of endothelial integrins in a temporal manner, the Cre/LoxP system 
was utilised. Mice containing an endothelial cell specific Cre-recombinase gene construct, 
Pdgfb/iCreERT2 (located on the Rosa26 locus) in this instance, were crossed to mice containing our 
gene(s) of interest flanked by loxP sites (floxed) on both alleles. Briefly, Pdgfb/CREERT2 mice were 
crossed to integrin-β3fl/fl (β3fl/fl), integrin-α5fl/fl (α5fl/fl) and neuropilin-1fl/fl (Nrp1 fl/fl) mice, generating 
inducible knock-out animals for each of the respective genes [141,244–246]. Animals containing 
single target floxing were then crossed to generate all double floxed target, and the triple floxed 
target, combinations: β3.α5fl/fl; β3.Nrp1fl/fl; α5.Nrp1fl/fl; β3.α5.Nrp1fl/fl. In breeding trios, 
Pdgfb/iCreERT2 was maintained only on the male mice allowing the generation of both Cre-positive 
and Cre-negative offspring; Cre-negative serving as littermate controls for all in vivo experiments.  
2.2.2 Timed mating 
To study the effects of angiogenesis on the murine mammary gland during pregnancy, female mice 
underwent timed mating. Female triple floxed mice were individually housed alongside a triple 
floxed male. In the evening, females were introduced into the male’s cage, then the following 
morning all females were plug checked and returned to their home cages; presence or evidence of 
a vaginal plug was an indication of successful mating and was considered E0.5 [247]. If a plug was 
found, the female(s) were not paired again in the evening. Females who were plugged were 
weighed every other day to monitor weight gain (a positive indicator of pregnancy). Upon reaching 
the embryonic day of interest (E10.5 and E15.5 for work conducted in this thesis) the female and 
her embryo(s) were sacrificed, and tissue was harvested.  
2.2.3 Genotyping 
To ensure all animals contained our genes of interest, DNA genotyping was performed. All PCR 
reactions were run on a 1.8% agarose gel, to allow for sufficient separation of wildtype and floxed 
bands. Gels were imaged using BioDoc-It Transiluminator (UVP). 
 




 DNA Preparation 
Ear punch biopsies from mice were collected and DNA was isolated for PCR analysis. Briefly, ear 
biopsies were digested overnight at 56°C in tissue lysis buffer (100µl): Tris-HCL (50mM, pH 8.5), 
EDTA (10mM, pH 8.0), NaCl (100mM), SDS (0.2%) plus proteinase-K (100µg/ml – Sigma-Aldrich). 
DNA was precipitated by the addition of isopropanol (100µl) then collected by centrifugation at 
1200 X g for 30 minutes. The supernatant was removed, the pellet left to air dry at room 
temperature for 2 hours and once dry re-suspended in Tris-HCL/EDTA (TE) buffer (200µl): Tris-HCL 
(10mM, pH 7.5), EDTA (1mM). 
 PCR Reactions 
Analysis of the floxed alleles (integrin-β3, integrin-α5 and neuropilin-1) and the Cre-recombinase 
PDGFb, and the TdTomato reporter gene were performed as follows. DNA (0.4µl), MegaMix-Blue 
(10μl) (Microzone: a 1.1X reaction buffer containing Taq polymerase, 2.75mM MgCl2, 220μM 
dNTPs, blue agarose loading dye) and 0.08μl of the forward (F) and reverse (R) primers (from a 100 
µM stock) were combined and loaded into a 96-well PCR plate. 




















Table 2.6 Primers and reaction conditions used for the PCR of all GEMMs. 
Gene Primers Amplification Programme 
Integrin-β3 
 
F: 5’ – TTGTTGGAGGTGAGCGAGTC – 3’  










HT030: 5’ –GCAGGATTTTACTCTGTGGGC– 3’ 
HT0311: 5’ –TCCTCTGGCGTCCGGCCAA– 3’ 










F: 5’ –AGGTTAGGCTTCAGGCCAAT– 3’ 






















WT F: 5’ – AAGGGAGCTGCAGTGGAGTA – 3’ 
WT R: 5’ – CCGAAAATCTGTGGGAAGTC – 3’ 
Tom F: 5’ – GGCATTAAAGCAGCGTATCC – 3’ 





















2.3 Tamoxifen Preparation 
Tamoxifen was prepared by dissolving 0.3g of Tamoxifen (Sigma-Aldrich) into 1.5ml of corn oil 
(Mazola). To this, 13.5ml of 100% ethanol was added and the mixture was shaken at ~180rpm at 
55°C for 6 hours. This produced a stock solution of 20mg/ml. Once dissolved, aliquots were 
prepared in UV-proof tubes (Eppendorf™) and stored at -20°C until use.  
 
2.4 Orthotopic Mammary Gland Tumour Assays 
Mouse breast carcinoma cells derived from MMTV-PyMT mice (B6BO11) were prepared at 1x105 
per 50µl in a 1:1 mixture of phosphate buffered saline (PBS) to Matrigel then injected, under 
anaesthesia, into the left number 4 abdominal mammary fat pad (MFP) of age matched (8 – 12 
weeks) Cre-positive and Cre-negative littermate control female mice. Cre-recombinase activity was 
initiated and sustained as follows. One week prior to tumour cell implantation, Cre-positive and 
Cre-negative littermate control mice underwent thrice weekly (Monday, Wednesday and Friday) 
intraperitoneal (I.P.) injections of Tamoxifen (75mg/kg of bodyweight – Jackson Laboratory 
Protocol, Bar Harbor, Maine, USA); this thrice weekly regimen continued throughout the duration 
of the experiment(s). Post-implantation, tumour growth was permitted for 15 days, at which point 
all animals were sacrificed by cervical dislocation and tumours were harvested. Upon collection, 
tumours were weighed (g), measured (length x width) and imaged prior to being bisected then snap 
frozen for subsequent analysis. Tumour volume was calculated using the following formula:  
(length x width2) x 0.52 – length being the larger measurement recorded [248]. 
2.4.1 Immunofluorescent Staining and Analysis – Tumours 
Frozen tumours were mounted and sectioned at 6µm using a Cryostat HM-560 (Microm) and 
mounted onto positively charged slides . Once sectioned, slides were air dried for 10 minutes before 
being fixed in 4% paraformaldehyde (PFA) for 10 minutes. Slides were then washed two times, for 
15 minutes each, in PBS/0.3% Triton X-100. Next, slides were washed twice in PBLEC (1x PBS, 1% 
Tween 20, 0.1 mM CaCl2, 0.1 mM MgCl2, 0.1 mM MnCl2), 15 minutes each, before being blocked for 
30 minutes at 37˚C with Dako Block (Agilent-Dako). Slides were then incubated with primary 
antibodies (Abs) (1:500 in PBLEC) o/n at 4˚C (Table 2.3). The following day, slides were washed 
three times, for 5 minutes each, in PBS/0.3% Triton X-100 before being incubated in secondary Abs 
 
1 Kindly provided by Professor Katherine Weilbaecher (Washington University, St Louis, MO, USA). 
 




(1:500 in PBS) for 2 hours (Table 2.5). Post-incubation, slides underwent three 5 minute washes in 
PBS, followed by one 5 minute wash in PBS/0.3% Triton X-100, before being blocked with 5% 
BSA/PBS for 15 minutes. Once blocked, slides were incubated with a second primary Ab (1:500 in 
5% BSA/PBS) for 1 hour (Table 2.3). Next, slides underwent three 5 minute PBS washes before being 
incubated with a second secondary Ab (1:500 in PBS) for 1 hour (Table 2.5). Finally, slides were 
immersed in Sudan Black (0.1% in 70% EtOH) for 5 minutes (in order to quench auto-fluorescence), 
briefly rinsed in dH2O before being mounted with Fluoromount-G™ with DAPI (4′,6-diamidino-2-
phenylindole – nuclear DNA stain). Note: not all slides underwent two rounds of primary/secondary 
Ab incubation. Only slides which required targets to be probed for using primary Abs of the same 
species received this preparation; all other slides went from secondary straight to the Sudan Black 
step.  
 
2.5 Endothelial Cell Culture and Isolation 
Incubation of cell cultures were performed under the following conditions: 37°C, 5% CO2 and 95% 
humidity. Primary mammary endothelial cells (MECs) were seeded into flasks pre-coated with 0.1% 
gelatin (type A from porcine skin – Sigma-Aldrich), human plasma fibronectin (FN, 10μg/ml – Sigma-
Aldrich) and PureCol (10μg/ml – Nutacon B.V.). Immortalised MECs were seeded into flasks pre-
coated with 0.1% gelatin only. Cell detachment for sub-culturing was performed using a 0.25% 
Trypsin-EDTA solution (Sigma-Aldrich). Culturing of cells for experimental purposes is described 
within the relevant sections. 
 
2.5.1 Triple-floxed Mammary Endothelial Cell Isolation 
Primary MECs were isolated and prepared from the number 4 abdominal mammary glands of 
β3.α5.Nrp1fl/fl female mice, aged 8-12 weeks, as previously described [249]. Mice were sacrificed 
by cervical dislocation, the mammary glands were collected aseptically and placed into Mouse Lung 
Endothelial Cell media (MLEC – 1:1 Ham’s F-12:DMEM (low glucose, 20% fetal bovine serum (FBS); 
penicillin/streptomycin (100units/ml), L-glutamine (2mM – Sigma-Aldrich), heparin (50μg/mL), 
endothelial mitogen (25mg – Bio-Rad)). Once extracted, the lymph node within the mammary gland 
was removed then the glands were rinsed in 70% EtOH before being placed into fresh MLEC. From 
here, glands were homogenised to a paste like consistency with scalpels (No. 10 – Medisave) then 
digested at 37°C for 1 hour in the following solution: PBS containing Ca2+Mg2+ (1mM), 0.1% 
Collagenase I (Gibco), 0.01% DNase (Sigma-Aldrich), with agitation every 15 minutes. Post-
digestion, the solutions were aspirated through a 19G needle (Medisave) five times followed by a 




21G needle (Medisave) four times before being passed through a 100µm sterile cell strainer. 
Strained digests were then centrifuged at 300 X g for 3 minutes, resuspended in PBS and 
centrifugation repeated before finally being resuspended in MLEC and seeded into a pre-coated 
T75 flask. The next day, two PBS washes were performed to remove red blood cells and cellular 
debris generated from the digest, prior to fresh MLEC being added.  
Upon reaching ~80% confluency, the MECs were positively sorted by their expression of endomucin 
using Magnetic-Activated Cell Sorting (MACS) [250]. Flask(s) were placed at 4°C for 20 minutes prior 
to incubation with rat-anti-mouse endomucin (Santa Cruz ) (1:1000 in PBS) for a further 30 minutes 
at 4°C. Flask(s) then underwent one PBS wash before incubation with sheep-anti-rat IgG coated 
magnetic beads (Invitrogen) (1:1000 in MLEC) for 30 minutes at 4°C. Following this, three PBS 
washes were performed prior to the cells being detached with trypsin and placed into a magnetic 
rack for 3 minutes. Supernatant was re-seeded into a T75 (in case the positive sort failed), and MECs 
bound to the beads within the magnetic field were re-suspended in MLEC and placed back into the 
magnetic rack for a further 3 minutes. Supernatant from this sort was then discarded, MECs bound 
to the magnetic beads were then resuspended in MLEC and seeded into a pre-coated T25. Upon 
reaching confluency, a second positive sort was performed (as above) to ensure only MECs were 
isolated and expanded.  
2.5.2 Mammary Endothelial Cell Immortalisation 
Immortalized MECs were generated from primary MECs which underwent transfection with 
polyoma-middle-T-antigen (PyMT) retrovirus as previously described [251]. Briefly, primary MECs 
that had undergone 2 positive sorts and reached ~80 confluency were incubated with PyMT 
conditioned media supplemented with Polybrene for 6 hours at 37°C and 5% CO2, then refreshed 
with MLEC media overnight (o/n). The following day the treatment was repeated however the MECs 
were fed with Immortalised Mouse Lung Endothelial Cell media (IMMLEC – 1:1 Ham’s F-12:DMEM 
(low glucose), 10% FBS; penicillin/streptomycin (100units/mL), L-glutamine (2mM), heparin 
(50μg/mL)). Immortalised MECs were subsequently expanded, frozen down and used at between 








2.5.3 TAT.Cre-recombinase Nucleofection 
The deletion of floxed target genes within immortalised MECs was achieved via the nucleofection 
of TAT.Cre-recombinase. Briefly, MECs were nucleofected, using programme T-005 on the Amaxa 
Nucleofector II (Amaxa Biosystems), with TAT.Cre-recombinase (70units – Sigma-Aldrich), seeded 
into pre-coated flasks and allowed to recover for two days, followed by a repeat of the 
nucleofection. Cells were than expanded, a portion of which were lysed and utilised to confirm 
target deletion via western blot.  
 
2.6 Western Blotting 
2.6.1 Western Blot Sample Preparation 
Samples were manually lysed, with the aid of a rubber policeman, in electrophoresis sample buffer 
(ESB – Tris-HCl (65mM, pH 7.4), sucrose (60mM), SDS (3%)). Once lysed, lysates were transferred to 
a safe-lock microfuge tube containing acid-washed glass beads (Sigma-Aldrich) and homogenised 
in a tissue lyser (Qiagen) at 50Hz for 2 minutes, followed by centrifugation at 16,000 X g for 10 
minutes. Protein concentration was then quantified using the BioRad DC protein assay (Bio-Rad). 
Prior to loading, the required volume of each sample for a given concentration was reduced by the 
addition of lithium dodecyl sulfate (LDS) sample buffer and sample reducing agent to a final 
concentration of 1X then boiled at 95°C for 5 minutes. 
 
2.6.2 8% Polyacrylamide gel (SDS-PAGE) and Gradient gel (5 – 12%) Electrophoresis 
Prepared lysates were loaded and run on either homemade (5% stacking, 8% resolving) or pre-cast 
gradient (NuPAGE™ 4 – 12%) polyacrylamide gels. Gels were run until sufficient resolution of 
proteins was achieved. Running buffer for homemade gels was used at 1X concentration in distilled 
water (dH2O): 10X running buffer stock (glycine (1.92M), Tris (250mM), SDS (1%) in dH2O). The 
running buffer used was the NuPAGE™ MOPS SDS 20X Running Buffer at 1X concentration in dH2O 








2.6.3 Protein Transfer and Immunoblot  
Resolved proteins were transferred onto nitrocellulose at 30V for 3 hours. Transfer buffer used at 
1X concentration in dH2O with the addition of MeOH (20%): 10X transfer buffer stock (glycine 
(1.92M), Tris (250mM) in dH2O). The transfer buffer used for proteins resolved on gradient gels 
utilised the same buffer with the addition of antioxidant (NuPAGE™ – 0.25%). Post-transfer, 
membranes were incubated with Ponceau S stain (0.1% in 5% acetic acid) for 5 minutes to confirm 
the presence of proteins.  
Following confirmation of complete transfer, membranes were blocked in 0.1% Tween-20/PBS 
(PBSTw) containing 5% milk powder for 1 hour. Once blocked, membranes underwent three 5 
minute washes in PBSTw prior to incubation with the appropriate primary Ab, prepared in 5% 
milk/PBSTw, o/n at 4°C. All primary Abs, excluding loading controls, were used at a dilution of 
1:1000 (Table 2.1). Primary Abs used for loading controls were all used at a dilution of 1:2000: anti-
GAPDH and anti-HSC-70 (Table 2.1). Post-incubation with primary Ab, membranes were washed 
three times for 5 minutes in PBSTw then incubated with the appropriate horseradish peroxidase 
(HRP) conjugated secondary Ab(s) (Table 2.4) for 2 hours in the dark. Secondary Abs were prepared 
in 5% milk/PBSTw and used at a dilution of 1:2000 for proteins of interest and 1:5000 for loading 
controls. Membranes were again washed three times for 5 minutes in PBSTw, treated with Pierce® 
ECL Western Blotting Substrates and imaged via detection of chemiluminescence on a ChemiDoc 
XRS+ (Bio-Rad). Chemiluminescence was converted to densitometric readings and quantified using 
ImageJ [252]. 
 
2.7 Whole Mammary Gland Extraction  
Female Cre-positive and Cre-negative mice were administered Tamoxifen (50µl – 2mg/ml) following 
either the pubertal or pregnancy regimen described in section 3.2 (Figure 3.3). Once induced mice 
reached the desired experimental endpoint, they were sacrificed by cervical dislocation, the lower 
thoracic and abdominal mammary glands were harvested into histological cassettes and placed into 
Tellyesniczky/Fekete (Telly’s) fixative (100ml: 87% EtOH (70%), 8.5% formaldehyde (37% stock), 
4.5% glacial acetic acid) o/n for haematoxylin whole gland staining, or into 4% PFA: 2 hours for 
whole gland clearing and immunofluorescence staining (section 2.7.2) or o/n at 4°C for 
haematoxylin and eosin (H&E) (section 2.7.3).  
 




2.7.1 Haematoxylin Staining  
Mammary glands fixed in Telly’s were washed three times for 1 hour each in acetone before two 
subsequent washes in 100% EtOH and 95% EtOH respectively. The mammary glands then 
underwent whole gland staining for 3 hours in the following haematoxylin stain: 0.8% stock 
haematoxylin (10% in 95% EtOH), 93% EtOH (95%), 6.2% dH2O, 0.06% FeCl3, pH1.25, adjusted with 
concentrated HCl (~37%) once all components had been combined. Stained glands were then 
washed in the following regime: two times for 1 hour each in tap water, once for 1 hour in 50% 
EtOH containing 2.5% 1N HCl, once for 1 hour in 70% EtOH, one time for 1 hour in 95% EtOH, two 
times for 1 hour each in 100% EtOH and finally two times 1 hour each in Xylene washes. Glands 
were then transferred from the final xylene wash into methyl salicylate for long term storage before 
imaging. 
 Haematoxylin Analysis  
Haematoxylin stained glands were imaged using a Brunel Stereoscope (Brunel Microscopes – BMDZ 
SD2) at 7.5x magnification unless otherwise stated. Epithelial expansion was analysed and 
quantified from the images obtained using ImageJ. Briefly, masks of the epithelium were manually 
sketched, binarized and subsequently quantified using the Simple Neurite Tracer plugin. Then 
epithelium was sketched and measured for each experimental timepoints accordingly. Pubertal 
glands utilised the lymph node within the abdominal gland as a consistent reference point to sketch 
and therefore measure epithelial expansion from (supplementary Figure 9.3). Pregnant glands at 
stage E10.5 were sketched and consequently measured at, and across, the lymph node region of 
the abdominal gland to provide a point of consistent measurement across all E10.5 glands 
(supplementary Figure 9.4).  
2.7.2 Immunofluorescent Staining and Analysis – Mammary Glands 
Mammary glands fixed in 4% PFA were blocked at 4°C o/n in a permeabilization-blocking buffer 
composed of: 10% BSA/PBS containing 1% Triton X-100. The following day the glands were 
incubated in primary antibody prepared in the permeabilization-blocking buffer at 4°C for 4 days. 
Primary Abs were used at a dilution of 1:200 (Table 2.1). After incubation with primary Abs, glands 
were washed three times each for 1 hour in PBS/1% Triton X-100 before being incubated with 
secondary Abs (1:500) at 4°C for 2 days (Table 2.5). Glands were then washed three times each for 
1 hour in PBS/1% Triton X-100, two times each for 30 minutes with PBS and incubated with DAPI 
for 2 hours at a dilution of 1:1000. Once staining was complete, glands were serially incubated with 
fructose solutions (w/v in dH2O containing 0.5% 1-thioglycerol (Sigma-Aldrich)) for a minimum of 




16 hours each; solutions respectively were 20%, 40%, 60%, 80%, 100% and 115%. Glands were 
imaged using Zeiss LSM880 Airyscan confocal (Zeiss) at 10X magnification.  
 
2.7.3 H&E Staining 
Post-fixation (section 2.7), cassettes containing mammary glands were placed into the Leica Tissue 
Processor ASP-300S (Leica) for tissue processing prior to H&E staining. Briefly, cassettes are moved 
through a series EtOH, increasing in concentration: 70% (1 hour); 80% (90 minutes); 90% (2 hours); 
100% (1 hour); 100% (90 minutes); 100% (2 hours), before undergoing three xylene washes: 30 
minutes, 1 hour and 90 minutes respectively. Lastly, cassettes were passed through three Paraffin 
wax incubations: 2 hours, 2 hours and 1 hour respectively. Once processed, mammary glands were 
embedded in paraffin using a Leica EG-1150H Paraffin Embedding Station (Leica) before being 
sectioned using a HM-355S Microtome (Microm). Sectioning was performed at 10µm and sections 
were mounted onto positively charged slides; sections were dried o/n at 37°C. Deparaffinisation 
and H&E staining was performed using a Leica Tissue Multistainer ST5020 (Leica). Briefly, slides 
were washed twice in Xylene for 5 minutes, washed in a series of ethanol’s, of decreasing 
concentrations, 2 minutes each: 100%, 80% and 70%. Next, slides were submerged H2O 5 minutes 
before being placed into haematoxylin for 5 minutes. Next, slides were moved through a series of 
H2O, five 1 minute washes, before 15 seconds in 1% HCl/70% EtOH, a dip in H2O before by 1 minute 
in 0.1% Sodium Bicarbonate (). Follow this, slides were moved through a series of H2O, five 1 minute 
washes before 30 seconds in eosin. Slides were then washed in a series of ethanol’s, of increasing 
concentrations, 2 minutes each: 70%, 80% and 100%, before two 5 minutes washes in xylene and 
finally being mounted with Neo-Clear® hard set mounting medium (Sigma-Aldrich). Slides were 
imaged using an Olympus BX60 (Olympus). 
 
2.8 Placental Extraction and Processing 
Alongside extraction of the mammary glands, placentas were harvested from the embryos of the 
pregnant female mice, both Cre-positive and Cre-negative, at E15.5. Placentas were carefully 
removed from the embryonic sack, weighed, and bisected; with half fixed in 4% PFA for 2 hours 
then stored in 70% EtOH while the other was snap-frozen in liquid nitrogen and stored at -80°C.  
 




2.8.1 Placental Immunohistochemistry and Stereology  
Post-extraction, subsequent embedding, sectioning, staining and analysis were performed by Jorge 
López-Tello as described [253]. Briefly, the PFA fixed placental halves were paraffin embedded and 
sectioned at 7µm. Of the sections collected, three non-adjacent sagittal sections (spaced by at least 
200µm) underwent immunohistochemical analysis to enable visualisation of the three distinct 
layers of the placenta, the Decidua (DB), Junctional Zone (JZ) and Labyrinth Zone (LZ). Stereology 
was performed on these sections to determine the proportion of each of the three regions within 
each placenta, then compared to the relative controls (e.g. Cre-positive to Cre-negative).  
 
2.9 Flow Cytometry 
Flow cytometry was performed on immortalised ECs (see Section 2.5) and tumour homogenates to 
confirm EC status plus check the absence or presence of the proteins of interest (the floxed targets).  
 
2.9.1 Cell Isolation 
 Tumour Lysate 
Tumour bearing mice (Section 2.4) were sacrificed by cervical dislocation and tumours removed. 
Tumours were manually homogenised to a paste like consistency using scalpels (No. 10 – Medisave) 
and then digested at 37°C for 1 hour in the following solution with agitation every 15 minutes: 0.2% 
Collagenase IV (Invitrogen); 0.01% Hyaluronidase (Sigma-Aldrich); 2.5U/ml DNAse I (Sigma-Aldrich) 
in hanks’ balanced salt solution (HBSS). The homogenate was passed through a 70µm cell strainer 
before being centrifuged at 300 X g for 5 minutes at 4°C. Post-centrifugation, the pellet was washed 
twice in PBS under the same centrifugal conditions and subsequently stained (Section 2.9.2) 
 
 Immortalised Endothelial Cells  
Immortalised ECs were detached non-enzymatically with citric saline buffer (135mM potassium 
chloride, 15mM sodium citrate in dH20. Once detached, cells were stained according to Section 
2.9.2 omitting the incubation step with the red blood cell lysis buffer.  
 
 




2.9.2 Staining Protocol 
Cells from homogenised tumour tissue were resuspended and incubated in 1X red blood cell lysis 
buffer (Invitrogen) for 5 minutes. Cells, from homogenised tumour tissue or immortalised ECs, were 
then washed in PBS, 300 X g for 5 minutes, before being resuspended in flow cytometry staining 
(FACS) buffer (1% FBS in PBS) and counted using a haemocytometer (Sigma-Aldrich). Into a 96-well 
plate (Corning), cells were aliquoted at 1x106 per well, centrifuged at 300 X g for 5 minutes at 4°C 
and resuspended in Fc Block (1:200 – Miltenyi, Bergisch Gladbach, Germany) for 10 minutes at 4°C. 
Once blocked, cells were resuspended in 100µl of the appropriate primary Ab solution and 
incubated for 30 minutes at 4°C in the dark (Table 2.2). Cells were then washed twice in FACS buffer 
prior to fixation in 4% PFA for 30 minutes at 4°C, washed once in PBS, and finally resuspended in 
FACS buffer and stored at 4°C before analysis.  
 
2.9.3 Data Collection and Analysis 
Data was collected using a Becton Dickinson (BD, Franklin Lakes, NJ, USA) LSR II Fortessa with 
standard filter sets and five lasers. Data were analysed using FlowJo software (BD). 
 
2.10 Immunocytochemistry 
Acid washed coverslips, one per well of a 24-well plate (Corning), were coated with FN prepared in 
PBS (10μg/ml – Sigma-Aldrich) o/n at 4°C. The coverslips were then washed in PBS before being 
blocked with a 1% BSA/PBS solution for 1 hour. Cells were then detached from their flask using a 
0.25% trypsin-EDTA solution (Sigma-Aldrich), counted and seeded at 2.5x104 per well o/n at 37°C. 
Coverslips were then washed once in PBS before being incubated with 4% PFA for 10 minutes. Once 
fixed, coverslips were blocked in 10% goat serum/0.3% Triton X-100 in PBS for 1 hour before being 
incubated with primary Abs o/n at 4°C. All primary Abs were prepared in PBS and used at 1:200 
(Table 2.3). Coverslips were then washed three times (3 second submerge) in PBS before being 
incubated with secondary Abs for 2 hours (Table 2.5). The coverslips were then washed three times 
(3 second submerge) in PBS before being mounted onto glass slides using Prolong Gold with DAPI 
(Thermo Fisher) and stored at 4°C in the dark until imaging. Imaging was performed on the Axioplan 
Epifluorescent microscope (Zeiss) and the AxioCam MRm camera (Zeiss) at 63X oil immersion. 
 




2.11 In Vitro Assays 
2.11.1 VEGF Stimulation and Signalling Assay 
Immortalised endothelial cells were seeded at densities of 2x105 and 5x106 per well on 6-well plates 
and 15cm dishes respectively (Corning), pre-coated o/n at 4°C with FN in PBS (10μg/ml – Sigma-
Aldrich), and left to adhere o/n. The following morning, all cells were starved for 3 hours in reduced 
serum media (Opti-MEM™) prior to being stimulated with VEGF (30ng/ml in Opti-MEM™) for 5, 10, 
15 and 30 minutes – one well remained in Opti-MEM™ only to serve as an unstimulated control. 
Post-stimulation, wells were lysed in ESB and prepared for western blot analysis as detailed in 
Section 2.6.1. Cells seeded and treated in 15cm dishes were prepared for Microarray analysis 
(Section 2.11.3). 
 
2.11.2 Non-Pregnant Serum and Pregnant Serum Stimulation and Signalling Assays 
Non-pregnant serum (S) was collected from virgin female mice aged between 8-12 weeks. Pregnant 
serum (PS) was collected from Cre-negative and Cre-positive female mice at E15.5 of pregnancy – 
alongside the harvest of mammary glands, embryos and placentas detailed in Section 2.8. Briefly, 
blood was extracted via cardiac puncture from freshly euthanised mice, left to coagulate at room 
temperature for 20 minutes, and then spun for 15 minutes at 2600 x g at 10°C. Serum was the 
carefully aliquoted off the pelleted blood, pooled and stored at -80°C until use.  
Immortalised endothelial cells were seeded at densities of 2x105 and 5x106 per well of 6-well plates 
and 15cm dishes respectively (Corning), pre-coated o/n at 4°C with FN in PBS (10μg/ml – Sigma-
Aldrich), and left to adhere o/n. The following morning, all cells were starved for 3 hours in reduced 
serum media (Opti-MEM™), prior to being stimulated with either S or P serum (5% in Opti-MEM™) 
for 15 minutes – one well remained in Opti-MEM™ only to serve as an unstimulated control. Post-
stimulation, wells were lysed in ESB and prepared for western blot analysis as detailed in Section 
2.6.1 or were prepared for microarray analysis (see Section 2.11.3).  
 
2.11.3 Microarray Sample Preparation 
Microarray analysis was performed by Kinex™ KAM-1325 Antibody Microarray Services (Kinexus, 
Vancouver, Canada). Samples were prepared according to sample preparation guidelines and sent 
to Kinexus for quantification and analysis (KAM-Kit Instruction manual, Kinexus). Briefly, cells ready 
for lysis were washed twice in ice-cold PBS before being added to Kinexus Lysis Buffer containing 
1X HALT™ protease and phosphatase inhibitor cocktail at 4°C. Lysed samples were then collected 




into safe-lock Eppendorf tubes containing acid-washed glass beads and homogenised in a tissue 
lyser (Qiagen) at 50Hz for 2 minutes. Next, lysates were cleared by centrifugation at 21,000 X g on 
a benchtop centrifuge for 30 minutes at 4°C. The supernatant was then transferred to a new safe-
lock Eppendorf and protein quantification was performed using BioRad DC protein assay (Bio-Rad). 
Samples were used at 50µg of protein for protein labelling and purification with the appropriate 
volume being aliquoted into an Eppendorf for proceeding steps. Each sample underwent chemical 
cleavage for 30 minutes at 37°C before being incubated with biotin for 1 hour. Next, samples were 
aliquoted into and spun in Microspin columns for 2 minutes at 750 X g. Meanwhile, microarray 
slides were blocked for 1 hour, prior to incubation with samples, using reagents supplied in the 
Kinex™ KAM-1325 Antibody Microarray kit. The recovered samples were then loaded onto the now 
blocked microarray slides and incubated in a humidity chamber for 2 hours. The microarray(s) then 
underwent eight 5 minute washes in the supplied wash buffers before being incubated in the dark 
with a supplied biotin antibody for 15 minutes. The microarray slides were then washed twice more, 
5 minutes, in supplied wash buffers before being stored in the dark at 4°C prior to shipping to 
Kinexus for analysis and quantification. Excess sample was stored at -70°C for use in follow up 
analysis and validation studies.  
 
2.12 Statistical Analysis 
Statistical analysis was performed on Cre-positive cells/mice (induced in vivo by Tamoxifen 
administration or in vitro by TAT-Cre recombinase as detailed in Sections 2.4 and 2.5 respectively) 
against their appropriate Cre-negative controls. Values for in vitro experiments were calculated and 
presented as a percentage normalised to Cre-negative controls – controls response being arbitrarily 
set to 100% for comparison. In order to determine significance between Cre-positive and Cre-
negative mammary glands at the various time points investigated, unpaired T-tests were 
performed. To establish significance between the several mouse models used to study 
tumorigenesis, unpaired T-tests were performed on data normalised to the respective Cre-negative 
controls (e.g. each genetic line compared to its own Cre-negative). Welch’s correction was 
performed where variances were significantly different – an F test was used to compare variances. 
All statistical analysis was performed using GraphPad Prism 6. Error bars shown on graphs represent 
the Standard Error of the Mean (SEM). Asterisks represent P values that have fallen into the 
following ranges: (* = P<0.05), (** = P<0.01), (*** = P<0.001) and (**** = P<0.0001). NS = not 
significant. 
Graphical figures were designed on either Microsoft PowerPoint or BioRender (Biorender.com). 




2.12.1 Power Calculations 
As an initial estimate for tumour studies we analysed similar experiments in animals carrying B6BO1 
orthotopic allografts. The variation in statistical power as a function of sample size is presented 
below. The calculations were based on performing two separate two-sided Welch T-tests where 
the group means (standard deviation) were assumed to be 5.50 (0.33), 6.27 (0.54) and 4.93 (0.33) 
for Control, Antibiotic treatment “X” and Antibiotic treatment “Y”, respectively (based on 
preliminary data). The desired significance level was set to α = 0.025 to control the family-wise error 
rate. Each tumour experiment will aim to have a minimum of 12 animals (Table 2.7). Due to a lack 
of preliminary data we were unable to perform power calculations for mammary gland studies. 










8 0.793 0.802 
9 0.854 0.859 
10 0.898 0.902 
11 0.930 0.932 
12 0.953 0.954 




3 Generating the in vivo and in vitro tools and models required to study 
the role of angiogenesis in the functional lifecycle of the murine 
mammary gland 
As alluded to in the introductory sections of angiogenesis (Section 1.2.2) and integrins (section 
1.2.3), integrins play a fundamental role in the successful modulation of angiogenesis. Our lab 
utilizes genetic tools to investigate the roles, interactions, and mechanistic functions of integrin-β3, 
integrin-α5 and neuropilin-1, in the process of angiogenesis [114,254,255]. We have generated 
genetically engineered mouse models (GEMMs) that allow us to inducibly delete the endothelial 
expression of these three molecules, either alone or in various double/triple combinations. Given 
their fundamental role in angiogenesis, depletion of all three of these pro-angiogenic targets grants 
us access to a powerful anti-angiogenic tool that can be used to study the rudimentary and 
progressive role of angiogenesis in developing systems; in the case of this thesis that system is the 
murine mammary gland (unpublished – Robert Johnson, Thesis, 2019). Given the (at times cyclical) 
proliferative capacity of the murine mammary gland, we hypothesized that angiogenesis must be 
dynamic within the mammary gland throughout its lifecycle to enable such mitogenic feats to occur 
in a temporally strict window. Supported by studies demonstrating an expansion in vasculature 
during pregnancy followed by regression, alongside an upregulation of VEGF throughout this 
process, angiogenesis should play a key role in mammary gland development and function [161]. 
With this hypothesis in mind, this section shall describe and detail the trials, tribulations, and 
successes in generating the tools required to explore the effects of angiogenesis in lifecycle of the 
murine mammary gland.  
 
3.1 The Cre/LoxP system – breeding and generating genetically engineered 
mouse models as an in vivo tool 
The modern era of biological science has yielded many powerful research tools, specifically ones 
that enable genome editing; one such tool is the Cre/LoxP system. Cre-recombinase (Cre) was 
originally isolated from bacteriophage P1 and was identified as a unique site-specific recombinase 
functioning through the recognition of 34-bp sequences referred to as LoxP sites (Figure 3.1b); an 
exploitable system for application in gene editing [256,257]. Harnessing this technology through 
means of molecular biology has yielded an invaluable gene editing tool, not only deleting genes of 
interests, but doing so in either a constitutive and/or temporal manner. First considerations when 
designing a Cre gene construct is the promoter region. The promoter region is vital in design 
consideration as this governs the tissue in which Cre is expressed and, in turn, the tissue in which 




Cre can become active. Once Cre is expressed, excision of its target, LoxP sites, can be utilised to 
enable specific gene deletion through Cre-mediated recombination (Figure 3.1a). Target gene 
constructs are engineered to contain the gene(s) of interest with LoxP sites situated in flanking 
positions of a coding region – a floxed gene (Figure 3.1b). In circumstances where the Cre construct 
is devoid of an exogenously inducible element, Cre will be expressed under the deemed promoter 
region, translocate to the nucleus post-translation, and proceed to recognise and mediate Cre 
recombination of the floxed gene(s). Further advances in this system have enabled a temporal 
adaptation; through incorporating an estrogen receptor with a mutated ligand binding domain, 
ERt2, within the Cre gene construct restricts the transcribed Cre to the cells cytoplasm upon 
transcription – the nuclear localisation signal (NLS) responsible for the translocation of Cre to the 
nucleus is blocked [258]. This CreERt2 is exogenously inducible through administration of Tamoxifen, 
which subsequently metabolised to 4-hydroxytamoxifen (4-OHT) in vivo via hepatocytes, binds to 
ERt2 receptor on CreERt2 (Figure 3.1d). Successful binding of 4-OHT enables the translocation of 
CreERt2 into the nucleus through NLS reveal, where Cre-mediated recombination can occur [259]. 
The consequence of Cre-mediated recombination between the LoxP sites results in the deletion of 
the floxed gene(s) from the genomic DNA, and creation of a circular closed loop of DNA consisting 
of the excised gene (Figure 3.1e) [260,261].  
The breeding regimen followed to generate the triple floxed GEMM used throughout this thesis can 
be seen in Table. 3.1. Briefly, β3fl/fl, α5fl/fl, and Nrp1fl/fl (FL0) mice were crossed to Pdgfb.iCreERT2 
heterozygous mice to generate each of the single floxed GEMMs with and without the Cre 
construct, producing i.e.: β3fl/fl.Pdgfb.iCreERT2 and β3fl/fl, respectively (FL1); Pdgfb is an endothelial 
cell specific promoter [244]. Crossing of the single floxed GEMMs to one another proceeded to 
generate double floxed variations, i.e.: β3.α5fl/fl.Pdgfb.iCreERT2 and β3.α5fl/fl (FL2). Finally, crossing 
of the double floxed variations to one another resulted in the generation of the triple floxed GEMM 
– β3.α5.Nrp1fl/fl.Pdgfb.iCreERT2 and β3.α5.Nrp1fl/fl (FL3); for simplicity throughout rest of this thesis, 
Cre-positive refers to the triple floxed GEMM containing Cre (β3.α5.Nrp1fl/flPdgfb.iCreERT2) whereas 
Cre-negative refers to the triple floxed GEMM lacking Cre (β3.α5.Nrp1fl/fl) which serves as a wild-
type littermate control. In a similar vein, we crossed GEMMs containing a TdTomato Cre-reporter 
gene to our Pdgfb.iCreERT2 GEMMs to generate TdTomato.Pdgfb.iCreERT2(Cre-neg/Cre-pos) GEMMs that 
upon administration of Tamoxifen should express red fluorescent protein (RFP); enabling us to test 
the efficacy of our Cre system [262].  
 






Figure 3.1 Illustration of the Cre/LoxP system. a) A single copy of the Cre-recombinase construct is present 
within the animal’s genome, located on the Rosa26 locus, containing CreERT2 driven by a Pdgfb promoter. b) 
For a complete homozygous deletion of the target gene(s), the gene(s) of interest are a flanked by LoxP sites 
as depicted. In the case of the triple, integrin-β3, integrin-α5 and neuropilin-1 are all floxed on both alleles 
(integrin-β3 is shown alone for simplicity). c) Under normal biological circumstances Cre is expressed and 
remains in the cytoplasm, HSP90 binds to ERT2. d) Post-administration, Tamoxifen is converted by hepatocytes 
to 4-OHT, and binds ERT2 enabling the translocation of Cre to the nucleus. e) Once inside the nucleus, Cre-
mediated recombination ensues at LoxP sites, resulting in the excision of the floxed gene to a non-expressible 








Table 3.1 Simple breeding schematic for the phases of breeding to achieve the triple floxed GEMM (FL3). 
 
 
Start (FL0) FL1 FL2 FL3 
β3fl/fl β3fl/fl.Pdgfb.iCreERT2(pos/neg) β3.α5fl/fl.Pdgfb.iCreERT2(pos/neg) β3.α5.Nrp1fl/fl.Pdgfb.iCreERT2(pos/neg)) 
α5fl/fl α5fl/fl.Pdgfb.iCreERT2(pos/neg) α5.Nrp1fl/fl.Pdgfb.iCreERT2(pos/neg)  
Nrp1fl/fl Nrp1fl/fl.Pdgfb.iCreERT2(pos/neg) β3.Nrp1fl/fl.Pdgfb.iCreERT2(pos/neg)  















3.2 Deduction of an effective tamoxifen regimen to induce target depletion 
without impeding epithelial growth 
The successful generation of the triple GEMM provided us an in vivo model in which we could study 
the effects of angiogenenic disruption throughout the mammary gland’s life cycle. However, given 
this model is inducible, a regimen of Tamoxifen administration needed to be determined to ensure 
effective target deletion was consistently achieved. Given that Tamoxifen can inhibit mammary 
epithelial proliferation (see below for more detail) we felt it important to establish an 
administration regimen that allowed Cre activity without having deleterious effects on the 
mammary epithelium [263]. Previous work by my supervisor investigated the role of Transforming 
Growth Factor Beta (TGFβ) in mammary gland development, specifically epithelial outgrowth [264]. 
The experimental design for these studies was centred on the local delivery of TGFβ to the 
mammary gland whilst preventing systemic circulation of such a biologically promiscuous growth 
factor. To achieve this, TGFβ was delivered locally via slow release implantable pellets made from 
Elvax-40P® copolymer resin. Elvax-40P is a biologically inert material capable of the sustained 
release of biological molecules. Using these implants, dose administration curves can be performed 
to determine at which point local effects, but not systemic effects, occur, using the contralateral 
gland as a control to measure systemic responses [264,265]. Once an appropriate dose is 
determined, an empty implant can be implanted into the contralateral mammary gland, as a control 
for measuring potential effects of surgical manipulation, such that each animal serves as its own 
control. 
I decided I might be able adapt Elvax-40P® implants to administer Tamoxifen locally to the 
mammary gland. Unfortunately, this endeavour ended swiftly. It was with great difficulty that the 
pellets were produced given the equipment available to me at the time. Furthermore, pellets were 
tricky to prepare, very small pellets needed to be prepared from the larger stock pellet, followed 
by even greater difficulty in implantation and recovery at experimental endpoint; pellets were very 
small to handle and upon performing histological analysis, and post-tissue harvest it was difficult to 
identify whether the pellet had remained in the gland, and if so its location. Additionally, despite 
the physical preparation and recovery of the pellet proving difficult, immunofluorescent analysis of 
Cre-activity, assessed by TdTomato expression discussed in the following section, revealed systemic 
delivery of Tamoxifen (supplementary Figure 9.1). The failure of this approach was disappointing, 
as it could have granted me a definitive negative control, in that the opposing mammary gland 
(implanted with an empty implant) would have served as a contralateral control as opposed to a 
Cre-negative littermate providing the control glands; subject to tittering down the pellet’s 
Tamoxifen dose to prevent the observed systemic effects. Furthermore, continual administration 




of Tamoxifen by Elvax-40P® implants would have required pellet resection to avoid the caveat 
discussed in the following passage.  
I therefore turned my attention to Tamoxifen regimens already used in the lab to induce endothelial 
target depletion in other biological systems. For example, the Robinson Lab routinely administers 
Tamoxifen via I.P. injection to deplete endothelial receptors in subcutaneously growing tumours 
(unpublished – Robert Johnson, Thesis, 2019). Following doses recommended by Jackson 
Laboratory (supplementary Figure 9.2), the regimen entails thrice weekly I.P. injections of 
Tamoxifen over the experimental period (Section 2.3). This regimen produces phenotypic effects 
on tumour growth through modulation of angiogenesis, implying it activates the Cre/LoxP system 
within our GEMMs (unpublished – see section 6). I decided to test a similar regimen in the 
mammary gland. Confirmation of Cre activity within the mammary gland using this regimen was 
achieved by testing it in a Cre-reporter mouse line that expresses TdTomato (a red fluorescent 
protein) in response to Cre activity. In this reporter line, the promoter region of the TdTomato gene 
is followed by a floxed stop codon, preventing reporter expression; the stop codon is removed upon 
Cre activation, thus allowing the expression of the TdTomato reporter. Crossing this reporter line 
to Pdgfb.iCreERT2 animals generated TdTomato.Pdgfb.iCreERT2(pos/neg) animals that, upon addition of 
Tamoxifen, would reveal where Cre is active in the mammary gland under the regimen being tested 
(section 2.2.1). I administered Tamoxifen to TdTomato.Pdgfb.iCreERT2(pos/neg) animals thrice weekly 
over two weeks (Figure 3.2a). Mammary glands were then harvested on day 14 and examined for 
TdTomato expression by immunofluorescence. As can be seen in Figure 3.2, the expression of 
TdTomato (red) overlaps with endomucin (a marker of endothelial cells) staining (green) indicating 
Cre-activity within ECs (Figure 3.2b-c). This not only indicates the EC specificity of the Pdgfb.iCreERT2 
within the mammary gland (which has not previously been tested), but it also demonstrates the 
effectiveness of this particular administration regimen in activating Pdgfb.iCreERT2 in the gland. 
Whilst these parameters were important to establish, systemic administration of Tamoxifen, at the 
dose being used, has been shown to inhibit epithelial growth in the developing mammary gland 
from between 3-8 weeks post treatment, with complete recovery observed after 8 weeks [263].  
Taking this into consideration, I wanted to design an experimental setup that would allow me to 
examine the effects of disrupted angiogenesis, without having Tamoxifen toxicity on the mammary 
epithelium as a confounder. I decided to start Tamoxifen administration when animals weighed 
15g. This experimental start point was decided upon for two reasons: (1) a multitude of literature 
exists demonstrating that early deletion of our EC targets results in embryonic lethality [266–270], 
and we have shown that even early postnatal deletion of the proposed EC targets leads to lethality 
(unpublished data); (2) 15 g is a documented indicator of the onset of puberty in C57/BL6 mice 




[271,272]. Therefore, a start weight of 15 g allowed me to have a consistent point at which to 
activate Cre and to then harvest glands in windows outside of the reported Tamoxifen toxicity.  
Thus, for all non-cancer studies, Tamoxifen treatment began when animals weighed ~15g. 
Developing glands were then harvested when animals weighed ~20g (mid puberty), which was 
generally two-weeks after the last Tamoxifen injection (before the beginning of Tamoxifen toxicity) 
[271]. I further modified the Tamoxifen regimen such that mice only received three I.P. Tamoxifen 
injections, administered every other day. I decided to only administer these three doses in order to 
further mitigate against potential Tamoxifen toxicity (Figure 3.3a). For all other non-pubescent 
studies (e.g. pregnancy, lactation, and involution) required the mice to be sexually mature. As such, 
the same Tamoxifen treatment regimen was followed, with mating not instigated until 8 weeks post 
final injection, thus well outside the window of potential Tamoxifen toxicity (Figure 3.3b). Late in 
my studies, I was able to confirm this adapted regimen provided effective Cre activity, in the 
mammary glands of mice that underwent the pregnancy regimen, by testing it in the TdTomato 
Cre-reporter mouse line (Figure 3.3b). Post-induction, 8 weeks later, TdTomato expression was 
detectable in vasculature, demonstrating that not only was our adapted regimen inducing Cre 
activity, but the vasculature of a mature gland was fully expressing TdTomato, implying the activity 












Figure 3.2 Immunofluorescent staining shows co-expression of TdTomato and endomucin in the pubertal 
gland.TdTomato.Pdgfb.iCreERT2(neg/pos) mice underwent the initial, experimental, Tamoxifen regimen in (a). b) 
Representative image of Cre-negative staining for DAPI (blue), TdTomato (red) and endomucin (green). c) 
Representative image of Cre-positive staining for DAPI (blue), TdTomato (red) and endomucin (green). Scale 
bar = 100µm. 
 
 





Figure 3.3 Experimental Tamoxifen regimens used for studying mammary morphogenesis at various stages. 
Pubertal and pregnancy experiments were performed under these regimens to ensure consistent timepoints 
for experimental start and harvest, and to avoid adverse effects of Tamoxifen. a) The Tamoxifen regimen 
used for all pubertal experiments. Mice weighing 15g underwent one round of three injections of Tamoxifen 
on alternating days and were monitored until their body weight reached 20g. Upon reaching 20g, 
approximately 2 weeks post final injection, mice were mid-puberty and the glands were harvested. b) The 
Tamoxifen regimen used for all experiments regarding pregnancy, lactation, and involution of the mammary 
gland is the same as the developmental regimen (a), following which mice were aged for 8-weeks to avoid 
potential effects of Cre toxicity, prior to timed mating. 
 
 
Figure 3.4 Immunofluorescent whole gland staining shows co-expression of TdTomato and endomucin in 
the mature virgin gland, 8 weeks post Tamoxifen administration. TdTomato.Pdgfb.iCreERT2(neg/pos) mice 
underwent Tamoxifen administration following the pregnancy regimen. a) Representative image of Cre-
negative staining for DAPI (blue), TdTomato (red) and endomucin (green). b) Representative image of Cre-
positive staining for DAPI (blue), TdTomato (red) and endomucin (green). Scale bar = 100µm. 
Week 1 
(15g/~3 weeks old) 
Monitor Body 
Weight 





D1 D3 D5 
Harvest Mammary Gland at 20g 
Week 1 
(15g/~3 weeks old) 







D1 D3 D5 
a) 
b) 




3.3 Isolation, transfection, and immortalisation of mammary derived endothelial 
cells provides a tool to study mammary endothelial cell behaviour in vitro 
The Robinson Lab has a history of studying EC biology and biochemistry using ECs derived from the 
lung microvasculature [254]. However, given the mammary focus of this project, and other 
literature identifying unique EC populations from different organs / systems, we sought to 
investigate how mammary derived ECs would differ to those from the lung, and attempt to have an 
EC line that might provide mechanistic insight into any mammary specific in vivo phenotypes (e.g. 
enabling me to unpick signalling pathways and interactions between the three molecules of interest 
in mammary-derived ECs) [10,273,274]. A previous researcher in the lab (Dr Robert Johnson) 
generated working immortalised lung microvascular EC (LECs) lines which are missing the 
expression of integrin-β3, integrin-α5 and neuropilin-1 (Table. 3.1 – F1, F2 and F3). Endothelial cells 
were isolated from lung microvasculature and were immortalised through transfection with 
polyoma-middle-T-antigen (PyMT) retrovirus (section 2.5.1 and 2.5.2). Target depletion was 
achieved by tat-Cre transfection after isolation of floxed/floxed cells, which allows us to have a 
‘parental’ control (mock transfected) line for each individual line we isolate (Section 2.5.3). Deleted 
lung EC lines will henceforth be referred to as LEC-KO, whilst floxed/floxed (e.g. essentially wild-
type cells) will be referred to as LEC-WT. 
I was able to successfully modify this approach to isolate and generate triple floxed endothelial cells 
from the mammary gland (mammary endothelial cells – MECs) as described for the LECs. The 
predominant modification added to the process was the removal of the lymph node from the 
number four mammary gland prior to tissue homogenisation, in an attempt to enrich our capillary 
population and reduce the proportion of lymphatic cells cultured post-homogenisation. 
Immortalisation and target deletion were achieved as described before, generating both MEC-KO 
and MEC-WT populations. Target depletion was confirmed through Western blot analysis (Figure 
3.5). A fibroblast cell line (3T3) lysate was probed alongside MEC lysates to provide a negative 
control for EC markers and target deletion, acknowledging 3T3 cells are known to express low levels 
of integrin-α5 (Unpublished – Jordan Lambert, Thesis, 2019). To note, the second, higher, band 
observed when probing for integrin-β3 is a commonly observed non-specific band (which appears 









Figure 3.5 Representative Western blot showing in vitro depletion of floxed target genes in MECs through 
tat-Cre-recombinase transfection. Mammary endothelial cells (MECs) were isolated from 
β3.α5.Nrp1fl/fl.Pdgfb.iCreERT2 triple floxed mice, immortalised through PyMT mediated retroviral infection 
and transfected with tat-Cre-recombinase (MEC-KO), and then immunoblotted for the targets of interest. 
Mock-transfected MECs (MEC-WT) serve as a wild-type parental line. Lysates from 3T3 fibroblasts were run 
alongside as controls because they are known to possess low (integrin-α5) or no (integrin-β3, neuropilin-1) 


























































3.4 Confirmation of mammary endothelial cell identity prior to in vitro studies 
Having successfully isolated, immortalised, and partitioned triple floxed MECs into KO and WT 
populations, I proceeded to confirm their identity as ECs. During the MEC preparation, endomucin 
was used as a marker to positively sort for ECs from the mammary gland homogenate; this step was 
performed twice (see Section 2.5.1). Though well established as an EC marker, endomucin is only 
one potential marker of EC identity, and it can be expressed by other cell types, specifically those 
from the hematopoietic cell lineage, such as myeloid and lymphoid cells [276,277]. Best practise 
entails the confirmation of newly generated cell line identities to ensure all work performed can be 
confidently attributed to the acclaimed cell type [278–280]. In addition, when isolating ECs from 
microvasculature, there is potential of co-isolating lymphatic ECs [281,282]. In addition, though we 
and others have shown that immortalised ECs maintain their identity post-immortalisation, we 
routinely confirm EC identity throughout the passaging of the cells during their culture 
[114,251,283,284]. 
Endothelial identity was assessed throughout the experimental study period, and up to passage 24, 
the maximum passage at which MECs were used. As expected, MECs continue to express 
endomucin, the marker against which they were originally isolated (Figure 3.6). In addition, we 
confirmed the expression of VEGFR2, a key receptor expressed by endothelium for the transduction 
of VEGF signals (Figure 3.6) [30]. Furthermore, the expression of CD31 (PECAM-1) and VE-Cadherin 
(Cdh5) were also detected, both highly expressed at, and essential in maintaining, EC cell-cell 
junctions (Figure 3.6) [285,286]. We also examined the expression of two more recently recognised 
markers of EC identity: claudin-V and ETS-Related Gene (ERG). The respective function of claudin-V 
and ERG on endothelium is to modulate tight junctions between ECs and control of vascular 
permeability respectively [287,288]. Both proteins were expressed by MECs, reinforcing the 
conclusion that I had successfully isolated ECs from the mammary gland, and their identity was 
maintained throughout culture (Figure 3.6). I also examined the expression of known lymphatic 
markers, namely LYVE-1 and PROX-1 [289,290]. PROX-1 expression was very low, and LYVE-1 
expression was not detected (Figure 3.6). Lysates from 3T3 fibroblasts were included as a negative 
control for all markers (note, low PROX-1 expression was observed in MECs and 3T3 fibroblasts, 
suggesting the antibody used detects a non-specific band). 





Figure 3.6 Western blot confirmation of endothelial cell status. An immune blot of MECs for endothelial and 
lymphatic markers. 3T3 is a fibroblast cell line used as a negative control for the expression of endothelial 
















The GEMMs used in my studies had already largely been established at the start of this project, thus 
there was little delay in undertaking in vivo studies. The ultimate task in hand which had been 
achieved prior to the project was the generation of the triple floxed animal 
(β3.α5.Nrp1fl/fl.Pdgfb.iCreERT2) upon which the entire project, in vivo and in vitro, was pinned. Aside 
the GEMM utilised for the developmental studies throughout this project, all other GEMMs 
generated (listed in Table. 3.1) were used for cancer studies in a bid to ascertain the value of each 
molecule individually in modulating pathological angiogenesis with respect to the cancer model 
used (see section 6).  
Although the tools required to pursue this project had successfully been generated, there are 
several drawbacks. First and foremost is the efficacy of our Cre, specifically its off-target activity. 
Pdgfb.iCreERT2 has been shown to lack sole EC specificity [291,292]. Expression of Pdgfb has been 
documented in neurons, smooth muscle, macrophages and megakaryocytes [293–296]. Despite 
this, Pdgfb.iCreERT2 has demonstrated, and continues to demonstrate, efficient target depletion in 
our GEMMs [114,254]. Having stated Pdgfb is not exclusive to ECs, without experimental evidence 
we cannot say for certain any findings observed can be solely a result of a lack of angiogenesis. 
Specifically, macrophages are known to play a vital role in remodelling the ECM during mammary 
gland morphogenesis. As such, phenotypes associated with epithelial development could be a 
consequence of macrophage related deletions of our targets as opposed to endothelial [297]. 
Advances in the Cre/LoxP system have resulted in the development of new inducible EC specific 
Cre-promoters, one worthy of mention is Cdh5.iCreERT2. Cdh5 driven Cre demonstrates EC 
specificity whilst boasting no off target expression [291,298]. Our lab is now in the possession of 
Cdh5 Cre, however we had already established our GEMMs on the Pdgfb Cre prior to its 
obtainment.  
Coinciding with the effort to generate and maintain these GEMM lines, we developed a routine of 
“best breeding practice”, involving: genotype confirmation by PCR of all GEMMs to be used for 
breeding trios to ensure the correct animals are bred, PCR analysis of all floxed alleles for every first 
litter across all breeding trios in all of our GEMM lines to confirm the former checkpoint, and 
confirmation of the allelic status, post-harvest, for all experimental animals to ensure correct 
genotypic parameters; Pdgfb.iCreERT2 status was also checked and confirmed at these checkpoints, 
as well as on every litter weaned. 
Having access to the triple floxed animals at the start of this project not only facilitated the in vivo 
studies but it also enabled the isolation of MECs. LECs are often widely used as an in vitro model to 




study angiogenesis [284,299,300]. Albeit valid, this wholistic approach overlooks literary evidence 
for differences between “identical” cells isolated from unique locations, i.e. ECs from lung vs 
mammary gland [10,273,274]. The success of isolating MECs, in conjunction with already having 
access to triple LECs, grants us the opportunity to begin exploring the tissue specificity of ECs, and 


























4 Angiogenic signalling mediated through integrin-β3, integrin-α5 and 
neuropilin-1 is not required for successful epithelial morphogenesis in 
the murine mammary gland during pubertal development 
Having determined a Tamoxifen regimen suitable to induce target depletion that should not impact 
normal epithelial growth, the exploration into the role of angiogenesis in the murine mammary 
gland could begin. I initially explored the role of angiogenesis during the rapid epithelial expansion 
the mammary gland undergoes during puberty. As with any tissue, allometric growth alone requires 
angiogenic activity to ensure growing tissues stay within sufficient range of blood vessels to allow 
diffusion of oxygen and nutrients [301,302]. During puberty, the mammary gland undergoes 
expansion at exceptional speed, faster than that of allometric growth; I hypothesised this rapid 
growth would require angiogenesis to meet the needs of the developing organ.  
 
4.1 Epithelial outgrowth of the murine mammary gland during pubertal 
development is not affected by angiogenic impediment 
The ventral surface of the mouse is comprised of five pairs of mammary glands running in parallel, 
cranial to caudal (Figure 4.1). Of the five pairs, the easiest to harvest are the mammary glands 
located at positions three and four, with the number three also lying the flattest, and therefore 
offering the greatest clarity in terms of visualisation post-staining (Figure 4.1a). In fact, the number 
three gland is that which is most often used for examining the effects of experimental 
manipulations on mammary gland morphogenesis. However, for my studies the quantitation of the 
number three glands proved difficult due to a lack of a reference point from which epithelial 
outgrowth could be measured consistently. To facilitate easy visualisation, this gland requires 
manual stretching to original size over a tissue cassette before fixation and staining. Because this 
stretching exercise varies from gland to gland, and from user to user, we felt this manipulation 
might lead to variability in the quantification of total epithelial growth, if, for example, we were to 
measure distance from nipple to epithelial front (Figure 4.2). Moreover, the margins of glands in 
positions two and three overlap, and the number three glands sits in close proximity to muscle 
situated on the forelimbs and spine. Practically speaking, this means that part of the number two 
gland and some muscle is inevitably harvested along with the number three gland, and these must 
be manually separated after whole gland staining, which generally leads to structural damage in 
the number three gland. Thus, we decided to harvest and perform analyses in the number four, 
abdominal, mammary gland. Although this gland is thicker than the number three gland, and 
consequently lacks the same level of clarity in epithelial structure post whole gland stain (WGS), it 




requires very little stretching back to original size and it contains a central lymph node: a structure 
















































Figure 4.1 Ventral diagrams of the mouse depicting the position and location of all five pairs of mammary 
glands. Mouse possess five pairs of mammary glands on the ventral surface. a) A sketched ventral diagram 
of the mouse displaying the five pairs of mammary glands located on the ventral surface. The numbers 
running down the centre denote the position of the mammary glands. Highlighted are one of the two number 
three glands (blue) and one of the number four glands (red). b) An anatomical photo displaying the five pairs 
of mammary glands. Note, the situation of glands two and three with respect to each other and muscle from 





Figure 4.2 Quantification of epithelial outgrowth of the number three gland proved difficult due to imaging 
limitations. Representative images of the number three glands following WGS with haematoxylin, 
highlighting the difficulties in quantifying the number three mammary gland. The peripherally located tissue 
(black dashed lines) highlights the boundary of the mammary gland, demonstrating the artificial area 
produced by the manual spreading of the gland into the tissue cassette. Depicted by the red arrows, 
measuring epithelial outgrowth from nipple to epithelial front can be difficult due to the high density of tissue 




















Having established the number four gland to be optimal for my studies, I proceeded to treat 15g 
female mice with the Tamoxifen regimen discussed previously (section 3.2) (Figure 3.3a) and 
harvested their glands when they reached 20g. Glands were then processed for WGS so that the 
epithelium was discernible and visual interpretation of epithelial outgrowth ensued. To my surprise, 
upon visual inspection, it appeared that impeding angiogenesis through the co-depletion of 
integrin-β3, integrin-α5, and neuropilin-1 in Cre-positive animals showed no gross deviation in 
epithelial expansion compared to their Cre-negative counterparts (Figure 4.3a-b). I then proceeded 
to quantify a number of epithelial parameters. First, the epithelium adjacent to, and extending past, 
the lymph node was traced as a separate image layer (GNU Image Manipulation Program – GIMP) 
and measured using the Simple Neurite Tracer plugin (ImageJ) (Supplementary Figure 9.3). This 
quantification supported the observation from the WGS; epithelial outgrowth measured in this way 
showed no significant difference between Cre-positive and Cre-negative animals (Figure 4.3c). 
Because visually there seemed to be differences in the epithelial distribution about the lymph node, 
I next quantified the maximum directional epithelial outgrowth (from the lymph node) to assess 
whether direction of growth was affected in Cre-positive animals. The top edge (above) and either 
side of the lymph node were measured (Figure 4.3a). Although total epithelial outgrowth was not 
altered between Cre-positive and Cre-negative animals, the extent to which the epithelium at the 

















                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
Figure 4.3 Epithelial outgrowth of the mammary gland during pubertal development is not impeded by co-
depletion of endothelial integrin-β3, integrin-α5 and neuropilin-1.Cre-positive and Cre-negative animals 
underwent Tamoxifen-induced Cre-recombinase activation following the pubertal Tamoxifen regimen 
described in section 3.2. a-b) Representative images of whole gland stained number four mammary glands. 
c) Quantification of the area of total epithelial outgrowth measured from the base of the lymph node 
outward. d) Average omnidirectional epithelial extension (right – overlaid with an example of quantification 
method). e) Maximum directional extension of mammary epithelium from the lymph node, left, above and 
right respectively. LN = Lymph Node. N=11, Cre-negative n=31, Cre-positive n=21. Scale bar = 2mm. Error bars 




























































































































Finally, I also measured epithelial density and number of branch points within each of the three 
measured areas near the lymph node (e.g. top edge (above), left and right). Like overall outgrowth, 
I observed no statistical difference in these two measurements when comparing Cre-positive to 
Cre-negative glands (Figure 4.4). Taken collectively, these findings suggest that impeding 























Figure 4.4 Epithelial density and the number of branch points are unaffected when endothelial integrin-α5, 
integrin-β3 and neuropilin-1 are depleted. Cre-positive and Cre-negative animals underwent Tamoxifen-
induced Cre-recombinase activation following the pubertal Tamoxifen regimen described in section 3.2. 
Three 1x106 µm2 regions around the lymph node were quantified (left, above, right) for epithelial density and 
number of branch points. a) Area specific quantification of epithelial density as a percentage of the 1x106µm2 
region. b) Average epithelial density as a percentage of the 1x106µm2 region. c) Area specific quantification 
of the number of branch points. d) Average number of branch points. N=11, Cre-negative n=31, Cre-positive 


















































































































































4.2 Terminal end bud trifurcation events are significantly increased in the 
absence of pro-angiogenic targets 
Upon closer visual inspection of stained whole glands, I noted occasional trifurcation at branching 
points (Figure 4.6a), suggesting that whilst overall epithelial outgrowth may not be affected by 
angiogenic perturbation, other aspects of developmental morphogenesis might be. Thus, I decided 
to quantify additional morphometric parameters.  
Terminal end buds (TEBs) are small robust structures found within the post-natal mammary gland, 
fundamental in permitting epithelial expansion through their motility and proliferative capacity 
[304]. Found at the migratory front of the mammary epithelium during pubertal development, 
hormonal stimulation of TEBs during puberty is responsible for instigating mitotic events which 
summate in the growth, and subsequent penetration, of the epithelium through the mammary fat 
pad [305]. As they grow through the fat pad, TEBs branch, filling the available space as they grow, 
but maintaining sufficient space for alveoli to form during later stages of the mammary gland cycle 
[306]. Bifurcations are the most common form of branching, but trifurcations do form on occasion. 
The mechanisms leading to rare trifurcation events are poorly defined, but increased trifurcations 
are more frequently associated with an over expression of the Rho GTPase CDC42, a key protein in 
regulating mammary morphogenesis whose aberrant expression has been linked with BC 
formation, suggesting the process is tightly controlled [307]. Thus, I decided to examine TEBs and 
branch points in greater detail, with the aim of addressing whether the modality in which the 
epithelium is expanding via TEBs differs between Cre-negative and Cre-positive animals. Given the 
lack of an overall phenotype with respect to epithelial “coverage” in Cre-positive animals, I 
hypothesised that the type of branching is altered such that overall epithelial density, which may 
be essential for later stages of mammary gland differentiation and function, is maintained even 
when angiogenesis is impaired. 
As mentioned, TEBs are the drivers of epithelial growth during pubertal development and can be 
considered to directly relate to epithelial growth; the greater the number of TEBs the greater the 
growth rate [308]. Thus, I first quantified the overall number of TEBs per gland, using the multi-
point tool on ImageJ (section 2.7.1.1, Figure 4.5). There was no significant difference observed in 




































Figure 4.5 Depletion of endothelial integrin-α5, integrin-β3 and neuropilin-1 does not affect terminal end 
bud (TEB) number. Cre-positive and Cre-negative animals underwent Tamoxifen-induced Cre-recombinase 
activation following the pubertal Tamoxifen regimen described in section 3.2. Total TEB counts were 
enumerated from WGS images using ImageJ. a) Representative images of WGS mammary glands with TEBs 
marked (white arrows). b) TEB quantification from WGS images. N=11, Cre-negative n=31, Cre-positive n=21. 























































I next counted the number of epithelial trifurcations in Cre-negative and Cre-positive glands. This 
quantification revealed a significantly greater number of these events in the Cre-positive mammary 
glands compared to the Cre-negative (Figure 4.6). This finding suggests that epithelial outgrowth in 
Cre-positive animals is maintained by increasing the number of trifurcated branch points. Finally, 
during my enumeration of TEBs, I noted they were not always easy to identify in Cre-positive glands 
as they occasionally lacked typical TEB size, they appeared smaller, but were exhibiting bifurcation 
or were located at the migratory front (Figure 4.5a). Thus, I decided to investigate the 
histoarchitecture of TEBs and bifurcations is H&E sections.  
An explanation for this given the data discussed so far, is that an increase in TEB trifurcations is a 
response to impaired angiogenesis to supplement epithelial growth. In turn, increased mitotic 
activity at TEBs, to accommodate impaired angiogenesis, could consequently be coming at a 
structural cost, resulting in TEBs losing their traditional shape. Altogether, this suggests the robust 
bulb like structure normally exhibited by TEBs may not have fully recovered prior to the next 
bifurcation, or trifurcations, event, perpetuating this lack of typical structure.  






Figure 4.6 Trifurcation events take place more frequently in the mammary gland when when endothelial 
integrin-α5, integrin-β3 and neuropilin-1 are depleted. Cre-positive and Cre-negative animals underwent 
Tamoxifen-induced Cre-recombinase activation following the pubertal Tamoxifen regimen described in 
section 3.2.Total trifurcation events were quantified from WGS images. a) Representative WGS images of 
mammary glands with points of trifurcation highlighted (red rings). b) Quantification of trifurcation events in 
Cre-negative and Cre-positive mammary glands. N=11, Cre-negative n=31, Cre-positive n=21. Scale bar = 




















































Investigating regions of bifurcation and trifurcation at a structural level was achieved through H&E 
staining (section 2.7.3). Serial sections of Cre-negative and Cre-positive glands were collected in 
their entirety and stained, enabling clear visualisation of epithelium undergoing bifurcation and 
trifurcation (Figure 4.7). Despite the typical TEB structure being infrequent, reminiscent of the 
observation made in the WGS images, points of bifurcation were discernible based upon their 
known location, the end of epithelium, alluding to the location of TEBs. Close examination of these 
areas confirmed their identity as TEBs, exhibiting bifurcation or trifurcation whilst showing no 
abnormalities in terms of structure (Figure 4.7a-b). Clearly visible were the cap cells followed by a 
larger layer of cells, the body cells, trailed further by the luminal and myoepithelial cells (Figure 
4.7a). Additionally, we were successful in identifying trifurcation events in both Cre-negative and 
Cre-positive glands, both of which exhibited normal structure as observed in normal bifurcation 












































Figure 4.7 H&E staining shows terminal end bud (TEB) structure is unaffected when endothelial integrin-
α5, integrin-β3 and neuropilin-1 are depleted. Cre-negative and Cre-positive mice underwent Tamoxifen-
induced Cre-recombinase activation following the pubertal Tamoxifen regime, whole mammary glands were 
paraffin embedded and serial sectioned at 10µm before H&E staining. a) Top panel – representative images 
of Cre-negative epithelium undergoing bifurcation (red arrows), cap cells (black arrows) and body cells (blue 
arrows). b) Bottom panel – representative images of Cre-positive epithelium undergoing bifurcation (red 
arrows), cap cells (black arrows) and body cells (blue arrows). c) Top panel – representative images of Cre-
negative epithelium undergoing trifurcation. d) Bottom panel – representative images of Cre-positive 
epithelium undergoing trifurcation. Red dots indicate the heads of trifurcation. N=2, Cre-negative n=3, Cre-
positive n=3. Scale bar(s) = 100µm. 





Angiogenesis is a fundamental process throughout embryogenesis and postnatal development 
[309]. Besides allometric growth, angiogenesis also occurs to supplement developing tissues, e.g. 
the retina, and to accommodate new biological functions, e.g. pregnancy, when a demand for 
oxygen and nutrients is not being met [310,311]. This chapter sought to determine the role, if any, 
angiogenesis plays during the process of epithelial growth in the murine mammary gland during 
pubertal development. Through targeted co-depletion of endothelial integrin-β3, integrin-α5 and 
neuropilin-1, we sought to impair angiogenesis in vivo, during puberty (section 3.2). Previous work 
in our lab, utilising the retinal angiogenesis assay, has demonstrated their collective depletion elicits 
a potent anti-angiogenic effect (unpublished – Robert Johnson, Thesis, 2019). In addition, tumour 
studies performed by our lab utilising this same combination of target depletion leads to a 
significant reduction in tumour volume and weight. Together, this indicates co-depletion of these 
targets effectively impairs both physiological and pathological angiogenesis (unpublished – Robert 
Johnson, Thesis, 2019, and see section 6). All in all, given epithelial growth during pubertal 
development is a rapid process, that undoubtedly requires a steady supply of oxygen and nutrients, 
I was keen to explore the effects that impairing the process of angiogenesis, using this combination 
of target depletion, would have on the developing mammary gland. 
To address whether the collective removal of these molecules affected epithelial development I 
quantified the growth of the epithelium from a range of perspectives. Specifically, I measured: 
epithelial outgrowth, epithelial extension, epithelial density, number of branch points, number of 
TEBs, number of trifurcation events and TEB structure. To my surprise, and in stark contrast to my 
initial hypothesis that impeding angiogenesis would impair epithelial morphogenesis, there was 
little change in morphogenesis when endothelial integrin-β3, integrin-α5 and neuropilin-1 were co-
depleted. Only two of the parameters measured showed any significant change when comparing 
Cre-positive (angiogenesis impaired) to Cre-negative (normal angiogenesis) animals: maximum 
epithelial growth at the top edge of the lymph node and the number of trifurcation events. Even 
here, I felt the differences were relatively subtle. The mean trifurcation events were 2.1 and 4.5 
and mean distance from the top edge (above) of the lymph node were 3.2 and 4.4 mm, when 
comparing Cre-negative and Cre-positive glands, respectively. There are three easy explanations 
for the lack of a phenotype at this developmental stage of the gland, which I see as being related 
to the EC proteins we chose to disrupt: (1) I have not impaired angiogenesis as expected (i.e. the 
Tamoxifen regimen did not work in the mammary gland); (2) epithelial outgrowth at this stage does 
not require what is considered classical angiogenesis; and (3) angiogenesis in the mammary gland 
is not driven by the VEGF pathway, meaning I chose the wrong EC targets to impede angiogenesis 




and/or cross-talk between the vasculature and the epithelium in the mammary gland. I will discuss 
each of these possibilities in turn. 
Despite our target deletion having previously demonstrated potent anti-angiogenic effects we were 
unable to demonstrate target deletion in the pubertal, and subsequently pregnancy, studies. 
However, we were successful in demonstrating target deletion in tumour studies, discussed in 
section 6. Furthermore, as we were unsuccessful in obtaining a WGS of our TdTomato Cre-reporter 
at the experimental start and end point of the pubertal studies, we cannot comment on the extent 
to which Cre was active in the pubertal gland, nor whether the vasculature of the pubertal gland 
was formed at experimental start point. However, we were successful in obtaining this information 
for proceeding pregnancy experiments (section 5) – Cre activity following our Tamoxifen regimen 
is near fully active amongst mammary endothelium. 
Through the use of corrosion casts, Djonov et al showed between 5 and 12 weeks of age that Swiss 
MORO mouse mammary gland exhibits a slight increase in capillary size and complexity, whilst also 
noting morphological characteristics of sprouting angiogenesis [161]. However, if we assume that 
depleting our EC targets during puberty would impair angiogenesis (if it is occurring), we can only 
conclude that the vasculature required for mammary epithelial morphogenesis is pre-existing 
throughout the fat pad and not formed during puberty.  
Aside from de novo vascular formation playing a role in epithelial morphogenesis, there is 
precedence in the literature to suggest that signal from the endothelium are essential for 
tissue/organ formation (coined angiocrine signalling) [312]. For example, Barry et al. recently 
deciphered a complex interplay between kidney vascularisation and gross kidney development. 
Utilising bulk and single RNA-seq they managed to identify six unique vessel types within the kidney. 
In addition, they also noted several unique gene signatures within kidney vasculature all of which 
became robustly expressed upon birth, with loss of function experiments demonstrating their 
tissue specific importance. The group hypothesise that this post-birth shift in gene expression could 
be related to physiological load not previously experienced by the kidney whilst in utero, a concept 
that is supported by noting that transport proteins essential for kidney function are not expressed 
until after birth [313]. Relating this field of study to the results of this section, it seems feasible to 
suggest that angiocrine signalling between the native vasculature of the mammary gland and the 
mammary epithelium is a driving force in propagating epithelial expansion during puberty, but the 
EC molecules we have chosen to deplete are not involved in the angiocrine signalling that is taking 
place. Literature, and our own findings discussed later in this thesis, point to hormonal cues, 
specifically progesterone, as a potential mechanism by which the vasculature of the mammary 




gland is modulated; in part supporting the angiocrine theory given the tissue specific response of 
the mammary vasculature. Although debated, literature exists for progesterone being both pro- 

























5 Maturation and alveologenesis of the mammary epithelium during 
pregnancy is moderately reduced when angiogenesis is impaired, but 
lactation and involution appear unaffected 
The mammary gland is a unique organ in the way it demonstrates post-embryonic feats of rapid 
proliferation, functional differentiation, milk production and organised cell regression (involution), 
with the ability to repeat the cycle over multiple times. Pregnancy is the ultimate phase of the 
mammary lifecycle, exhibiting all the aforementioned processes, and in the case of the mouse, in a 
relatively small timeframe. Given the massive changes in epithelial growth and restructuring that 
occur, it seems rational to propose that angiogenesis and/or vascular remodelling would occur 
alongside; especially since epithelial activity during pregnancy is even greater than during puberty. 
Supporting this proposal, corrosion cast data collected by Matsumoto et al. detected an increase in 
capillary number, density and ramification during pregnancy [320]. Therefore, although epithelial 
outgrowth during pubertal development was unaffected by impeding angiogenesis, we 
hypothesised that the increased metabolic state of epithelium during pregnancy would be 
dependent on sufficient angiogenesis, specifically VEGF driven; expression of VEGFs and VEGFRs 
have been detected in the virgin gland with a marked increase in expression during pregnancy [321]. 
To test this hypothesis, I assessed the maturation of the mammary epithelium at two timepoints 
during pregnancy, E10.5 and E15.5, one timepoint during lactation (P2) and one timepoint at which 
involution was induced (P10+48hours).  
Between E0.5 and E10.5 the mammary gland undergoes rapid epithelial expansion through means 
of secondary and tertiary branching. From E10.5 up until birth the mammary gland transitions from 
epithelial maturation to alveologenesis; the formation of bud-like structures referred to as alveoli 
(lobuloalveolar) which encompass the side-branches [306,322,323]. E10.5 and E15.5 coincide with 
the two major phases of epithelial growth, thus I decided to examine phenotypic consequences of 








5.1 Epithelial maturation during mid-gestation (E10.5) is unaffected by 
angiogenic impairment however embryo weight is significantly reduced 
The triple GEMMs used for E10.5 pregnancy studies received the same Tamoxifen regimen that was 
used for the induction of Cre in the developmental studies; at a body weight of 15g, animals 
received three injections of Tamoxifen, once every other day (Figure 3.4b). Post Cre-induction, 
animals were left to age for a further 8 weeks to accommodate for any stunting in epithelial growth 
caused by the Tamoxifen administration (Tamoxifen toxicity) (previously discussed – section 3.2). 
At 8 weeks post injection, female triple GEMM mice were paired with triple GEMM males in the 
evening followed by unpairing and plug checking in the morning; evidence of a plug was considered 
E0.5 and the female(s) were weighed to track weight gain as a positive indicator of pregnancy [324]. 
Upon reaching mid-gestation, E10.5, the female(s) were sacrificed, and the number four glands 
were harvested, fixed and WGS was performed (see section 2.7). Of note, the embryos at this 
timepoint were collected (placenta included), counted and weighed. Interestingly, despite no 
significant difference observed in the number of embryos in the Cre-positive females when 
compared to Cre-negative females, the weight of the embryos was significantly different (Figure 
5.1a-b). The glands that underwent WGS allowed clear visual discernment of the epithelium (Figure 
5.1c-d). Casual visual examination of images suggested that some areas within the fat pad of Cre-
positive glands exhibited lower epithelial density compared to Cre-negative glands (Figure 5.1c-d). 
Quantification was then performed on the epithelium directly adjacent to the lymph node. This 
region was chosen to allow a consistent point in which the epithelium could be measured across all 
E10.5 glands (supplementary Figure 9.4). Whilst the overall measured mean difference between 
Cre-negative and Cre-positive glands supported the visual observations, it did not reach statistical 
significance (Figure 5.1e). 
Whilst not wanting to fall into a trap of believing a ”trend” that is not supported by statistical 
analysis is meaningful, in this particular instance I felt that the quantification of the epithelial 
density near the lymph node did not reflect the overall picture of what I was observing across the 
entire gland. I felt that perhaps by measuring the epithelial density across the entire WGS, I might 
achieve a better reflection of what I was observing. However, having attempted to utilise ImageJ 
numerous times to automate epithelial quantification to no avail (at all stages of development), 
and with the density of the epithelium too great at E10.5 to reliably execute manual quantification, 
entire gland quantification was unachievable – see supplementary Figure 9.5 for all E10.5 gland 
images. Thus, I conclude that impeding angiogenesis impairs epithelial outgrowth in the mammary 
gland during the early stages of pregnancy, but I cannot yet support that statement mathematically. 







Figure 5.1 E10.5 embryonic weight is significantly reduced, and embryonic number and epithelial 
maturation are (statistically) unaffected when endothelial integrin-α5, integrin-β3 and neuropilin-1 are 
depleted. Cre-negative and Cre-positive females underwent Tamoxifen-induced Cre-recombinase activation 
following the pregnancy Tamoxifen regimen described in section 3.2. a) Number of embryos present at E10.5. 
b) Embryo weights at E10.5 (P=0.0033). c-d) Representative images of E10.5 whole gland stained number four 
mammary glands. e) Quantification of epithelial growth on both sides of the lymph node. Cre-negative, N=5. 
Cre-positive, N=6. Embryos: Cre-negative, n=39 and Cre-positive n=46. Scale bar = 2mm. Error bars = ±SEM. 




































































5.2 Epithelial maturation during late gestation (E15.5) is unaffected by 
angiogenic impediment through the co-depletion of endothelial integrin-β3, 
integrin-α5, and neuropilin-1 
Encouraged by my observations in the E10.5 mammary gland, I proceeded to explore the same 
parameters at a later stage of pregnancy, E15.5. As mentioned above, I chose this stage of 
pregnancy because it serves as a transition point between the final stages of epithelial maturation 
and alveologenesis within the gland. Alveologenesis primes the mammary gland for lactation. 
During this stage of pregnancy, epithelial growth and side-branching quiesces and proliferative cells 
within newly formed side-branches generate alveolar buds which mature, through cleavage and 
differentiation, into alveoli [306]. Furthermore, the period of time between E10.5 and E15.5 is 
approximately a quarter of the entire gestation period; five days. I considered this time difference 
sufficient to explore whether the phenotype observed at E10.5 persisted, and/or was augmented, 
without the gland becoming entirely saturated with alveoli, which I thought might make 
quantification even more difficult than it already was. 
Finally, E15.5 was also chosen because of difficulties I had early on in my pregnancy studies with 
achieving successful timed mating in Cre-positive animals. When I began studying the mammary 
gland at E10.5, I was finding it very difficult to obtain Cre-positive females that were carrying any 
pups when they were harvested at E10.5. I began to question whether this lack of success stemmed 
from a lack of a proper angiogenic response in the placenta, resulting in the inability to support 
embryo growth. In later months, I was able to implement a modified timed mating scheme 
(proposed by technicians in our animal facility) which alleviated this problem, but by this time I had 
already (fortuitously) begun to explore the placentas of E15.5 animals (see section 5.3).  
As in E10.5 pregnancy studies, Cre-negative and Cre-positive animals were treated with Tamoxifen 
as described in section 3.2, and at E15.5 the number four glands were harvested, fixed and 
processed for WGS (section 2.7). As well as the mammary glands, embryos and placentas from 
these animals were collected, weighed, the uterine position of embryos recorded, and any 
reabsorption events were documented along with their respective uterine locations (Figure 5.2); at 
this timepoint the placenta can easily be separated from the embryo and subsequently fixed in 4% 
PFA overnight and stored in 70% ethanol until further processed (see section 5.3 below). All of these 
parameters measured yielded no significant difference in Cre-positive animals when compared to 
Cre-negative (Figure 5.2); between E10.5 and E15.5 a loss in significance in embryo weight was 
observed.  





Figure 5.2 Number of embryos, embryonic weight, placental weight, uterine line position, number of 
reabsorption events and location of reabsorption events at E15.5 are when endothelial integrin-α5, 
integrin-β3 and neuropilin-1 are depleted. Cre-negative and Cre-positive female mice underwent Tamoxifen-
induced Cre-recombinase activation following the pregnancy Tamoxifen regimen as described in section 3.2. 
a) Total number of embryos present at E15.5. b) Number of embryos per uterine line. c) Total number of 
reabsorption events observed. d) Number of reabsorption events per uterine line. e) Embryo weight at E15.5. 
f) Placental weight at E15.5. Cre-negative, N=3. Cre-positive, N=3.Embryos: Cre-negative, n=26 and Cre-











































































































































































































At E15.5 the mammary gland is saturated with epithelium beyond that of the E10.5 gland and 
begins to saturate the fat pad further by the addition of alveoli through alveologenesis, taking place 
on secondary and tertiary epithelia, in preparation for postpartum milk production. Having 
quantified the epithelium of the E10.5 WGSs, we sought to stain and quantify glands collected from 
E15.5. However, the level of epithelial density at E15.5 rendered manual quantification impossible, 
and automated quantification was not considered given the inability of the method to yield 
representative epithelial masks of developmental glands which provided fewer, yet more distinct, 
epithelia. Aside from this drawback to quantifying the WGSs, wholistic examination of E15.5 WGS 
yielded no grossly obvious differences in the epithelia of the Cre-positive glands when compared to 












Figure 5.3 Epithelial development at E15.5 is unaffected when endothelial integrin-α5, integrin-β3 and 
neuropilin-1 are depleted. Cre-negative and Cre-positive female mice underwent Tamoxifen-induced Cre-
recombinase activation following the pregnancy Tamoxifen regimen as described in chapter 3.2. Cre-












5.3 The junctional zone of the placenta is larger when endothelial integrin-β3, 
integrin-α5, and neuropilin-1 are co-depleted 
The placenta is an organ which brings together embryo and mother, allowing their interaction and 
function, permitting nutrient supply and subsequently embryo growth, whilst preventing tissue 
rejection; development of the placenta is paramount to successful gestation [325]. Intrauterine 
Growth Restriction (IUGR) is a common problem that can occur during pregnancy, often stemming 
from defects/failure of the placenta. This disorder manifests in foetuses being stillborn, premature 
birth and lifelong risk of adverse health (i.e. poor neurological development and immune 
deficiencies) [239]. As mentioned, my initial attempt at timed mating for the E10.5 experiments 
proved difficult, vaginal plugs were infrequently found and when they were, they rarely resulted in 
a successful pregnancy; I was unable to track abortion therefore I cannot comment on whether 
litters were lost pre-term. As such, alongside the mammary gland, I proceeded to explore placental 
development at E15.5. I reached out to Amanda Sferruzzi-Perri (Cambridge University), and started 
a collaboration with Jorge Lopez-Tello, a postdoctoral researcher in her lab. 
Placentas from the embryos of E15.5 mice underwent stereology. Two placentas per litter, based 
on mean placental weights, were chosen. Analysis was performed on three sagittal sections, non-
adjacent and evenly spaced by 200µm. Subsequent analysis was performed using the Image J Grid 
tool to quantify the regions of the placentas (section 2.8). Despite the weight of Cre-positive 
placentas showing no significant difference when compared to Cre-negative placentas (Figure 5.2f), 
the quantification of placental regions, the decidua (DB), junctional zone (JZ) and labyrinth (LZ), 
revealed something interesting. The DB and LZ are comparable between Cre-positive and Cre-
negative (Figure 5.3a and c). However, the JZ was significantly larger in Cre-positive placentas when 
compared to Cre-negative (Figure 5.3b). This finding was unexpected given the roles of these 
regions, specifically the JZ and the LZ. The LZ is the vascular region of the placenta, vital for 
physically connecting the embryo to the uterine wall whilst also permitting the exchange of 
nutrients and gas between mother and embryo [326]. As such, I hypothesised if a region of the 
placenta were to show alteration in response to a lack of maternal angiogenesis this would be the 
region; it might increase in size to compensate the uterine wall failing to sufficiently vascularise to 
permit nutrient and gas exchange. To my surprise, instead I observed changes in the JZ, the 
endocrinal powerhouse of the placenta.  
 
 




The JZ produces hormones, growth factors and cytokines which collectively perpetuate normal 
pregnancy by modulating the physiology of both mother and foetus [239]. Given the normality of 
the pups, one would assume fetoplacental growth and placental efficiency were unaltered through 
the deletion of my EC targets, and as such the mouse work to explore this phenotype halted. 
However, I pursued an understanding of this phenotype in vitro, utilising mammary and lung ECs, 
in a bid to explore whether hormonal response of the endothelium in the mammary gland was 
aiding in normalising angiogenesis following target deletion, and whether any response was specific 

















Figure 5.4 The volume of the junctional zone (JZ) is significantly increased, at E15.5, when endothelial 
integrin-α5, integrin-β3 and neuropilin-1 are depleted. Cre-negative and Cre-positive female mice 
underwent Tamoxifen-induced Cre-recombinase activation following the pregnancy Tamoxifen regimen as 
described in chapter 3. Following timed-mating, placentas were collected at E15.5. a) Representative image 
of Cre-negative placenta. b) Representative image of Cre-positive placenta. Volume of the decidua (DB) (c), 
junctional zone (JZ) (d) and labyrinth (LZ) (e) compared to Cre-negative counterparts. Cre-negative, N=3. Cre-
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5.4 Lactation (P2) and involution (P12) were not affected by the depletion of 
integrin-β3, integrin-α5, and neuropilin-1 
To come full circle in my endeavour to explore the role of angiogenesis in the lifecycle of the 
mammary gland, I proceeded to investigate lactation, at P2, and involution, at P12. I chose P2 as a 
timepoint for lactation for two reasons. Firstly, P2 is soon after the gland has transitioned from 
alveologenesis to lactation, making it an ideal timepoint to explore whether the gland is functional; 
pups will have gained a small amount of weight and will have milk present in their stomachs. 
Secondly, exploring an early timepoint reduces the possibility for a phenotype to be missed, be it 
by the epithelium recovering as lactation persists, or being visually undiscernible come later days 
of lactation as alveoli become engorged with milk, and thus opaque.  
 
5.4.1 The epithelium of the mammary gland during lactation (P2) and involution (P12) 
by the depletion of integrin-β3, integrin-α5, and neuropilin-1 resembles that of 
the Cre-negative 
Cre-negative and Cre-positive females underwent the experimental regimen discussed in section 
5.1 and were sacrificed at P2. Following sacrifice, the number four glands were harvested, fixed and 
processed for WGS. Visual examination of the glands at P2 revealed no gross morphological changes 
in the epithelium when comparing the two genotypes (Figure 5.5). Equally, WGS images of the 
gland at P12 revealed no gross morphological changes in the epithelium (Figure 5.6) – for entire 
gland images of both experimental timepoints see supplementary Figure 9.6 and 9.7. 
Unfortunately, glands at these two timepoints were difficult to collect. More often than not, 
animals which were gaining weight or visually pregnant seemingly aborted/lost their pups as litters 
were not found. Similarly, litters were sometimes found dead upon birth or were consumed prior 
to one of the two timepoints being reached. Without surmountable evidence it is very difficult to 
comment on the cause, although we did not observe this as a trend in Cre-positive animals 
therefore it is unlikely to be a phenotype arising from target depletion. Other factors may have 
contributed to this outcome. It is not uncommon for first litters to be lost, whether loss is through 
poor practice on the mothers part, behavioural changes postpartum, or due to infanticide which is 
not largely understood [327,328]. Furthermore, some of the females being bred were older than 
would be advisable by best breeding practice (a result of Covid-19 lockdown); a diminished 
economic breeding life could impede successful mating. Lastly, as an overarching consequence of 
the factors discussed, extrapolating data from the pups that were successfully weaned may vary. 
The ability of the mother to produce milk is thought to correlate with the number of pups, which is 




subsequently thought to diminish to reduce in utero competition to avoid recombination events 
resulting in abnormalities [329–331]. Taken collectively many of these factors may explain the 
difficulty I had in obtaining sufficient data to fully discuss the effects of angiogenesis on the murine 


















Figure 5.5 Epithelial density is unaffected during lactation (P2) when endothelial integrin-α5, integrin-β3 
and neuropilin-1 are depleted. Cre-negative and Cre-positive female mice underwent Tamoxifen-induced 
Cre-recombinase activation following the pregnancy Tamoxifen regimen as described in chapter 3.2. a) Cre-















Figure 5.6 Epithelial density is unaffected during involution (P12) when endothelial integrin-α5, integrin-
β3 and neuropilin-1 are depleted. Cre-negative and Cre-positive female mice underwent Tamoxifen-induced 
Cre-recombinase activation following the pregnancy Tamoxifen regimen as described in chapter 3.2. a) Cre-



















The lifecycle of the murine mammary gland begins during embryogenesis and completes once the 
virgin gland has successfully nurtured offspring and returned to its pre-pregnancy state. Having 
assessed the role of angiogenesis in the developing gland in the previous chapter, this chapter 
sought to address the role of angiogenesis in the mammary gland during pregnancy, E10.5 and 
E15.5 through to lactation, P2, and ultimately involution, P12. Angiogenesis is vital in permitting 
tissues and organs sufficient gas exchange and nutrient access, specifically where rapid growth or 
development is occurring. As with pubertal development, the demand for oxygen and nutrients 
increases throughout pregnancy to accommodate epithelial maturation and alveologenesis, and in 
pre-emption to support the generation of milk during lactation. Furthermore, it has been 
documented that during pregnancy, concomitant with epithelial expansion and morphogenesis, the 
vasculature of the mammary gland also undergoes rapid expansion, ramification and anastomosis 
to increase vascular density, in turn increasing oxygen and nutrient supply [161]. Given this, 
combined with evidence demonstrating an increased expression of VEGFs during pregnancy, 
modulating angiogenesis throughout pregnancy using our model has the potential to elicit potent 
angiogenic effects on the maturation of the mammary gland [321]. 
To assess the role of our pro-angiogenic targets in the maturation of the mammary gland, we 
examined the epithelium of E10.5 and E15.5 mammary glands. Accompanying this we also 
measured and recorded the number, and weight, of embryos present per pregnant female, with 
the position in the uterine line also recorded for E15.5 embryos – discussed later. Gross observation 
of WGS images from E10.5 glands suggested epithelial maturation (e.g. epithelial density) of Cre-
positive glands was decreased compared to Cre-negative glands. However, manual quantification 
of the epithelium flanking the lymph node of E10.5 glands indicated there was no significant 
differences in the density of epithelium when comparing the two genotypes, though the caveats 
associated with this analysis have been discussed above. For the sake of further discussion, and 
until a better method of quantification can be devised (one where the entire epithelial tree can be 
measured), I will assume there is a small change in epithelial density in the E10.5 mammary gland 
when angiogenesis is disrupted by EC depletion of integrin-β3, integrin-α5, and neuropilin-1. As 
mentioned previously, Djonov et al. (2001) demonstrated angiogenesis to be active during 
pregnancy by noting an increase in vascular density throughout [161]. Therefore, although my 
findings are not as robust as might be expected given the extent to which Djonov et al. noted a 
change in vasculature, my findings do suggest that angiogenesis is required for mammary epithelial 
morphogenesis during pregnancy. The lack of a more robust phenotype lends weight to the idea 
(as proposed in section 4.2) that perhaps angiogenesis in the mammary gland is not primarily driven 




by the EC targets we have chosen to deplete, targets we know to mediate VEGF-driven migration 
responses [114,254,255]. Whatever changes in epithelial growth I observed at E10.5, they were 
gone by E15.5. Also gone was the significant reduction in embryo weight that was observed at 
E10.5. Both observations suggest some sort of compensatory mechanism in Cre-positive animals 
kicks in between E10.5 and E15.5 that allows mammary and embryo development to overcome an 
early delay. A likely mechanism is signals coming from the placenta.  
The exploration of the placenta was originally conceived through the difficulty in successfully time-
mating our Cre-positive females. I hypothesised this difficulty was a consequence of embryos failing 
to develop due to a lack of maternal angiogenesis, specifically affecting the development of the 
placenta. Whilst the uterus undergoes rapid neovascularisation early on during embryo 
implantation, a subset of uterine stromal cells proliferate and differentiate, forming the decidua. 
Maternally derived, the decidua becomes the first vascular interface between mother and embryo 
– vital for embryo survival and pregnancy success. Interestingly, although somewhat debated, the 
process of decidual angiogenesis is driven by VEGF-A, regulated by the steroid hormones 
progesterone and estrogen [315,316,332]. Indeed, I noted decreased embryo weights at E10.5 
(Figure 5.1b), suggesting that defects in decidual angiogenesis, if present, might retard early 
embryonic development. To date, I have not had time to revisit placental analyses at E10.5. 
However, examination of the placentas from E15.5 females shows no significant difference in the 
decidua region of the placenta in Cre-positive mothers, compared to Cre-negative mothers. At E9.5 
in mice the formation of the labyrinth begins [239]. The labyrinth proceeds the role of the decidua 
as the fetal-maternal interface that will orchestrate oxygen and nutrient supply. Being foetal-
derived, the labyrinths in both Cre-positive and Cre-negative mothers is derived from wild-type 
embryos – although the embryos may express Cre-recombinase, an absence of Tamoxifen renders 
the Cre inactive and thus embryos express all floxed targets. Given our phenotype of embryo weight 
is lost by E15.5, a timepoint at which the labyrinth is mature and has taken over the decidua’s 
vascular interface role, it could be speculated that this shift from a potentially under vascularised 
decidua to an embryo-derived labyrinth resolves the lagging embryo development. In fact, the 
labyrinth at E15.5 does not differ between Cre-positive and Cre-negative, an observation which 
might support the above conclusions – early defects in maternally derived decidual angiogenesis 
are overcome by normal embryo-derived labyrinth angiogenesis. Although there is no change in 
volume, this region could still compensate the decidua by E15.5.  
 




Strikingly, however, the junctional zone (JZ) in the Cre-positive mothers was significantly larger than 
that of Cre-negative mothers. The JZ is an endocrinal region vital in permitting successful pregnancy 
through the production of hormones, growth factors and cytokines that regulate pregnancy 
through modulating mother and embryo physiology [241,333,334]. Like the labyrinth, the JZ is 
embryo derived. Why would there be a larger JZ in Cre-positive mothers? Does this zone become 
enlarged in Cre-positive animals to compensate for early defects in placental angiogenesis? Is there 
increased production of hormones/growth factors in Cre-positive animals that lead to increased 
angiogenesis, and the loss of the mammary epithelial phenotype observed at E10.5? The timing 
would certainly coincide with changes in circulating factors produced by the placenta (e.g. 
increased progesterone production occurs between E10.5 and E15.5 [335]). Further studies are 
certainly warranted and must occur before I can begin to answer these questions. Nonetheless, 
chapter 6 explores (at least in part) the idea that MECs derived from Cre-negative and Cre-positive 
animals are differentially responsive to angiogenic signals, including progesterone.  
To backtrack, although there was no significant difference observed in embryo number in Cre-
positive compared with Cre-negative at E15.5, there was a near significant increase in the number 
of reabsorptions in Cre-positive females (P=0.0573). Unfortunately, the practice of recording the 
position of embryos as well as occurrence of reabsorption events was not implemented until E15.5 
experiments when suggested by Jorge as a best practice when exploring fetoplacental growth – 
E10.5 experiments are lacking this parameter. Despite this, these trends at E15.5 support further 
the hypothesis that our target deletion is modulating embryo development, such that embryo 
viability is compromised. Of note, the uterus undergoes profound levels of angiogenesis during 
pregnancy to supplement the embryo with oxygen and nutrients, prior to the placenta becoming 
structurally and functionally competent, driven by VEGF-A [336]. Given our model utilises this 
pathway as a means to impair angiogenesis, this may allude as to why reabsorptions were greater 
in the Cre-positive mothers. 
Glands from lactation and involution experiments were impossible to quantify due to the density 
of the epithelium at both experimental timepoints. However, as no phenotypic trends were 
observed in E15.5 glands it is not surprising there is no observable difference in the epithelium at 
P2 (lactation); discussed previously E15.5 marks the process of alveologenesis where angiogenesis 
may proceed via intussusception, increasing vascular density around alveoli through basket like 
modification of existing vessels – independent of VEGF [320,337]. 
 




6 Exploring the effects of combinatorial depletion of endothelial integrin-
β3, integrin-α5 and neuropilin-1 in the development of breast cancer 
Breast cancer (BC) is the most common form of cancer in the United Kingdom, impacting people 
and societies on financial, emotional and personal levels [338]. Often with disease a strong 
understanding of its aetiology, development and progression naturally leads to the conception of 
an effective treatment or treatment strategy. The same is true with BC. Tumour angiogenesis is one 
of the classic hallmarks of cancer, enabling tumours to grow and ultimately metastasise about the 
body [95]. Conceptualised and demonstrated over four decades ago, cancer cells infused into 
vascular regions were able to grow to and exceed a volume of 2mm3 by hijacking angiogenesis 
[339,340]. Conversely, tumour cells situated in avascular regions were restricted to a growth of 
2mm3, even exhibiting necrosis and becoming apoptotic [341,342]. To no surprise, these early 
findings triggered a cascade of research into developing anti-angiogenics to mitigate the ability of 
tumours to grow and spread, with the extended benefit of potentially initiating apoptotic 
regression – discussed in detail in sections 1.2.2.5 and 1.2.3. Despite the variety of studies 
demonstrating, and in some cases opposing, the role of certain molecules in the angiogenic 
response, integrin-β3, integrin-α5 and neuropilin-1 have all been shown to elicit an anti-angiogenic 
response when inhibited or removed [343,344]. As touched upon in section 1.2.2.5, some studies 
extrapolate too greatly the implications of their findings, arguably using cancer models lacking in 
physiological relevance or drug doses beyond human efficacy; subsequent, humanised, studies do 
not reflect the preliminary findings [26,107]. 
In a bid to address the final point made above, in conjunction with coming full circle in my studies 
of the murine mammary gland, I proceeded to explore the effects of our EC targets in an orthotopic 
model of BC. In line with previous findings from our lab using different (non-breast) cancer models, 
I hypothesised that depletion of EC integrin-β3, integrin-α5 or neuropilin-1 alone would have 
minimal effects on tumour growth, but co-depletions would inhibit growth, with the greatest effects 








6.1 Triad depletion of endothelial integrin-β3, integrin-α5 and neuropilin-1 
significantly impairs tumour growth and vascularisation 
To begin exploring the angiogenic contribution of endothelial integrin-β3, integrin-α5 and 
neuropilin-1 in the progression of BC, I chose to investigate the effects of each molecule in singular 
depletion, dual depletion and triad depletion. This approach allowed me to explore the role of each 
molecule, individually and in combinations, in modulating tumour angiogenesis. Tumours were 
allowed to grow for 14 days post-implantation, with collection on day 15; sufficient time for 
tumours to grow past 1mm in diameter and hijack angiogenesis as a means to enhance growth [95]. 
Furthermore, to enhance the clinical relevance of this work, in contrast to tumour studies 
previously performed by the Robinson Lab, we altered the Tamoxifen administration from slow 
release Tamoxifen pellets (5mg, 21 day release) to thrice weekly I.P. injections of Tamoxifen 
(75mg/kg Tamoxifen per bodyweight) (Monday, Wednesday and Friday), starting one week prior to 
tumour cell implantation (Figure 6.1a); the Robinson Lab has already demonstrated thrice weekly 
injections elicits target depletion in another cancer model (unpublished – Robert Johnson, Thesis, 
2019). To model BC, we utilised a murine breast carcinoma cell line, B6BO1, isolated from MMTV-
PyMT mice (gifted from Dr Katherine Weilbaecher, Washington University, St Louis, MO, USA), 
known to readily metastasise to lung and bone. Under anaesthesia, 1x105 B6BO1 cells were injected 
into the abdominal, number four, mammary gland of female mice – section 2.4. After 14 days of 
growth, tumours were harvested at day 15, weighed, measured and volume calculated using the 
follow formula: (length x width2 ) x 0.52 [248]. Given these experiments were conducted across all 
seven of our GEMM lines, tumour weight and volume from Cre-positive mice were expressed as a 
percentage of their relative Cre-negative littermates (controls). This data processing step was taken 
to account for potential genetic background differences of the mice used for each EC depleted 
strain; that is to say, the GEMMs are on a mixed C57BL/6;129Sv background, and the contribution 
of each individual strain (C57BL/6 and 129Sv respectively) may vary from GEMM line to GEMM line. 
Single depletion of either integrin-β3 or neuropilin-1 did not result in a significant reduction in 
tumour weight nor volume, corroborating previous findings by our group and others (Figure 6.1c-
d) [114,345]. Controversially, despite Murphy et al. agreeing with our β3 findings, our α5 data does 
not support their findings, and also contradicts recent findings in our lab utilising the same GEMM 
with a different cancer model (unpublished) [345]. Instead, results shown here suggest single 
depletion of integrin-α5 does significantly reduces tumour volume; though this result is caveated 
by the fact that , due to time constraints, I was unable to complete three experimental repeats for 
the α5 genotype (Figure 6.1c-d). Interestingly, dual depletion (EC-KOβ3/α5, EC-KOβ3/Nrp1 and EC-
KOα5/Nrp1) resulted in no significant reduction in tumour weight or volume when compared to their 




respective Cre-negative littermates (controls). This is surprising given recent findings by our lab 
showing that dual depletion, in any combination, markedly deceases tumour weight and volume in 
other cancer models (Supplementary Figure 9.12). However, triple-depletion of our EC targets (EC-
KOα5/Nrp1/β3), showed significant inhibition of BC tumour growth (Figure 6.1). This is consistent with 
findings in other cancer models in the Robinson Lab (Supplementary Figure 9.12).  
I attempted to confirm target depletion in tumour blood vessels by flow cytometry. Whole tumour 
homogenates were prepared and stained for two out of three endothelial markers (endomucin, 
CD31 (PECAM-1) and Cdh5) along with staining for the three molecules, integrin-β3, integrin-α5 
and neuropilin-1 (section 2.9). Despite my best efforts, I was not able to sufficiently optimise the 
flowcytometry enough to convince myself that I was uniquely detecting ECs (Supplementary Figure 
9.8, 9.9 and 9.10). However, I was able to stain for the targets and confirm target deletion in tumour 
blood vessels (supplementary Figure 9.11). In line with modulating angiogenesis, I would expect to 
see trends reminiscent of the tumour volumes (Figure 6.1d) in terms of vascular density – BAN Cre-
positive tumours should exhibit significantly fewer blood vessels compared to BAN Cre-negative 
tumours. Unfortunately, due to time constraints I was unable to quantify the vasculature of the 











Figure 6.1 Triad-depletion of integrin-β3, integrin-α5 and neuropilin-1 impairs tumour growth. Female 
GEMMs of the indicated genotypes were implanted with 1x105 B6BO1 breast carcinoma cells, orthotopically 
into the inguinal mammary gland. a) Experimental regimen: Thrice weekly I.P. injections (Monday, 
Wednesday and Friday) of Tamoxifen (75mg/kg bodyweight) for three weeks, B6BO1 implantation on day 8 
(red) post-initial I.P., and tumour harvest on day 15 (red) post-implantation. b) Representative images of Cre-
negative and Cre-positive B6B01 tumours at day 15. c) Tumour weight at day 15 as a percentage of relative 
Cre-negative littermate controls. d) Tumour volume ((length x width2) x 0.52) at day 15 as a percentage of 
relative Cre-negative littermate controls. A: N=1, n=13, Others: N=3, Cre status, n≥7. Scale bar = 5mm. Error 



























































































Having discussed extensively the targeted approach researchers have taken to prevent 
angiogenesis as a means of treatment for cancer (section 1.2.2.5) whilst also illustrating the global 
impact of BC (section 1.3.6), we sought to take a step back and re-assess the potential of pro-
angiogenic molecules as a target for preventing/impeding tumour growth. Mentioned previously 
(section 1.2.2.5), the experimental design, models used, and findings extrapolated do not always 
lend themselves to success in terms of follow up studies or pre-clinical trials. In line with this, we 
executed our BC studies using orthotopically implanted, MMTV-PyMT derived, mouse BC cells 
(section 2.4) to enable physiologically relevant data to be collected and commented on.  
Of the single and combinatorial deletion of our targets we only observe a significant reduction in 
tumour volume in integrin-α5 single (A) depleted, and triple depleted (BAN) tumours (Figure 6.1d). 
We see a similar trend with the weights for these two genotypes, however due to the heterogeneity 
of tumour tissue and large tumours exhibiting necrotic cores, weight may not always correlate with 
tumour size (Figure 6.1c). To reiterate, the integrin-α5 single depleted experiment is an N of 1, 
therefore biological repeats in this genotype may see this statistical difference evaporate. However, 
for the sake of the data presented I shall discuss this result as it is. Previous work by a former PhD 
student in the lab (Dr Robert Johnson, unpublished) performed in the same GEMMs has elicited 
different findings. In contrast to the findings I present here, Dr Johnson analysed CMT19T tumours 
growing subcutaneously and showed that the depletion of two targets in any combination 
significantly decreased tumour volume (supplementary Figure 9.12); both models show the 
greatest inhibition of tumour growth with simultaneous depletion of all three targets. Why the 
difference? The cancer model used throughout this work was an orthotopic model of BC implanted 
into the mammary gland. The other data referred to is a lung carcinoma subcutaneously implanted 
into the flank. Furthermore, although both studies follow thrice weekly injections, the latter study 
ran longer (tumours harvested on day 18) and started with a higher baseline of cells per animal 
(1x106 as opposed to 1x105). Having noted these two points, it is important to consider that both 
studies findings are accurate – maybe lung tumours respond robustly to anti-angiogenic treatment 
compared to breast tumours? This example of disparity between two tumour experiments 
highlights the short-term differences that can arise when modelling different cancer models in 
genetically similar mice, not to mention the potential differences which could occur over longer 
experimental periods or in instances of metastasis.  
Integrin-β3, integrin-α5 and neuropilin-1 have all been implemented as targets for anti-angiogenic 
drug development, having all been shown to exhibit anti-tumorigenic effects when their expression 
or function is impeded. Our group has previously demonstrated that inhibition of integrin-β3 




provides short-term anti-tumorigenic effects with tumours recapitulating wild-type levels of 
growth, whilst others have shown inhibition to result in enhanced pathological angiogenesis 
[114,254,346]. Likewise, integrin-α5 was identified as a prime anti-tumorigenic target in mice 
however these results did not fully translate to clinical trials [347,348]. Studies have also 
demonstrated the upregulation of neuropilin-1 to be present in primary tumours of both mouse 
and human, whilst also demonstrating inhibition of neuropilin-1 to markedly decrease tumour 
angiogenesis and tumour size [150,349]. Despite a multitude of evidence for these three molecules 
as candidates for anti-tumorigenic therapies, the tumour data presented here does not coincide 
with these published findings, pre-clinically, but does fit with the lack of benefit observed in clinical 
trials. Granted, we see a large reduction in tumour volume when all three molecules are depleted, 
suggesting the presence of one of the three molecule is sufficient to execute tumour angiogenesis. 
The complementary nature of these findings with regards to the clinical trial failures also attributes 
the point touched upon in section 1.2.2.5. Physiologically, findings from mouse models can lack 
relevance in terms of drug dose, tumour model or even study type (e.g. intervention and 
prevention) owing failure come clinical application. 
Furthermore, anti-angiogenic treatment, targeting the VEGF pathway, has proven largely 
ineffective in the long term survival of BC patients whilst being effective in the treatments of other 
cancer, such as renal cell carcinoma, colorectal cancer and non-small cell lung cancer [99,350–352]. 
Given other types of cancer utilise VEGF as a major driver of tumour angiogenesis, and as such 
respond to VEGF targeted anti-angiogenics, BC was assumed to respond in a similar manner [353]. 
However, it has been shown that VEGF expression in primary breast tumours compared with 
contralateral, normal/healthy, breast tissue shows no significant change in VEGF expression [354]. 
Therefore, whilst BC does exhibit tumour angiogenesis, the pathway through which it achieves 
vascularisation is seemingly independent of VEGF. Furthermore, studies have demonstrated the 
use of anti-angiogenics against the VEGF pathway can consequently lead to the upregulation of 
alternative pro-angiogenic factors, such a basic fibroblast growth factor (bFGF), interleukin-8 and 
stromal derived factor-1 (SDF-1) [355–357]. This upregulation is thought to be subject to the 
inhibition of the VEGF pathway, in turn inducing tumour hypoxia, increasing HIF-1 expression and 
consequently the expression several compensatory pro-angiogenic factors – potentially 
exacerbating tumour growth as opposed to no change at all or a reduction [353]. As such, it is 
reasonable to perceive that BC utilises an alternative, VEGF independent, form of angiogenesis. Of 
note, literature also presents a disputed role for hormones in the process of angiogenesis, however 
this will be explored, in a non-malignant setting, in section 7.  
 




7 Mammary gland derived endothelial cell isolation, characterisation and 
comparison to lung derived endothelial cells 
To enable researchers to follow up on specific findings they often require a model in vitro system 
upon which to administer the same treatment or condition to extrapolate detailed cellular 
responses. Often stemming from the result of an in vivo study, or from large scale multiplex analysis 
to follow up a specific hit, the isolation and use of an individual cell type in vitro enables targeted 
follow up of cellular behaviour and/or mechanism [358]. Typically, when exploring the behaviour 
or signalling response of specific cells, an organ rich in the desired cell type is harvested, followed 
by the extraction and isolation of that cell type for subsequent study. As such, we hope to assess 
the credibility of utilising system/tissue specific ECs for studying a respective system/tissues 
angiogenic behaviour. LECs are widely used to study angiogenesis, even within the Robinson Lab. 
For my project, I wanted to explore and characterise the differences, if any, between MECs and 
LECs, whilst also seeking to understand if there is a role for progesterone in angiogenesis during 
pregnancy [284,299,300].  
In light of the placental findings discussed in section 5.3, where we observed a significant increase 
in the size of the JZ, we became interested in whether hormonal input was playing a significant role 
in angiogenesis throughout pregnancy. More so, we wondered whether hormones present during 
pregnancy were helping to orchestrate angiogenesis, either with or without VEGF. Although an 
array of hormones, growth factors and cytokines are produced by the JZ, we set our sights on 
progesterone for two reasons. Firstly, a multitude of literature exists arguing both for and against 
the pro- or anti-angiogenic role of progesterone – the takeaway message being it plays a disputed 
role during angiogenesis [273,314–319]. Secondly, our placental phenotype was seen at E15.5, the 
point at which serum levels of progesterone are at their highest during pregnancy (81.9ng/ml) 
[335]. Having successfully isolated MECs from both Cre-negative and Cre-positive animals, 
alongside having access to LECs isolated from the same genotype (triple GEMM – β3.α5.Nrp1fl/fl 
mice), I hypothesised that these two different types of ECs would differ in their responses to VEGF 








7.1 Target depleted mammary derived endothelial cells show only modest 
changes in VEGF signalling 
To begin characterising target depleted mammary endothelial cells (MEC-KO), we performed a 
VEGF-induced time course to assess their response to VEGF in terms of phosphorylated ERK 1/2 
(pERK) expression, and at the same time, compare it to that observed in LECs. Given VEGF is a 
predominant stimulant of ECs in vivo, inducing an angiogenic response, it is commonly used to 
stimulate cells in culture as a means to study angiogenic signalling. ECs were seeded onto 
fibronectin coated plates and treated with VEGF for 0, 5, 15 or 30 minutes, lysed, and western blot 
analysis performed (sections 2.6 and 2.11.1). Much like their LEC-KO counterparts (supplementary 
Figure 9.13), MEC-KOs show a dampened response to VEGF compared to MEC-WT cells when 
examining pERK expression (Figure 7.1). Given ECs generally respond to VEGF, is it not surprising a 
pERK signal is detected in the MECs. However, since only mild phenotypes in both developing and 
pregnant mammary glands are observed when angiogenesis is impaired, it was surprising to see a 
reduced response in MEC-KO ECs; wild-type responses to VGEF in these cells would have been 
expected given the lack of robust phenotype(s). 
Having observed similar VEGF-induced responses in MECs compared to LECs, alongside an reduced 
PgR expression upon target deletion (see below), I proceeded to explore the potential for other 
differences in signalling between these two cell types in a bid to understand how they might differ 


















Figure 7.1 VEGF stimulation of triple MECs shows a dampened response to VEGF as determined through 
pERK expression. PyMT immortalised ECs (MEC-WT and MEC-KOβ3/α5/Nrp1) were seeded onto fibronectin and 
were subsequently treated with VEGF for 0, 5 15 and 30 minutes. Post-treatment, cells were lysed and 
western blot analysis was performed to compare protein expression between MEC-WT and MEC-KOβ3/α5/Nrp1. 
a) Western blot of lysates from MEC VEGF time-course. b-c) Densitometric analysis of western blot (a) 


























7.2 Progesterone receptor is profoundly decreased in target deleted lung 
endothelial cells compared to mammary endothelial cells  
Having already alluded to the potential of progesterone playing a key role in modulating 
angiogenesis in the mammary gland, expression of the progesterone receptor (PgR) seemed a 
logical place to begin examining responses to other angiogenic stimuli. I first sought to compare the 
expression of PgR in LECs and MECs, with and without target depletion. PgR has been shown to 
exhibit differing levels of expression in ECs derived from different tissues, specifically showing 
human lung ECs lack PgR expression [273].  
Assessment of PgR was performed through immunocytochemistry (ICC) of both WT and KO LECs 
and MECs. MECs and LECs were seeded onto fibronectin coated coverslips and left to adhere 
overnight prior to fixation and staining (section 2.10). ICC and subsequent Corrected Total Cell 
Fluorescence (CTCF – QBI, The University of Queensland, Australia) revealed an interesting 
expression profile of PgR. Both LEC- and MEC-WTs express PgR and do so at a similar level (Figure 
7.2). However, target depletion alters this expression. LEC-KOs show a significant reduction in PgR 
expression whereas MEC-KOs show a very minor, non-significant, reduction in PgR expression 
(Figure 7.2). I found this interesting given the speculated importance of progesterone in modulating 
angiogenesis during pregnancy [336]. Our working hypothesis entailed the involvement of 
progesterone as a pro-angiogenic molecule aiding in overcoming the anti-angiogenic phase we 
were inducing through our target depletion. In light of our hypothesis and current literature, the 
MEC finding fits this supposition; target depletion does not affect PgR expression, therefore 
progesterone could still positively modulate angiogenesis in MEC-KO cells. The LEC finding not only 
demonstrates mouse LECs express PgR, it also shows LEC-WTs have an equivalent level of PgR as 
MEC-WTs with a marked decrease in PgR expression post-target deletion. This is an interesting 
finding which demonstrates the differences in ECs isolated from different tissues [273,359]. Of note, 














Figure 7.2 Target deletion in lung derived endothelial cells significantly reduces progesterone receptor 
(PgR) expression. LECs and MECs were seeded overnight on fibronectin coated coverslips before being 
stained and fixed the following day. a) Representative images of immunocytochemistry stained LEC-WT, LEC-
KO, MEC-WT and MEC-KO cells: PgR (green) and Dapi (blue). b) Corrected Total Cell Fluorescence (CTCF) of 
immunocytochemistry in (a). N=3, Cre-negative, n=45. Cre-positive, n=45. Scale bar = 20µm. Error bars = 

























































7.3 Treatment of mammary derived endothelial cells with pregnant serum 
results in altered signalling responses when EC targets are depleted 
Having established differences in PgR expression between LEC-KOs and MEC-KOs, we proceeded to 
explore the role of progesterone in angiogenic signalling pathways in ECs. In a bid to assess 
progesterone’s involvement in MEC signalling, we extracted blood, and subsequently serum, from 
non-pregnant and pregnant mice (E15.5) to stimulate MECs with. MEC-WT and MEC-KO cells were 
seeded overnight on pre-coated fibronectin plates and were treated with non-pregnant serum (S) 
or pregnant serum (PS) the following day (section 2.11.2). To ascertain whether progesterone was 
indeed stimulating signalling pathways, and whether these pathways differed between MEC-WTs 
and MEC-KOs, we probed for several proteins known to be involved in angiogenic signalling. PS was 
used as opposed to neat progesterone to maintain physiological relevance when assessing 
signalling responses. Target proteins for western blot analysis post-treatment included VEGFR2, 
AKT, FAK, ERK and p38 (Figure 7.3). 
I initially wanted to examine changes in VEGFR2 phosphorylation (pVEGFR2). VEGFR2 is a key 
component of the angiogenic signalling cascade vital in transducing VEGF signals in ECs. Our target 
depletion affects VEGF signalling directly as the molecules depleted are involved both down- and 
upstream of VEGF stimulation. Given we are treating cells with S and PS, and our target depletion 
is directly relatable to VEGFR2, it seemed a relevant protein to investigate [360–362]. We were 
unable to detect pVEGFR2 within our samples however we detected a significant reduction in total 
VEGFR2 in cells treated with PS, and a marked decrease in cells treated with S (Figure 7.4a). An 
absence of a pVEGFR2 signal suggests there is no VEGF present in the serums used for these studies. 
The fact that total VEGFR2 decreases in response to serum stimulation suggests that VEGFR2 is 
quickly degraded in response to these treatments (VEGFR2 is known to be degraded post-activation 
by endocytosis, ubiquitination and proteolysis), but there appears to be no difference between 
MEC-KO and MEC-WT cells [363,364]. Probing for pERK revealed both S and PS stimulated ERK 
phosphorylation, but there were no differences between MEC-KOs and MEC-WTs (Figure 7.3). This 
reinforces the idea that S and PS contain little to no VEGF, as the previous section demonstrated a 
depressed pERK response to VEGF in MEC-KOs (Figure 7.4b). Another VEGF thematic signalling 
pathway is AKT, commonly activated in response to VEGF to promote EC survival with literature 
supporting progesterone upregulating the AKT signalling pathway to support EC viability [365]. 
However, whilst target depletion in MEC-KOs led to reduced total AKT expression, no significant 
differences were noted when comparing pAKT relative to tAKT levels (Figure 7.4c). The two final 
signalling proteins we explored were FAK and p38. Both FAK and p38 are downstream signalling 
proteins of VEGF stimulation, orchestrated via neuropilin-1, with downstream effects on EC 




proliferation and migration [366–368]. We were unable to detect pFAK however we did detect total 
FAK, which showed a slight, but non-significant, decrease in expression when MECs were treated 
with either S or PS (Figure 7.4d). Examining p38 expression was problematic as expression seemed 
low and background was relatively high, making accurate quantification impossible. It appears, 
however, that p38 phosphorylation was decreased in MEC-KO cells, in both S and PS conditions, 
but I cannot currently comment on whether this is statistically significant.   
  








Figure 7.3 Western blot analysis of MECs treated with serum and pregnant serum. MECs were seeded 
overnight on fibronectin coated plates, serum starved and treated with serum or pregnant serum. Lysates 
were collected and probed for the indicated proteins labelled above. N=3 lysates per condition. 
  








Figure 7.4 Densitometric analysis of western blotting performed on MECs treated with serum and pregnant 
serum. Densitometric analysis of western blot targets normalised to Hsp70 or respective total protein. a) 
Total- VEGFR2 (tVEGFR2) relative to Hsp70. b) Phospho-ERK relative to Hsp70 and total-ERK (tERK), and tERK 
relative to Hsp70 respectively. c) Phospho-AKT (pAKT) relative to Hsp70 and total-AKT (tAKT), and tAKT 
relative to Hsp70 respectively. d) Total-FAK (tFAK) relative to Hsp70. N=3. Expression levels are presented 
relative to those observed in control (MEC-WT – black bar) for each treatment. US = unstimulated, S = Serum 















7.4 Microarray, and subsequent STRING analysis, reveals signalling differences 
between mammary and lung derived endothelial cells in response to VEGF, 
serum and pregnant serum 
The Western blots described above pointed toward a couple of signalling leads, but were, overall, 
rather disappointing. Thus, I sought to investigate the signalling response of MECs and LECs on a 
larger scale. To provide a broad insight into potential signalling pathways at work, I proposed 
performing microarray analyses on the following cells and treatments: LEC-WT, LEC-KO, MEC-WT 
and MEC-KO treated with VEGF; MEC-WT and MEC-KO treated with serum; MEC-WT and MEC-KO 
treated with serum from pregnant mice (E15.5). This combination of treatments would enable 
comparative discernment between LEC and MEC in terms of signalling responses to VEGF, whilst 
the latter would enable me to explore the effects of our target depletion with regards to how MECs 
respond to bio-actives found in serum and pregnant serum. 
The microarray analysis I chose to perform was the Kinex™ KAM-1325 Antibody Microarray. This 
microarray provides exclusive readings for 627 signalling proteins alongside duplicate 
measurements to enhance accuracy and internal cross-validation using antibodies to the same 
signalling protein specified to a different epitope. Samples were prepared as per section 2.11.1-3. 
Briefly, LEC/MEC-WT and LEC/MEC-KO cells were seeded onto fibronectin coated plates, stimulated 
with the designated treatment and lysed before being loaded onto the microarray; microarrays 
were subsequently shipped and analysed by Kinexus™ (supplementary Figure 9.14). Unfortunately, 
the LEC-KO +VEGF sample leaked out of the chamber during incubation, so this treatment was lost 
from subsequent analyses, and consequently, so too was the LEC-WT +VEGF sample. Initial analyses 
performed by Kinexus highlighted changes that the company considered to be significant (based on 
fold differences in expression between comparisons). Comparing the MEC-WT to the MEC-KO for 
each treatment, nothing “jumped out” as being an obvious lead to follow. However, I thought I 
might increase the power of the comparisons by pooling all the data into a single analysis, even if 
the treatments were different (that is all the MEC-WT samples and all the MEC-KO samples were 
considered as biological repeats) I surmised that I might be able to uncover common signalling hubs 
through which my EC targets were functioning, even if the treatment was different. To do this, I 
used Qlucore™ bioinformatics software to bring together all “priority” leads from the microarray 
reports for the three MEC-WT and MEC-KO conditions; VEGF, serum, pregnancy serum. Using this 
software to generate a hierarchical protein clustering heatmap, I narrowed down the proteins of 
interest – cut offs for considering a pathway to be of interest were set to P<0.05 (Figure 7.5). This 
clustering algorithm compares the mean reading for each protein and compares them between 
MEC-WT and MEC-KO samples. Out of the 627 unique signalling proteins assayed, we identified 33 




leads from the microarray analysis and subsequent hierarchical clustering (Figure 7.5). These leads 
were fed into STRING in order to generate a protein interaction network, proposing a visual map of 
how signalling proteins detected between samples may be interacting. Of note, we performed 
Qlucore™ analysis on samples denoted by Kinexus™ as “priority” leads. Besides these leads, there 
were also numerous potential leads, however we did not pursue these. To enable us to perform 
analysis with Qlucore™ we pooled the “priority” leads for the three MEC-WT samples and for the 
three MEC-KO samples, VEGF, Serum and Pregnant Serum respectively, to grant us a refined panel 
of signalling proteins which we could follow up with string analysis and ultimately western blot 















Figure 7.5 Hierarchical protein cluster analysis, performed on Qlucore™, from the three MEC-WT and MEC-
KO samples. MEC-WT and MEC-KO samples were treated with either VEGF, serum or pregnant serum and 
microarray analysis performed – samples are not replicates but are VEGF, serum or pregnant serum treated, 
respectively. Yellow = high expression, blue = low expression. 
 
 






Figure 7.6 STRING analysis generated from hierarchical protein clustering. The output from hierarchical 
protein clustering, from data generated from the microarray analysis, were inputted into STRING (String 



















7.5 Subsequent western blot analysis for signalling proteins identified by STRING 
analysis reveals differential signalling responses to hormonal input 
Directed by the results of the Qlucore™ analysis, and subsequent STRING analysis, follow up 
western blotting was performed on the lysates that were generated for the microarray. Of the 
proteins inputted into, and interactions mapped by, STRING, I decided to follow up on four proteins, 
namely: Protein Kinase B or RAC-alpha serine/threonine-protein kinase (AKT), Vimentin (VIM), 
Vasodilator-stimulated phosphoprotein (VASP), and Abelson tyrosine-protein kinase (ABL). Situated 
at the centre of the STRING analysis. AKT is accountable for many of the downstream responses, 
induced by growth factors, in ECs and has been shown to mediate the recycling and trafficking of 
integrins-αVβ3 and α5β1 – two targets which we have depleted [369,370]. Thus, even though 
earlier findings were disappointing, I decided to reanalyse signalling through this molecule. Both 
VIM and VASP are key molecules in generating and mediating focal adhesion formation, maturation 
and subsequent signalling, as previously demonstrated by our lab when integrin-β3 is depleted, and 
by others demonstrating VIM to be essential in the localisation and phosphorylation of VASP, 
subsequently controlling EC migration and proliferation [255,371]. ABL is directly related to 
neuropilin-1 activity; dependent on the presence of neuropilin-1 to enable subsequent VEGFR2 
activation, ABL phosphorylation and SFK activation, and ultimately vascular permeability [372]. Of 
note, as I only possessed one lysate per microarray condition, I did not perform densitometry, and 
I cannot comment statistically on any observed differences. I also decided to include lysates from 
the LECs since I had them and was interested in potential differences between LECs and MECs. 
At the heart of the STRING analysis, AKT was our first protein of interest for follow up. I performed 
the western blot analysis on the microarray samples for both AKTThr308 and AKTSer473; covering all of 
the phosphorylation sites of AKT [373]. Western blot analysis of AKTThr308 revealed increased 
phosphorylation, and expression, of AKTThr308 in MEC-KOs treated with VEGF or S, but decreased 
expression in MEC-KO treated with PS and LEC-KO treated with VEGF (relative to their WT 
counterparts) (Figure 7.7a). In contrast, AKTSer473 phosphorylation only changed in MEC-KO +S. 
(Figure 7.7b). The reason for the discrepancy with earlier findings (see above) is unknown, but the 
array findings, on whole, suggest this is an important signalling hub to pursue in future work.  
I next probed for VIM and VASP; separately on freshly prepared lysates. Phosphorylated VIM (pVIM) 
was really only detected in the MEC+VEGF samples. However, total VIM (tVIM) levels look as if they 
are decreased in MEC-KO +VEGF cells, and tVIM levels drop dramatically in MEC cells in response 
to PS treatment (though there does not appear to be a difference between KO and WT ECs (Figure 
7.7c). Examining VASP expression turned out to be quite interesting. In general, both LEC and MEC 




KO cells show a reduction in total VASP. However, taking this into consideration relative changes in 
phosphorylated VASP, in relation to total VASP, look unchanged. (Figure 7.7d). Finally, I probed for 
ABL, but was unable to detect any phosphorylated ABL in any of the samples. In general, total levels 
of ABL were unaltered when comparing WT ECs to KO ECs, with an absence of total ABL when MECs 
were treated with PS (Figure 7.7e).  













































Figure 7.7 Western blot analysis of mammary and lung derived endothelial cells treated with VEGF, and 
MECs treated with serum (S) or pregnant serum (PS).MECs and LECs were seeded overnight on fibronectin 
coated plates, serum starved and treated with VEGF, serum or pregnant serum f0r 30 minutes. Lysates were 
collected and probed for phosphorylated (p) and total (t) levels of (a, b) AKTThr308 and AKTSer473; (c) VIM; (d) 













In this section I sought to not only characterise the difference in signalling response between MEC-
WT and MEC-KO cells, when treated with either VEGF, S or PS, but I also began to explore whether 
there are fundamental signalling differences between MECs and LECs. I began this journey 
predominantly for two reasons. Firstly, the phenotype observed during pubertal development, (e.g. 
a lack of any robust phenotype in animals missing EC expression of integrin-a5, integrin-b3 and 
neuropilin-1) contrasts significantly with the depletion of these three molecules in other systems in 
the lab, such as retinal angiogenesis. This suggest these molecules may not play a role in mammary 
gland angiogenesis. Secondly, this intimates that LECs may differ from MECs in their response to 
common angiogenic stimuli, such as VEGF.  
The ECs isolated from the mammary gland and the lungs of our triple floxed mice have been grown, 
isolated, immortalised, and a subset nucleofected with TAT-Cre, to generate WT (MEC-WT and LEC-
WT) and target depleted populations (MEC-KO and LEC-KO) respectively from each organ. We have 
demonstrated the identity of our MECs (section 3.4) and LECs (data not shown) through their 
expression of known endothelial markers, whilst also showing our WT cells express our targets and 
our KO cells do not. As such, we proceeded to explore the response of MECs to VEGF, the major 
driver of sprouting angiogenesis. Interestingly, despite deleting three of the major receptors 
involved in VEGF signal transduction the MECs showed only modest changes in ERK signalling, 
especially in comparison to their lung counterparts; LECs exhibit a harsh reduction in ERK expression 
and phosphorylation. This result prompted us to question whether angiogenic signalling in these 
cells is tissue specific, potentially offering an explanation as to why genotypically identical ECs differ 
in their response to VEGF.  
Although repeats and follow up signalling assays need to be performed, findings can be 
extrapolated from what we have found. Generally, stimulation of MEC-KOs with VEGF summated 
in no change, or a decrease, in the expression of proteins measured, with the exception of AKTSer473, 
compared to LEC-KOs where only a small decrease in AKTSer473 and tVASP was observed (Figure 7.7f). 
Interestingly, the decrease in the signalling proteins measured in MEC-KOs treated with PS would 
suggest ablation of our targets is impacting the ability of either a growth factor or hormone present 
in PS to transduce a signal, especially when compared with S treated MEC-KOs where we do not 
see the same changes in expression. On from this point, S treated MEC-KOs show an increase in the 
phosphorylation of AKT. This suggests our target ablation dampens a signalling pathway via a 
molecule present within PS, whilst concomitantly increasing a signalling pathway via a molecule 
present within S. To tie back to the ICC for PgR, LEC-KOs exhibit significantly less PgR than LEC-WTs, 
MEC-WTs and MEC-KOs, all of which display equivalent levels to one another. This reduction in PgR 




may suggest a homeostatic balance whereby a decrease in a pro-angiogenic pathway (induced by 
our target depletion) also reduces an anti-angiogenic pathway, potentially progesterone. Although 
there is insufficient evidence to support the previous claim, it is certain that we have a phenotype 
in the expression of PgR between LECs and MECs, and that our target depletion in MECs is altering 


























8 Final discussion and future work 
Angiogenesis has long been deemed a fundamental process by which tissues and organs undergo 
vascular expansion. Occurring allometrically, in response to tissue and organ growth, and 
pathologically, angiogenesis is a valuable process to have an understanding of. In the instance of 
this thesis, the focus was the murine mammary gland. With considerable evidence for the pro-
angiogenic involvement of integrin-β3, integrin-α5, and neuropilin-1, both collectively and 
individually, our lab possesses a powerful tool to ascertain the level of importance of angiogenesis 
during the normal and malignant lifecycle of the mammary gland [114,140,141]. Our overarching 
hypothesis was that the depletion of key fibronectin binding receptors and neuropilin-1 would 
impede the pubertal and gestational expansion of the mammary epithelium. As such, we required 
a suitable model. Fortunately, the conception of this project required no creation of an in vivo 
angiogenic model as the triple floxed GEMM had already been generated (Table. 3.1). Additionally, 
this facilitated the establishment of the MECs from the mammary glands of the triple GEMM 
following an adapted LEC isolation protocol; isolated, immortalised and transfected with tat-Cre-
recombinase we were able to generate target depleted and Cre-negative (wild-type) lines (Figure 
3.3). Whilst having both an in vivo and in vitro model of angiogenesis, caveats exist. The activity of 
our Pdgfb Cre, albeit active in ECs, needs to be investigated for off target expression as studies have 
demonstrated PDGFb expression in a variety of cell types. Funa and Sasahara demonstrated 
neuronal cell expression of PDGFb and noted its importance in neurogenesis [374]. Furthermore, a 
comparative study exploring the cell specificity between Cdh5 driven Cre compared to PDGFb 
discovered a small number of hematopoietic cells to be expressing PDGFb [294]. Of specific 
importance, macrophages fall under the hematopoietic lineage and have well defined roles in the 
expansion of the mammary epithelium; to fully account for our partial phenotype(s) observed in 
section 4 to angiogenic impediment we need to verify cell specificity [297]. Furthermore, to fully 
describe the anti-angiogenic model we are generating through target depletion we should quantify 
the expression of other integrins, namely the heterodimeric partners of our targets, integrin-αV 
and integrin-β1; the expression profile of integrin-αV and integrin-β1 may differ between MEC and 
LEC.  
Utilising our triple GEMM as a model for angiogenic impediment, we set out to assess the 
involvement of angiogenesis in the pubertal, gestational, and pathological lifecycle of the murine 
mammary gland. Beginning with pubertal growth, we delved into assessing the direct effects of 
ablating our three molecules of interest (as a means to impede angiogenesis) on the epithelial 
growth in the pubertal mammary gland. Establishing the number four gland as the gland of study, 
for reasons previously discussed (section 4), we proceeded to collect pubertal glands that had 




undergone the pubertal Tamoxifen regimen (section 3.2), followed by WGS to assess the 
epithelium. To our surprise we saw no change in epithelial outgrowth, however we noted a 
significant increase in epithelial outgrowth directionally in Cre-positive mammary glands; at the top 
edge (above) the lymph node (Figure 4.3c and e). However, despite this finding, when we 
attempted to quantify other parameters as a means to explore and understand why we were seeing 
this change we found little of note. Namely, epithelial density and number of branch points did not 
significantly differ between Cre-positive and Cre-negative animals, either overall or in a specific 
direction about the lymph node (Figure 4.4). However, upon visual inspection it appeared the Cre-
positive glands may be exhibiting more trifurcations than Cre-negative glands. Quantitation of 
these events led us to discover that whilst TEB number did not vary between Cre-negative and Cre-
positive, Cre-positive glands were displaying significantly more trifurcations events. Subsequent 
H&E analysis revealed no structural alteration in TEB structure (Figure 4.7). Taken collectively, 
perturbation of angiogenesis by our target depletion results in no significant changes in the 
mammary epithelium during puberty, with the exception of a significant increase in trifurcation 
events and a directional increase in epithelial growth – of note, position of trifurcations were not 
predominant at top edge (above) the lymph node and hence do not account for the significant 
increase in epithelial growth observed in that direction. The obvious explanation for these findings 
is that the significant increase in trifurcation events is a result of impeded angiogenesis in a bid to 
maintain epithelial growth. Consequently, towards the end of puberty the migratory front naturally 
exists at the top edge (above) the lymph node. As such, TEBs will predominantly be present at the 
top edge (above) of the lymph node and could therefore amplify epithelial growth, beyond that of 
a Cre-negative when measured and compared. Taken further, previously mentioned was the 
observation by Matsumoto et al. noting the close association of endothelium with epithelium [320]. 
Given the endothelium of the pubertal gland is likely largely formed prior to pubertal onset, the 
instance of trifurcation may be consequence of the interaction of the epithelium with the 
endothelium – via angiocrine signalling. Although we have not shown the endothelial composition 
of the mammary gland during, or before, puberty, corrosion casts previously discussed would 
suggest a vasculature of some degree pre-exists within the pre/pubertal gland [161]. In line with 
these findings, it is plausible that angiocrine signalling is affected as a result of our target depletion, 
resulting in a mild phenotype. Rafii et al. comment on the organ specific role of ECs in inducing, 
specifying and guiding organ regeneration via angiocrine signalling [375]. Although focussed on 
tissue regeneration, it is conceivable that these signals equally propagate epithelial growth via TEBs; 
faulty angiocrine signalling could result in trifurcations instead of bifurcations. Although no unique 
chemoattractant has been defined for aiding epithelial expansion, Fibroblast Growth Factors 




(FGFs), Epidermal Growth Factors (EGFs) and Wnts have all been implicated in branching 
morphogenesis [376]. Additionally, Transforming Growth Factor-β (TGF-β) has been shown to 
restrict branching morphogenesis, negatively modulating the process [264]. Many of these growth 
factors can be produced by the endothelium. As such an array of EC-derived growth factors may 
play a cumulative role in regulating branching morphogenesis throughout the lifecycle of the 
mammary gland, and target depletion may disrupt the balance of these molecules resulting in 
trifurcation events.  
I next proceeded to assess the effect of angiogenic disruption on the cycle of pregnancy, specifically 
mid-gestation (E10.5), late gestation (E15.5), lactation (P2) and Involution (P12). Starting with 
E10.5, we observed only mild differences in epithelial outgrowth between Cre-negative and Cre-
positive mammary glands, saw no changes in embryo numbers, but did observe a significant 
reduction in embryo weight. Following up our E10.5 studies, E15.5 mammary glands proved too 
difficult to quantify in terms of epithelium, but visual examination revealed no grossly obvious 
differences between Cre-negative and Cre-positive glands (Figure 5.3). Furthermore, the number 
of embryos and their uterine location revealed no striking differences between genotypes, however 
the E10.5 phenotype of embryo weight differences was lost (Figure 5.2a-b and e). Also, despite a 
greater number of reabsorption events detected in Cre-positive E15.5 mice, specifically in the left 
position of the uterus, no significant changes were observed (Figure 5.2c-d). Lastly, I collected 
placentas from E15.5 mothers in a bid to address the difficulty I had when performing timed mating 
– was placental angiogenesis resulting in miscarriage or failure to fall pregnant? Despite new “best 
practice” for timed mating being implemented by our animal facility, and as such alleviating our 
difficulty to a degree, we had already begun our placental investigation. Although there was no 
difference in placental weight (Figure 5.2f), I did observe a significant change in the proportion of 
the placental zones, namely a significant increase in the JZ in Cre-positive mothers (Figure 5.3). 
Unfortunately, due to undefined circumstances of litter loss, I possess very little data bar WGS 
observations as to the effect of our target depletion on the lactating and involuting mammary 
gland, though no obvious changes are observed between genotypes. The takeaway message from 
this results section is that the phenotype observed in embryo weight differences was transient, 
observed at E10.5 but lost by E15.5, with the mechanism for normalising/redeeming embryo weight 
thought to be placenta derived.  
The maternal decidua is the first vascular interface, preluding the labyrinth, between mother and 
embryo, with angiogenesis within the decidua being driven by VEGF-A signals, which are 
hormonally regulated by progesterone and estrogen [315,316,332]. An emerging idea from my 
pregnant studies is that early defects in angiogenesis (both within the mammary gland and the 




uterus) that occur as a result of target depletion, are overcome by increases in progesterone-driven 
angiogenesis later on. In line with this concept, I detect a significant increase in the size of the JZ, 
the endocrinal compartment of the placenta responsible for cytokine, growth factor and hormone 
production; bolstering progesterone as a vital player [239]. Thus, come E15.5, augmentation of the 
JZ occurs in Cre-positive mothers leads to increased progesterone production, which in turn 
increases angiogenesis, thus abrogating the effects of target depletion. Granted, as previously 
stated, the JZ is also responsible for the production of a range of other growth factors and cytokines; 
cumulative upregulation of an array of pro-angiogenic molecules could equally circumvent the lack 
of angiogenesis incurred through our target depletion. This is, of course, entirely speculative. In 
order to confidently correlate the augmentation of the JZ to hormone production I would need to 
culture the JZ of both Cre-negative and Cre-positive mothers and subsequently perform mass 
spectrometry on the conditioned media – at which point I would also be able to gauge differences 
in growth factor and cytokine excretion. 
Coming full circle in the lifecycle of the mammary gland, we proceeded to explore the pathological 
side of angiogenesis, specifically during BC. The BC experiments performed in this thesis aimed to 
assess the involvement of all three of our target molecules in tumour angiogenesis and 
subsequently BC progression. Utilising a MMTV-PyMT derived breast carcinoma cell line (B6BO1) 
for our model of BC, we proceeded with tumour experiments (described in section 2.4) in all of our 
GEMM lines (Table. 3.1). Given previous findings by our lab, the findings from the cancer studies in 
this thesis were lacklustre, at least with respect to double EC knockouts; single and double target 
depleted experiments yielded no significant reduction in tumour volume. However, the triple EC 
knockout did show a significant reduction in tumour growth, providing evidence that the 
triumvirate might serve as an anti-angiogenic “target” in BC, though this concept needs to be 
considered alongside the clinical feasibility of inhibiting all three molecules simultaneously. To 
contrast my findings with those achieved in other cancer models, we have shown in lung cancer 
models that dual target depletion is sufficient to block tumour growth (see supplementary Figure 
9.12). Clearly, there exists a difference between the cancer models used (section 6.3), highlighting 
the importance of studying organ-specific responses when considering the design of anti-cancer 
therapeutics. Interestingly, the B6BO1 cell line is PgR positive (unpublished).  
In an effort to address the potential role of progesterone in orchestrating a pro-angiogenic 
response, and to ascertain whether the mammary gland yields a tissue specific EC population, I 
generated ECs from the mammary gland(s) of our triple GEMM for stand-alone studies, and 
comparative analysis to LECs. MEC-WT and MEC-KO cells were treated with VEGF, S or PS, whilst 
LECs were treated with VEGF, to answer: (1) do mammary and lung ECs differ in their response(s) 




to VEGF; (2) do MEC-WT and MEC-KO cells respond differently to VEGF, S and PS. The findings from 
these studies (particularly with respect to VEGF-induced responses) are somewhat ambiguous, and 
there is clearly plenty more comparisons that need to be performed when comparing LECs to MECs. 
Moreover, there is huge scope to explore differences that might occur in the ECs isolated from the 
different organs in response to target depletion. The most interesting finding to emanate from my 
in vitro analyses relate to responses to pregnant serum (presumably driven by progesterone). There 
is a clear reduction in total VIM and total VASP levels in MEC-KO cells in response to PS. These 
observations certainly merit further investigation. 
In summary, this thesis aimed to address how impaired angiogenesis, mediated by the collective 
depletion of EC integrin-β3, integrin-α5 and neuropilin-1, impacts on epithelial morphogenesis 
throughout the lifecycle of the murine mammary gland. Summarised in Figure 8.1, the mammary 
gland was largely unaffected by the absence of these molecules, with the exception of early-on 
during pregnancy. The ultimate reasons for this are largely unknown but are likely not related to 
inefficient target depletion in the gland (see Figure 3.4, section 3.2). I postulate that in the pubertal 
gland, the most likely explanation is that what we think of as “classical” angiogenesis is not needed; 
it may well be that the empty mammary fat pad into which the developing gland is growing is 
sufficiently vascularised such that additional vessel growth is not required. Further careful analyses 
of the interplay between growing epithelium and existing vasculature should help answer this 
question, and this is now possible given the recently acquired ability to perform meaningful whole 
gland immunostaining. That said, I cannot rule out that the signals governing angiogenesis in the 
pubertal gland, if it does occur, might not be transmitted through the targets we have chosen to 
delete. This this seems unlikely given the targets would generally be considered essential for EC 
migration, which itself is essential for angiogenesis, but, again, this requires further testing, and the 
tools are in hand to do so. Findings in the pregnant gland intimate that angiogenesis as mediated 
by our EC targets is required early on, but then some other process takes over such that the targets 
are no longer involved. This could be through some as yet unidentified compensatory pathway, or 
it may be the result of a shift in what factors are driving EC responses (for example, a transition 
from VEGF-driven angiogenesis to progesterone-driven angiogenesis). Where I see a clear 
connection between angiogenesis and mammary epithelial growth is in the pathological setting. 
Depletion of our chosen targets, at least simultaneously, impairs BC growth. Whilst it might be 
impractical to target all three molecules in a patient, if we can understand on what signalling 
pathways the three molecules impinge upon during the tumour development, it might throw up 
anti-angiogenic targets that have yet to be explored.  















9 Appendix – Supplementary figures 
 
Figure 9.1 Tamoxifen delivery through Elvax-40P® yielded systemic administration of Tamoxifen, not local 
to the implanted mammary gland. TdTomato.Pdgfb.iCreERT2(pos) mice underwent Elvax-40P® (containing 
Tamoxifen) implantation in the left abdominal mammary gland. a) Schematic depicting the difference 
between I.P. and Elvax-40P® pellet method of Tamoxifen administration. I.P. administration is systemic and 
requires Cre-negative littermate controls (left). Elvax-40P® can provide local Tamoxifen administration, 
leaving the remaining mammary glands as contralateral controls (right). b) Representative images of 
mammary glands adjacent to the gland that underwent Elvax-40P® implantation exhibiting TdTomato 
expression (top and middle row), alongside the implanted gland also exhibiting TdTomato expression (bottom 
row): DAPI (blue), TdTomato (red) and endomucin (green). c) Diagrammatic representation of pellet 










Weight of Mouse (g)  Tamoxifen (mg)  Volume to Inject (μl)  
18 1.35 67.5 
19 1.425 71.25 
20 1.5 75 
21 1.575 78.8 
22 1.65 82.5 
23 1.725 86.25 
24 1.8 90 
25 1.875 93.75 
26 1.95 97.75 
27 2.025 101.25 
28 2.1 105 
29 2.175 108.75 
30 2.25 112.25 
31 2.325 116.25 
32 2.4 120 
33 2.475 123.75 
34 2.55 127.75 
35 2.625 131.25 
 
Figure 9.2 Tamoxifen administration doses as recommended by Jax Lab. Tamoxifen, 0.3mg – Sigma-Aldrich, 
was resuspended in 1.5ml ethanol, diluted with 13.5ml of corn oil giving a final concentration of 20mg/ml 
and administered by intraperitoneal injection (section 2.3) [262,377]. 
 
 





Figure 9.3 Quantification of mammary gland epithelial outgrowth in a pubertal gland after whole gland 
staining (WGS). Cre-negative and Cre-positive animals underwent the pubertal Tamoxifen regimen described 
in section 3. Following WGS epithelial outgrowth was quantified. a) Representative image of harvested 
number four mammary gland post WGS. b) The mammary epithelium is manually sketched to create a mask 
of the epithelium extending beyond the base of the lymph node. c-e) The mask of the epithelium is opened 
with ImageJ (c), Simple Neurite Tracer is loaded creating a copy of the mask in 8-bit (d) and is manually 
inverted to aid with quantification (e). f) Simple Neurite Tracer is used to mirror the mask (pink) and quantify 
















Figure 9.4 Quantification of mammary gland epithelial outgrowth in a E10.5 pregnant mammary gland after 
whole gland staining (WGS). Cre-negative and Cre-positive animals underwent the pregnancy Tamoxifen 
regimen described in chapter 3.2. Following WGS epithelial outgrowth was quantified. a) Representative 
image of harvested number four mammary gland post WGS. b) The mammary epithelium is manually 
sketched to create a mask of the epithelium adjacent to the lymph node; left and right. c-e) The mask of the 
epithelium is opened with ImageJ (c), Simple Neurite Tracer is loaded creating a copy of the mask in 8-bit (d) 
and is manually inverted to aid with quantitation (e). f) Simple Neurite Tracer is used to mirror the mask (pink) 




































Figure 9.5 All E10.5 whole gland stain images. Cre-negative and Cre-positive animals underwent the 
pregnancy Tamoxifen regimen described in chapter 3.2, underwent WGS and subsequently epithelial 
outgrowth was quantified. a) All Cre-negative E10.5 glands. b) All Cre-positive E10.5 glands. Cre-negative, 











Figure 9.6 All lactating (P2) whole gland stain images. Cre-negative and Cre-positive animals underwent the 
pregnancy Tamoxifen regimen described in section 3.2. a) All Cre-negative P2 glands. b) All Cre-positive P2 
glands. Cre-negative, N=2. Cre-positive, N=1. Scale bar = 2mm. 
 





Figure 9.7 All involuting (P12) whole gland stain images. Cre-negative and Cre-positive animals underwent 
the pregnancy Tamoxifen regimen described in section 3.2. a) All Cre-negative P12 glands. b) All Cre-positive 













Figure 9.8 Flow cytometric analysis on Nrp1fl/fl.Pdgfb.iCreERT2(pos/neg) tumours proves ineffective at 
identifying ECs, preventing confirmation of target deletion. Nrp1fl/fl.Pdgfb.iCreERT2(pos/neg) mice were 
implanted with 1x105 B6BO1 breast carcinoma cells, orthotopically into the abdominal mammary gland 
(section 2.4) following the experimental regimen shown in Figure. 6.1. Both EC-WT, top panel, and N-KO, 
bottom panel, tumours were stained and gated on endothelial markers CD31 (eFlour450) and endomucin 
(AF647). a-b, f-g) The lack of positive staining for CD31 resulted in subsequent gating for target deletion being 
performed on endomucin alone. c-e) EC-WT staining for integrin-α5 (FITC), integrin-β3 (PE) and neuropilin-1 
(PE/Cy7), gated on the endomucin population. h-j) EC-WT staining for integrin-α5 (FITC), integrin-β3 (PE) and 
neuropilin-1 (PE/Cy7), gated on the endomucin population. 
a) 
c) d) e) 
h) i) j) 
b) 
g) f) 





Figure 9.9 Using confirmed MEC-WT and MEC-KO cells to optimise tumour EC flow cytometry did not 
provide a straightforward answer. MECs were seeded into pre-coated flasks containing 0.1% gelatin and 
grown to confluency before being prepared for flow cytometry as described in section 2.9.1.2. Both MEC-WT, 
top panel, and MEC-KO, bottom panel, cells were stained and gated on endothelial markers Cdh5 (BV421) 
and endomucin (AF647). a, e) Despite western blot analysis proving these markers to be expressed in MECs, 
only a small proportion expressed both markers. Cells positive for both markers were gated on for target 
deletion. b-d) Subsequent MEC-WT staining for integrin-α5 (FITC), integrin-β3 (PE) and neuropilin-1 (BV711) 
shows all MEC-WT cells express all three targets. f-h) Subsequent MEC-KO staining for integrin-α5 (FITC), 
integrin-β3 (PE) and neuropilin-1 (BV711) shows a mixed population of MEC-KO cells expressing integrin- α5 







b) c) d) 
e) 
f) g) h) 






Figure 9.10 Further tumour EC flow optimisation using confirmed MEC-WT and MEC-KO cells, using a 
simplified antibody panel, yielded no improvement in optimisation. MECs were seeded into pre-coated 
flasks containing 0.1% gelatin and grown to confluency before being prepared for flow cytometry as described 
in section 2.9.1.2 – this panel of optimisation used the same fluorophore, separately, for two separate targets, 
specifically PE for integrin-β3 (top panel) and neuropilin-1 (bottom panel). Top panel – a, d) MECs cells were 
stained and gated on endothelial markers Cdh5 (BV421) and endomucin (AF647). b-c) Subsequent MEC-WT 
staining for integrin-α5 (FITC), integrin-β3 (PE) shows all MEC-WT cells express both targets. e-f) Subsequent 
MEC-KO staining for integrin-α5 (FITC), integrin-β3 (PE) shows a mixed population of MEC-KO cells expressing 
integrin- α5 with no expression of integrin-β3. The bottom panel shows the same as the top, with neuropilin-
1 in PE as opposed to integrin-β3. 
  
a) 
b c) e) f) 
d) 
g) 
h) i) k) l) 
j) 





Figure 9.11 Immunofluorescent staining of tumours derived from triple floxed GEMMs for our targets 
confirms target deletion. Triple floxed female GEMMs implanted with 1x105 B6BO1 breast carcinoma cells, 
orthotopically into the inguinal mammary gland following the experimental regimen shown in Figure 6.1a. a) 
Representative images of Cre-negative staining for DAPI (blue), endomucin (red) and respective target 
(labelled above – green). b) Representative images of Cre-positive staining for DAPI (blue), endomucin (red) 
and respective target (labelled above – green). White arrows indicate areas of overlap (yellow) between 









Figure 9.12 Co-depletion of endothelial fibronectin receptors impairs tumour angiogenesis. CMT19T lung 
carcinoma cells (1x106) were implanted subcutaneously into the flank of GEMMs and allowed to grow for 18 
days. (A) Experimental schematic – thrice weekly (Monday, Wednesday & Friday) I.P. injections of Tamoxifen 
(75 mg/kg bodyweight) were administered for the duration of the experiment, inducing Cre-recombinase 
activity. (B) Representative images of CMT19T tumours harvested following 18 days of growth (Scale bar = 1 
cm) (N =3, n ≥ 11 mice). (C & D) Ex vivo tumour measurements were expressed as a percentage of the average 
growth of their Cre-negative littermate controls. (C). Tumour weight at Day 18. (D) Tumour volume at Day 18 
calculated by the formula: length x width2 x 0.52. S.E.M. displayed as error bars. (* = P<0.05), (** = P<0.01), 
(*** P<0.001). Work by Dr Robert Johnson. 
 
 





Figure 9.13 VEGF stimulation of triple-depleted lung ECs (LECs) shows a dampened response to VEGF as 
determined through phosphorylated ERK (pERK) expression. PyMT immortalised LECs (LEC-WT and LEC-
KOβ3/α5/Nrp1) were seeded onto fibronectin and were subsequently treated with VEGF for 0, 5 15 and 30 
minutes. Post-treatment, cells were lysed and western blot analysis was performed to compare protein 
expression between LEC-WT and LEC-KOβ3/α5/Nrp1. a-b) Densitometric analysis of western blot (a) normalised 




































































































































































Figure 9.14 Microarray plate layout and sample comparisons made. MECs and LECs were seeded overnight 
onto pre-coated fibronectin plates and treated the following day with either VEGF, S or PS. a) Position of 
respective samples, their treatments and comparisons made (red and blue arrows). b) Sample IDs and the 

























Ab – Antibody 
ABL – Abelson tyrosine-protein kinase   
ADAM – A disintegrin and metalloproteinases 
AKT – Protein Kinase B or RAC-alpha serine/threonine-protein kinase  
ANG – Angiopoietin 
BC – Breast cancer 
BM – Basement membrane 
BRCA – Breast cancer gene 
BSA – Bovine serum albumin 
CDC42 – Cell division control protein 42 
CDH5 – Vascular endothelial cadherin 
CTCF – Corrected total cell fluorescence 
DAG – Diacylglycerol 
DAPI – 4’6-diamidino-2-phenylindole 
DB – Decidua 
dH2O – Distilled water 
DKK1 – Dickkopf-related protein-1 
DLL4 – Delta-like ligand 4 
DMEM – Dulbecco’s modified eagle medium 
DR – Death receptor 
E(x) – Embryonic day (x) 
EC – Endothelial cell 
EC-KO – Endothelial cell knock-out 
ECL – Enhanced chemiluminescence 
ECM – Extracellular matrix 
EC-WT – Endothelial cell wildtype 
EDTA – Ethylenediaminetetraacetic acid 
eNOS – NO synthase 
ER – Estrogen receptor 
ERG – ETS related gene 
ERK – Extracellular regulated kinase 
ESB – Electrophoresis sample buffer 




EtOH – Ethanol 
F-12 – Ham’s F12 nutrient mixture 
FACS – Fluorescent-activated cell sorting 
FAK – Focal adhesion kinase 
FBS – Fetal bovine serum 
FGF – Fibroblast growth factor 
Fl – Floxed 
Floxed – flanked by loxP sites 
FN – Fibronectin 
GAPDH – Glyceraldehyde 3-phosphate dehydrogenase 
GEMM – Genetically engineered mouse model 
GIMP – GNU Image Manipulation Program 
GPCR – G-protein coupled receptor 
H&E – Haematoxylin and eosin 
HBSS – Hank’s balanced salt solution 
HCl – Hydrochloric acid 
HER – Human epidermal growth factor receptor  
HIF-1 – Hypoxia inducible factors 
HR – Hormone receptor 
HRP – Horse radish peroxidase 
HSCs – Hematopoietic stem cells 
Hsp70 – Heat shock protein-70 
I.P. – Intraperitoneal 
IA – Intussusceptive angiogenesis 
IAR – Intussusceptive Arborisation 
IBR – Intussusceptive Branching Remodelling 
ICC – Immunocytochemistry 
ICM – Inner cell mass 
IF – Immunofluorescence 
IHC – Immunohistochemistry 
IMG – Intussusceptive Microvascular Growth 
IMMLEC – Immortalised mouse lung endothelial cell 
IP3 – Inositol trisphosphate 
JAK – Janus Kinase 




JZ – Junctional zone 
KO – Knock-out 
LEC – Lung microvascular endothelial cell 
LEC-KO – Lung microvascular endothelial cell Knock-out 
LEC-WT – Lung microvascular endothelial cell wildtype 
LIF – Leukaemia Inhibitory Facto 
LYVE-1 – Lymphatic vessel endothelial hyaluronan receptor-1 
LZ – Labyrinth zone 
M’ – Molecular weight 
mAb – Monoclonal antibody 
MACS – Magnetic activated cell sorting 
MAPK – Mitogen activated protein kinase 
MEC – Mammary endothelial cell 
MEC-KO – Mammary endothelial cell Knock-out 
MEC-WT – Mammary endothelial cell wildtype 
MeOH – Methanol 
MFP – Mammary fat pad 
MLEC – Mouse lung endothelial cell 
MMP – Matrix metalloproteases 
MMTV-PyMT – Mammary tumour virus-polyoma middle tumour-antigen 
MOPS – (3-(N-morpholino)propanesulfonic acid) 
NO – Nitric oxide 
Nrp1 – Neuropilin-1 
o/n – Overnight 
p38 – p38 mitogen-activated protein kinase 
PAGE – Polyacrylamide gel electrophoresis 
PBS – Phosphate buffered saline 
PBSTw – PBS supplemented with 0.1% Tween-20 
PCR – Polymerase chain reaction 
PDGF – Platelet derived growth factor 
PECAM1 – Platelet and endothelial cell adhesion molecule-1 
PFA – Paraformaldehyde 
PgR – Progesterone receptor 
PI3K – Phosphoinositide 3-kinase 




PL – Prolactin 
PLC- γ – Phospholipase C gamma 
PLGF – Placenta Growth Factor  
PLR – Prolactin receptor 
PROX-1 – Prospero homeobox protein-1 
PS – Pregnant serum 
RFP – Red fluorescent protein 
ROI – Region of interest 
S – Serum 
SA – Sprouting angiogenesis 
SDF-1 – Stromal cell-derived factor-1  
SDS – Sodium dodecyl sulfate 
SEM – Standard error of the mean 
Src – proto-oncogene tyrosine protein kinase 
STAT – Signal Transducer and Activator of Transcription 
TE – Tris-HCl-EDTA 
TEB – Terminal end bud 
TGC – Trophoblast giant cell 
TGF-β – Transforming growth factor-β 
TIMP – Tissue inhibitors of metalloproteinases 
TNF-α – Tumour Necrosis Factor-α 
TNM – Tumour Node Metastasis 
TOPGAL – TCF Optimal Promoter-beta-GALactosidase 
VASP – Vasodilator-stimulated phosphoprotein 
VEGF – Vascular endothelial growth factor 
VEGFR – Vascular endothelial growth factor receptor 
VIM – Vimentin  
WGS – Whole gland stain 
Wnts – Wingless-related integration sites 
WT – Wildtype  
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